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1.1  DNA 
 
Deoxyribonucleic acid (DNA) is central to all forms of life - it is a unique genetic blueprint 
present in every cell of an organism, from single celled simple life forms to immensely 
complex ones such as humans. The structure of DNA1 allows the genetic code to be both 
replicated during cell division and expressed in protein molecules, through the central 
dogma of molecular biology, first outlined by Crick in 1958 and re-stated in 19702, which 
defines the flow of information through different polymer molecules. The process of 
transcription transfers genetic information encoded as DNA to the messenger molecule 
ribonucleic acid (RNA), before translation results in the information from RNA being 
expressed in protein molecules that carry out cellular functions. The process of DNA 
replication ensures the hereditary information remains unchanged as it is copied and 












The primary structure of DNA is a single stranded polymer chain made up of the four 
nucleotide monomer units. A nucleotide is made up from a phosphate group, a sugar and a 
nitrogen-containing entity called a base. There are four different bases, two are purine 
derivatives, adenine (A) and guanine (G), and two are pyrimidine derivatives, cytosine (C) 










Figure 1.2 - Purine and Pyrimidine bases 
 
The sugar in DNA is deoxyribose, a ribose unit lacking the oxygen usually attached to the 2’ 
carbon atom. When one of the four bases is attached to a sugar via a glycosidic linkage, 
from the N9 (purine) or N1 (pyrimidine) of the base to the 1’ carbon of the sugar, a 
nucleoside is formed; such as deoxyadenosine in the case of the adenine base. A phosphate 
group attached to the sugar, on the 5’ carbon, completes the monomer to make a 
nucleotide. These nucleotides can be linked through phosphodiester bonds between the 
sugar and the phosphate groups to become DNA. The 5’ carbon and 3’ carbon ends of the 
sugar give rise to directionality for the bases in a single strand, which are always written in 
the 5’-to-3’ direction; also the direction of assembly in vivo as the polymerase attaches new 





Figure 1.3 - Chemical structure of single stranded DNA for the sequence AGCT (hydrogen 
atoms omitted for clarity, labelling convention included on the first nucleotide) 
 
The key to all of DNA’s remarkable functions are the specific interactions between the bases 
G-C and A-T through hydrogen bonding, known as complementary base pairing, when two 
single strands run anti-parallel to each other (Figure 1.4). The two sugar-phosphate 
backbones are held apart at a constant distance throughout the molecule because of the 
two base pairings having the same width. This leads to the secondary structure of DNA, 
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which allows the bases to be packed in the most energetically favourable way in the interior 
and leaves the negatively charged backbone exposed on the outside.3 The packing is most 
efficient when the backbones twist around one another, resulting in one complete turn 
every ten base pairs to give the classical double helix depiction of DNA - two polynucleotide 
chains held together by the hydrogen bonded base pairs that are perpendicular to a central 




Figure 1.4 – Above: Complementary base pairing. Below: Double helical DNA representation 
 
Adjacent base pairs are offset by a rotation of 36º and spaced 0.34 nm apart, which gives a 
repeating structure of ten base pairs in one 360º rotation over a 3.4 nm distance, and allows 
sufficient overlap of the planar surfaces for a stacking interaction that further stabilises the 
helix.4 The bases also twist slightly in the plane of the base pair (5º to 25º between two 
bases in a pair) to increase the packing efficiency further, although as purines occupy the 
centre of the double helix, when there is an alternating purine-pyrimidine sequences they 
overlap with purines in the opposite strand and cause steric hindrance, but purine-purine 
and pyrimidine-pyrimidine sequences have no such clashes.5  
 6 
Once the secondary structure of DNA was discovered by Watson and Crick in 19531 it was 
immediately clear from the nature of the complementary base pairing that DNA can be used 
as a template to copy itself.  This involves the double strand being reversibly unzipped by 
cellular machinery (the enzyme DNA helicase) to allow free nucleotides to partner each 
single strand and form two copies of the original double helix. This elucidated the 




There are 3 major conformations of DNA found in vitro – A, B and Z. Which conformation is 
adopted depends on two variations of the nucleotides sugar entity, which in turn 




Figure 1.5 - C3' and C2' endo conformations of the deoxyribose sugar 
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The two sugar conformations are determined by which of the carbon atoms are directed 
upwards in an ‘endo’ position, either the 3’ or 2’ carbon, which lead to the anti and syn 
conformations, respectively, of the corresponding nucleoside. In the syn conformation, if 
the position of the base is maintained, for a planar base pair, it is the direction of the sugar 
phosphate backbone which is distorted from the most commonly observed classical double 
helix conformation of B-DNA. The 3 conformations of DNA and some of their properties are 
shown in Figure 1.6.4 
 
Parameter A-DNA B-DNA Z-DNA 
Helix sense Right Right Left 
Residues per turn 11.0 10.5 11.6 
Axial rise 2.6 Å 3.4  Å 3.7 Å 
Helix pitch 28  Å 36  Å 45  Å 
Rotation per residue 33˚ 36˚ -9˚, -51˚ 
Diameter of helix 23 Å 20 Å 18 Å 
Sugar pucker:    
A, T, C C3' endo, anti C2' endo, anti C2' endo, anti 
G C3' endo, anti C2' endo, anti C3' endo, syn 
Major groove Narrow, deep Wide, deep Flattened 
Minor groove Wide, shallow Narrow, deep Narrow, deep 
 
Figure 1.6 - From left to right A-DNA, B-DNA and Z-DNA, and a table of parameters4. 
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The environmental factors that determine which of the conformations is adopted include 
relative humidity, the amount of salt retained and the cation species that are present. For 
example the most commonly occurring form, B-DNA, has a high level of hydration around 
the structure.4 
All of the conformations have strands running anti-parallel and A- and B-DNA are both right-
handed helices with the glycosidic link in the anti-conformation, so appear similar, but A-
DNA is wide and compact with bases displaced from the centre of the axis, whereas B-DNA 
is narrow and elongated with the bases perpendicular to the axis. The preference for the A-
DNA conformation arises in dehydrated conditions which is often the case in samples 
prepared for crystallographic studies. Using the hydrophilicity of base pairs as a key factor, 
accurate sequence based methods to predict the adoption of A- versus B-DNA have been 
determined.6 
Z-DNA is strikingly different because it is a left-handed helix and is the most elongated. It is 
most likely to form with long guanine and cytosine containing sequences. There is a 
distinctive zigzag in the backbone due to an alternating syn and anti conformation of 
guanine and cytosine that causes an inversion in the direction of the backbone; producing a 
repeating structure of only two base pairs (purine plus pyrimidine)4. A large body of work 
has been carried out looking into the occurrence and importance of Z-DNA in vivo7 but to 
date almost all the DNA in cells and aqueous solution has been found to be in the B-DNA 
form, therefore this is the most relevant conformation for research on DNA interactions. 
 
1.1.3 The Major and Minor Groove 
 
An important feature of the secondary structure of DNA is the major and minor groove - 
these are the areas between the phosphodiester backbones that are exposed as an external 
surface of molecule and have a chemical composition unique to the sequence. The width of 
the grooves depends on the conformation of DNA. In B-DNA the major groove, as the name 
suggests, is wider (12 Å) than the minor groove (6 Å). The asymmetrical groove width arises 
from the glycosidic linkage being off-centre of the base-pair, which results in the two 




Figure 1.7 - Major and minor groove relative to the two base pairs 
 
As neither base pair is symmetrical there are four combinations of bases that consist of 
different chemical environments with different hydrogen bonding abilities, through a 
pattern of donors and acceptors along with the non-hydrogen bonding lone hydrogen 
atoms, and on thymine, the steric contribution of a methyl group. These contributions to 
the surface form a pattern for each of the four base pair combinations and give a secondary 
code to supplement the primary base pair sequence, with the major groove offering four 
different patterns, but the minor groove having only two combinations, as the pattern is 
repeated when each of C-G and A-T are reversed. This information can be used by proteins 
and other biomolecules to read the DNA sequences without needing to unwind the double 
helix; generally through the major groove as this is definitively unique for different 
sequences. 
 
1.1.4 Cellular DNA 
 
In the cellular environment the amount of DNA is too great to simply exist as a double helix 
and it undergoes a remarkable packaging process to give the whole genome in highly-
condensed portions of unbroken DNA, known as chromosomes, contained within the 
nucleus, a sub-cellular compartment with its own membrane. To put the task into 
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perspective, if all of the double helices in a human cell were laid end to end they would 
reach 2 meters, yet the nucleus is only 6 μm in diameter.3 
The complex of DNA and associated proteins that exists in the nucleus of a cell is known as 
chromatin and is made up of several organisational tiers. Firstly, DNA wound around histone 
proteins forms nucleosome core particles which with an unwound linker region of DNA 




Figure 1.8 – The formation of chromosomes from duplex DNA8 
 
This assembly results in a length of chromatin approximately one third of the initial length, 
which is then packed on top of each other to make a fiber 30 nm in diameter, with the exact 
architecture not definitively determined but thought to be of a zig-zag form. This 30 nm 
wide chromatin fiber of packed nucleosomes, however, would still be 0.1 cm in length, so 
the chromatin is folded into a series of loops and coils and then, during cell division, is 
formed into the chromosomes often seen in microscopy images.3 
Chromatin can generally be described as either tightly condensed heterochromatin or lightly 
condensed euchromatin. Heterochromatin can commonly be seen forming structural 
regions of the chromosomes or as an example of genes switched off from expression by 
being inaccessible to transcription and translation processes. Euchromatin is often more 
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actively involved in transcription and generally has a higher concentration of genes than 
regions of heterochromatin.9 
In addition to the chromatin found in the nucleus, mitochondrial DNA also exists in the 
membrane-bound organelle responsible for energy production in the cell. This DNA, 
however, is not only a separate genome but rather than packaged into chromosomes, is 
present in a closed circular double helix form. The presence of this is an important 
consideration when thinking of direct molecular targeting of DNA within a cell, as the  
nuclear and mitochondrial forms that are present could offer different binding affinities and 
outcomes upon interference.3 In the studies within this thesis, however, molecular 
photophysical properties offer visualisation of DNA targeting to elucidate this possibility.   
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1.2  Binding Modes 
 
Many molecules ranging from small organics to vast protein structures can bind to DNA and 
this can occur both irreversibly and reversibly through several different binding modes. As 
DNA is responsible for all cellular functions it is a very important target for a massive range 
of therapeutics, and understanding the interactions that are possible is therefore a vital field 
of research.  
 
1.2.1 Irreversible Binding 
 
Irreversible (covalent) binding can occur on the backbone, sugar residue or base, resulting in 
the formation of a covalent bond. There can be one or more covalent bonds from the 
molecule to DNA formed, and in the case of multiple bonds they can either be on the same 
strand (intrastrand) or bridge across two strands (interstrand). When the structure of DNA is 
sufficiently modified to disrupt the reading of the DNA code then transcription is the main 
process affected, which results in modified gene expression or cell death. 
In therapeutic terms, this type of interaction covers the most successful treatment to date 
for a variety of cancers – cisplatin (diamminedichloroplatinum) and its derivatives.10 This 
class of molecule binds specifically to the N7 of guanine or adenine, across two strands, to 




Figure 1.9 – The irreversible binding mode of cisplatin with 2D NMR solution structure of 
DNA binding through a GpG intrastrand crosslink11 (PDB 1A84) 
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1.2.2 Reversible Binding 
 
Molecules can also bind to DNA through weaker non-covalent interactions, collectively 
known as reversible binding, of which there are three main modes - electrostatic binding, 
groove binding and intercalation.12 
 
1.2.2.1 Electrostatic Binding 
 
Electrostatic binding to DNA is the simplest of the reversible binding modes and relies on a 
non-specific electrostatic attraction between a cationic species and the negatively charged 
polyanionic phosphodiester backbone of DNA. The cationic species can be simple 
monovalent cations or larger polyatomic species, for example, organic species containing 




Figure 1.10 - Cationic species suitable for electrostatic binding to DNA 
 
The backbone of DNA is polyanionic therefore to remain stable in solution it must undergo 
an effect known as counter-ion condensation. First described by Manning’s theory in 1969, 
this states that counter-ions will condense onto the polyion until the charge density on the 
polyion is reduced below a certain critical value.13 It is termed condensation as the counter-
ions form a cloud rather than be associated to specific sites, with the ions retaining their 
inner hydration sphere and being allowed to move along the sugar phosphate backbone.13 If 
the salt concentration of the solution is diluted the condensed ions will remain constant per 
phosphate charge on the backbone.13 The uncondensed mobile anions are then treated in 
the Debye-Hückel approximation. The main effect of DNA condensation is an increase in the 
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melting temperature, Tm, the temperature at which the double stranded helix unwinds into 
two separate single strands.5 
Counter-ion condensation also becomes an important effect for the other two reversible 
interactions of groove binding and intercalation. The release of these counter-ions when 
displaced by the binding molecules is entropically favoured and can count towards the 
overall free energy of the binding.5 
 
1.2.2.2 Groove Binding 
 
Groove binding can occur in either the minor or major groove and relies on a combination of 
reversible van der Waals, hydrophobic or hydrogen bonding interactions. Molecules can 
show high sequence specificity due to the interaction with the edges of the base pairs that 
make up the inside of the grooves surface, and are usually specific to either the minor or 
major groove as there is a distinct difference in width and chemical environment.5 In 
general, groove binders are more sequence specific than intercalators because they can 
cover many base pairs.5 
Groove binders such as the well-studied molecule netropsin do not usually elongate the 
helix as the molecules bind.14 Although this molecule has been shown to widen the minor 
groove and bend the helix slightly as it binds, neither structural change unwinds or 
elongates the helix.15 In fact, these changes make only a subtle difference to the structure of 
DNA and it remains essentially unperturbed in B-DNA form.16  
The mechanism of groove binding can be likened to the enzyme-substrate lock and key 
model. Groove binders are often positively charged so with the counter-ion condensation 
effect there will be a displacement of counter ions as the charge density of DNA is 
decreased upon binding, which is an entropically favourable contribution to the overall free 
energy.5 
Minor groove binders often consist of aromatic rings with flexible linkages to allow an 
adjustable curvature in the molecule for an isohelical fit into the groove, maximising contact 
for van der Waals interactions. An example of specificity for the minor groove being 
increased is in adenine rich sequences which have an increased propeller twist that causes a 
narrowing of the minor groove, thus enhancing van der Waals contacts and producing more 
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favourable binding.5 In contrast, in the C-G base pair the C2 amine group on guanine 
projects out into the minor groove edge as it hydrogen bonds with the C2 carbonyl of 
cytosine, therefore disfavouring minor groove binding for C-G rich sequences.5 This, 
however, can be overcome if the molecule is capable of forming hydrogen bonds with the 
guanine C2 amine group. 
DAPI (4’,6-diamidino-2-phenylindone) is a another minor groove binder that can be used as 
a fluorescent stain for live or fixed cells with a high binding affinity for A-T rich regions of 
DNA.17 Another commonly used stain for nucleic acids is Hoechst 33258, which is also a 




Figure 1.11 – DAPI and Hoechst 33258 with crystal structure of DNA binding18 (PDB 264D) 
 
The major groove can offer even more sequence specificity than the minor groove because 
it has a greater number of variables in the pattern of different hydrogen bonding 
interactions i.e. for each base pair there are four different areas rather than three, and 
there is no symmetry in the pattern so four unique combinations, rather than two for the 
minor groove where the hydrogen bonding pattern has symmetry in each base pair. This 
results in many protein binding interactions where the function of the protein is highly 





Ligand intercalation is the insertion of a molecule into double stranded DNA, with an 
associated extension of the helix as the base pairs either side of the insertion site open up to 
accommodate the additional planar molecule, first proposed by Lerman in 1961.19–21 
The first evidence for intercalation was found through investigations of acridine complexes 
when bound to DNA and the effects this had on DNA viscometry and sedimentation. It was 
concluded that acridine complexes intercalated between adjacent nucleotide pair layers by 




Figure 1.12 - Chemical structure of the intercalators acridine, proflavine and acridine orange 
 
Intercalators usually consist of an extended, electron deficient, planar aromatic ring system, 
with two or more six-membered rings forming a platform similar to a DNA base pair.5 The 
intercalator has an associated van der Waals thickness that has to be accommodated in the 
intercalation site, which from a planar aromatic system usually results in an extension of the 
helix by 3.4Å.22 This unwinds the helix at the site of intercalation and although only reducing 
the degree of rotation between the immediate base pairs sandwiching the intercalator by a 
small amount, this then has a knock on effect seen throughout the whole structure, so it is 
the cumulative modification of the helical twist in all of the affected base pairs that is 
measured for the unwinding angle.5 
Since its identification in the 1960’s, the interaction has been intensively studied, with the 
changes that occur upon intercalation summarised in three steps: unwinding and 
lengthening of the DNA helix, electronic interaction of the intercalators within the helix, and 
rigidity and orientation of the intercalator.22 The electronic interaction is stabilised in the 
helix by π-π stacking and dipole-dipole interactions, and with substantial structural overlap 
of the base pairs and intercalator it is then held rigidly in place and orientated with the 
planar moiety perpendicular to the helical axis for the final step.22 From these three steps it 
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can be deduced that corresponding experimental criteria are to be fulfilled to confirm 
intercalation – evaluation of structural changes to DNA, indication of an electronic 
interaction and demonstration of molecular orientation or rigidity.22  
For the first criterion, macromolecular effects on the structure of DNA must be investigated, 
such as changes in the solution viscosity of bulk DNA or sedimentation coefficient, as 
originally used by Lerman.19 Also, a downfield shift in the 31P spectrum of the 
phosphodiester backbone can be observed.23 For the second criterion, hypochromism and a 
shift to longer wavelength of the transition for the intercalated chromophore can be 
observed24, along with emission enhancements if the molecule is capable of luminescence, 
showing a change in electronic structure of the excited state.22 From the 1H spectrum there 
should also be an upfield shift in the aromatic protons of the intercalator observed; due to 
the ring currents of the stacked aromatic bases.25 For the final criterion, the bound 
orientation of the molecule relative to the helical axis can be detected by dichroic 
techniques or luminescence polarisation which will also establish the time over which there 
is rigid binding.22,26 
Whilst indicating intercalation, not all of the investigations mentioned above can reliably 
differentiate from groove binding. The criteria for defining the difference between those 
two binding modes has been well documented and the techniques originally concluded to 
definitively differentiate between them were viscometry and fluorescence contact energy 
transfer measurements, but not other fluorescent techniques.16 The first technique uses the 
substantial change in the DNA structure after intercalation rather than the unperturbed B-
DNA form upon groove binding, and the second relies on the interaction of intercalators 
with base pairs.16 The fluorescence contact energy transfer, however, has since been found 
to occur in some cases of groove binding so is viewed with great caution as a differentiator. 
This leaves viscometry measurements as the only truly exclusive indication of 
intercalation.27 Another more recent technique used after this debate is Scanning Probe 
Microscopy, SPM, which measures the length of plasmid DNA in the presence and absence 
of DNA binders and therefore detects the lengthening of the helix from intercalation.28 
These techniques are all aside from conclusive atomically resolved crystallographic 
determination, an option employed in an ideal situation where a suitable crystal is obtained.  
As more intercalative molecules were investigated, with an expansion away from 
completely intercalative molecules to those containing merely functional domains or 
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regions, a review by Long and Barton highlighted that total molecular shape and function 
are of importance, particularly in systems with multiple binding modes and domains.22 The 
importance of such structural considerations was demonstrated in studies into intercalation 
of metalloporphyrins containing metals that were either capable or incapable of axial 
ligation29, an investigation of the effects of molecular twist on non-fused aromatic rings30, 
and a comparison of (bi-pyridyl)platinum(II) and bis(pyridine)platinum(II) species to 
demonstrate the need for ligand planarity.31 
As the significance of intercalative molecules grew, the specific structural aromatic 
requirements of the intercalating moiety were investigated by Sartorius et al. with 38 
different structures.32 It was concluded from this study, primarily using NMR, that single 
phenyl rings do not intercalate either as benzene or with additional charged side chains.32 
Two fused rings when unmodified (naphthalene) or with neutral side chains do not  
intercalate either, but when the naphthalene core has a charged side chain, it becomes an 
intercalator, and for three fused rings and higher there is intercalation even in their 




Figure 1.13 - Aromatic requirements for intercalation - 1-4 do not intercalate, 5-6 do 
intercalate 
 
The most important use of intercalators is as a therapeutic against a variety of diseases 
including cancer. A widely used class of intercalating drugs are anthracyclines which are 
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antibiotics obtained from the Streptomyces bacteria, for example the therapeutic 
daunomycin (also known as daunorubicin) in the treatment of a variety of cancers by 




Figure 1.14 – Chemical structure of daunomycin and crystal structure complexed to 
d(CGTACG) DNA35 (PDB 1DA0) 
 
The crystal structure of daunomycin bound to DNA, specifically the sequence d(CGTACG), 
has been resolved to show the exact binding orientation and an intercalation preference for 
insertion in-between adjacent C-G base-pairs flanked by A-T pairs, as predicted.36–38 The 
exact orientation is with the long axis of the four fused rings almost perpendicular to the 
base pair axis, with the central two rings (B and C) nestled in the cavity between base pairs 
but the methoxy substituted ring (A) protruding into the major groove and the amino sugar 
protruding into the minor groove (Figure 1.14).35 
The preference for insertion in-between G-C base pairs arises from the hydrogen bonds 
from the hydroxyl group on ring A donating to guanine N3 and being an acceptor for the 
guanine N2 amino group. Also, ring A and the amino sugar change their conformation as 
binding occurs to ensure a tight fit of the sugar into the minor groove, which is stabilised by 
two bridging water molecules between this group and the DNA. There is also stabilisation in 
the major groove by a hydrated sodium ion coordinated to the guanine N7 and the two 
carbonyl oxygen’s of daunomycin ring B with a distorted octahedral geometry.34 
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1.2.2.4 Mechanism of Intercalation 
 
The mechanism of intercalation is described as an ‘induced fit’ rather than the contrasting 
‘lock and key’ of groove binding.39,40 This mechanism requires three distinct steps of varying 
thermodynamic favourability.39 The first is the separation of DNA to form the site of 
intercalation: an energetically unfavourable conformational change as it unwinds the DNA 
and increases the phosphate spacing, although entropically favourable as this lengthening 
reduces the charge density of the backbone and releases condensed counter-ions. The 
intercalator must then move from the bulk solution to the site and as the planar aromatic 
moieties are hydrophobic it can be referred to as the ‘hydrophobic transfer process’, the 
main energetic driving force behind intercalation. This is due to more entropic favourability 
as DNA-bound water molecules, previously in a well ordered hydration layer, are released, 
as well as positively charged intercalators then facilitating the additional release of 
condensed counter ions. Finally the non-covalent interactions between the molecule and 
DNA are established, which involves a combination of hydrophobic effect, reduction of 
columbic repulsion, van der Waals interactions, π-stacking and hydrogen bonding.  
Chaires described how these mechanistic steps contributed to the overall free binding 
energy using Equation 1.1.39 The experimentally observed binding free energy is defined as 
ΔGobs and related to the binding association constant (K) by the standard Gibbs relationship 
seen in Equation 1.2. 
 
The contributions to the binding free energy are defined as follows: 
∆𝐺𝑐𝑜𝑛𝑓 = conformational changes in DNA structure and drug 
∆𝐺𝑡+𝑟  = losses in translational and rotational degrees of freedom 
∆𝐺ℎ𝑦𝑑 = hydrophobic transfer of drug from solution into its binding site 
∆𝐺𝑝𝑒 = polyelectrolyte contribution from released counter-ions 
∆𝐺𝑚𝑜𝑙 = formation of non-covalent interactions 
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∆𝐺𝑜𝑏𝑠 =  ∆𝐺𝑐𝑜𝑛𝑓 +  ∆𝐺𝑡+𝑟 +  ∆𝐺ℎ𝑦𝑑 +  ∆𝐺𝑝𝑒 + ∆𝐺𝑚𝑜𝑙  
 
Equation 1.1 - Contributions to the overall binding free energy 
 
∆𝐺𝑜𝑏𝑠 =  −𝑅𝑇𝑙𝑛𝐾 
 




As with many therapeutic molecules, the successful outcome from treatment with the 
intercalator daunomycin can be jeopardised by resistant cell lines. One interesting attempt 
to overcome resistance to daunomycin was to bind two of the drug molecules together to 
increase the binding affinity to DNA.41–45 Bis-daunomycin was designed from a consideration 
of the crystallographic information obtained on daunomycin bound to hexanucleotides in a 
2:1 ratio of drug to DNA duplex. This showed that one molecule intercalated at either end of 
the nucleotide, with the daunosamine moieties pointing inwards towards each other, 
revealing a logical link up between the two amino sugars: the reactive NH2 substituents 
which face each other with a separation of less than 7Å.41 In turn the crystal structure of the 
designed new molecule complexed to DNA was obtained to support the experimental data 
and confirm its bis-intercalation, with the para-xylene linker clearly seen to occupy the 




Figure 1.16 – Crystal Structure of DNA-bisdaunomycin complex45 (PDB 1AGL) 
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The concept of bisintercalators possessing stronger affinity comes from the theory of 
binding constants being the product of multiplication. Theoretically the binding free energy  
of the bisintercalator is equal to the addition of the two monomers (Equation 1.3).41 
 
∆𝐺𝑏𝑖𝑠 =  ∆𝐺𝑚𝑜𝑛𝑜 + ∆𝐺𝑚𝑜𝑛𝑜 
 
Equation 1.3 - The relationship between mono and bisintercalator binding free energies41 
 
However as to the relationship between ΔG and K is logarithmic (Equation 1.2) this means 
the binding affinity of the bisintercalator is the square of the monointercalator 
This theoretical relationship was experimentally observed as techniques, including 
differential scanning calorimetry, revealed ultratight binding with a binding constant of 3.1 x 
1011 M-1 at 20 °C.42 
Another theoretical advantage of bisintercalation is that sequence specificity should be 
increased as, for example, in the case of daunomycin the molecule now spans six base pairs 
rather than three. This site size is equal to the cleavage site for some restriction enzymes so 
there is potential for binding specificities analogous to these enzymes.41 The preferential 
binding site was found to be the expected sequence (G/C)(G/C)(A/T)(A/T)(G/C)(G/C) with no 
preference for unique di-, tri- or tetra-nucleotide sequences.43  
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1.3  Metal Complexes and DNA 
 
As studies into interactions with DNA continued and the range of small organic molecules 
capable of a variety of interactions expanded, attention was turned to transition metal 
complexes. This avenue of investigation is not immediately obvious as in nature transition 
metals are almost exclusively only found in the coordination sites of large proteins and 
cofactors, with the cell generally employing organic moieties for the binding and recognition 
of DNA.46 The advantages offered by metal centred systems, however, is that they are 
modular system with set geometries making a scaffold of functional ligands, and in addition 
a whole spectrum of photophysical and electrochemical properties.46 Although this project 
explores the non-covalent interactions of metal complexes and the effects they have, a 
related field of study is already well developed. The covalent interactions of metal 
complexes with DNA was started by the revolutionary discovery of the anticancer drug 
cisplatin.10 
 
1.3.1 Irreversibly Binding Metal Complexes 
 
The field of irreversibly bound metal-DNA complexes all started with a serendipitous 
discovery of cisplatin’s biological activity in 1965.10 With the continued development of this 
remarkably successful class of compounds came exploration into other metals, notably 
ruthenium.47–51 Osmium and iridium complexes have also been investigated with positive 
therapeutic outcomes from irreversible binding with DNA.52–55  
 
1.3.1.1 Cisplatin and Derivatives 
 
Rarely in science has there been such a significant and successful outcome from an 
unintentional discovery as that of cisplatin. The success story started with the work of 
Rosenberg investigating the possible effects of electromagnetic radiation on the division of 
mammalian and bacterial cells.10 In the case of Escherichia coli supposedly inert platinum 
electrodes were included in the growth chamber and when a current was applied, the 
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outcome was bacteria filaments that grew to three hundred times the expected length of 
the usual short rods.10 It was found that the electrolysis products from these electrodes that 
were the cause of the effects observed with two active products being formed – the neutral 
platinum(II) species cis-diamminedichloroplatinum(II), now known as cisplatin, and a 




Figure 1.17 - The two active electrolysis products of the platinum electrodes 
 
In contrast to the cis isomers, the trans isomer was found to be much less active.10 This 
active species was not a novel compound but one first synthesised in 1885 and known as 
Peyrone’s chloride.  In 1968, only three years after Rosenberg’s discovery, cisplatin was 
administered intraperitoneally to mice carrying a tumour and marked tumour regression 
was observed. After more confirmatory in vivo tests, in 1971 the first patients were treated 
to complete a remarkably quick turnaround from ‘on the bench’ discovery to the admission 
to humans in clinical trials. These trials culminated in US Food and Drug Administration 
(FDA) approval in 1978 to conclude the success story of anti-cancer treatment that is now 
used throughout the whole world. 
The mode of action of cisplatin centres on the formation of intrastrand crosslinks in DNA 
double helices. The first step in this process is the aquation of one of the labile chloride 
ligands, which occurs at chloride concentrations less than 100 mM, as found in cells.56 The 
aqua ligand is then easily displaced to allow covalent binding to one of the DNA bases, 
which in most cases has been found to be the N7 of guanine.57 The second chloride can then 
undergo aquation and form another covalent bond to an adjacent guanine on the same 
strand to form an intrastrand GpG 1,2 crosslink (60-65%) or in some cases adenine for an 
intrastrand ApG 1,2 crosslink (20-25%); with small proportions seen to bridge across a base 
in-between the two covalent linkages or bridge across two strands for an interstrand 
crosslink.57 These adducts result in the DNA bending and unwinding but the pathway from 
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these DNA-distorting-adducts to the usual outcome of apoptotic cell death is still debated.10 
It is thought that as well as the adducts impeding cellular processes such as replication and 
transcription they can be recognised by cellular proteins which in turn activates 
downstream signalling leading to apoptosis (programmed cell death).58 Targeting DNA has 
proved such a successful strategy in cancer treatments because rapidly proliferating cells of 
the tumour environment are preferentially targeted as they require high rates of DNA 
replication. Induced apoptosis is then a successful outcome as the apoptosed cells can be 
taken up by macrophages. 
The success of cisplatin is not without drawbacks – namely a very high toxicity and the 
possibility of resistance either intrinsically or acquired throughout treatment. Toxicity 
towards the kidneys and gastrointestinal tract is particularly apparent, as a consequence the 
search began for an alternative that retained anti-cancer activity yet lessened toxic side 
effects. The design principle pursued to achieve this goal was to replace the chlorides of 
cisplatin with a more stable leaving group, leading to clinical trials of carboplatin (cis-
diammine-[1,1-cyclobutanedicarboxylato]platinum(II) (Figure 1.18) which proved the 
hypothesis correct, as the compound negated the nephrotoxicity and reduced the other side 
effect toxixcities.59 It was shown that only the kinetics of DNA binding differed with a much 
slower aquation of carboplatin requiring thirty-forty times the dosage of cisplatin to achieve 
equivalent binding to DNA, but once bound exactly the same adducts were formed, 
resulting in the same cytotoxicity.60 Carboplatin was granted FDA approval in 1989 and in 
most countries replaced cisplatin regimes as an equivalent treatment, for example in several 
randomised clinical trials ovarian cancer survival rates are the same.61 
With one problem of cisplatin significantly reduced, attentions were focused on the other 
major drawback of intrinsic or acquired resistance. This resistance can be broken down into 
two categories – the prevention of cisplatin forming DNA adducts and the mechanisms used 
to counteract or remove the DNA adducts once they have been formed.10  
The first category covers the cellular uptake and any removal thereafter from the cytoplasm 
before association with the DNA occurs. The uptake of cisplatin is governed by molecular 
characteristics, for example its high polarity means its passive entry into cells is relatively 
slow and is dependent on factors such as salt concentrations and pH, for passive diffusion. 
However, it has been shown that the plasma membrane transporter copper transporter-1 
(CTR1) is also used in its cellular uptake.62 This is key to many cases of acquired resistance as 
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exposure to cisplatin, or copper, can lead to downregulation of this transporter; which 
mediates internalisation by macropinocytosis followed by proteasomal degradation.63 As 
well as the uptake of the drug, efflux out of the cell must be considered. There is now 
evidence that the same efflux proteins involved in copper transport can also be responsible 
for exporting cisplatin.64 A final factor prior to DNA binding is reactivity in the cytoplasm 
with thiol-containing species that act to detoxify the cell.10 For example the tripeptide 
glutathione as well as metallothioneins are rich in the sulfur-containing amino acids cysteine 
and methionine for which platinum has a high binding affinity.65,66 Binding of cisplatin to 
glutathione may also be mediated by glutathione-S-transferase (GST). The reactions 
catalysed by this enzyme makes the compound more anionic and readily removable from 
the cell via the ATP-dependant glutathione S-conjugate export (GS-X) pump67, with one 
study showing an increased level of GST in the resistant cell lines versus the sensitive cell 
lines.68 
The second category of resistance involves processing of cisplatin-DNA adducts. This is 
usually through an increased capacity to repair the DNA by the removal of the cisplatin 
adducts. Although this can occur through four different pathways, that involving nucleotide 
excision repair (NER) is known to be the major mechanism.69 NER has been shown to have a 
significant effect as when the expression of one of the key endonuclease proteins ERCC1 
(excision-repair-cross-complementing-1) involved in NER is reduced by interfering RNA 
molecules (containing a complementary code to the sequence of the gene) there is an 
increased sensitivity to cisplatin with less NER of cisplatin-DNA adducts.70 Another post-
adduct mechanism of resistance is increased tolerance to mismatch repair (MMR). Despite 
being one of the pathways in repairing adducts, it is postulated that when the associated 
proteins recognise the adducts several unsuccessful repair cycles are undertaken before an 
apoptotic response is initiated therefore loss of this mechanism results in less apoptosis.71 
Also there can be an enhancement in replicative bypass in which DNA polymerases overlook 
the cisplatin adducts.72 Finally, expression of apoptotic signalling pathways may be reduced 
through protein mediation.10 
The elucidation of some of these resistance mechanisms prompted a new wave of synthesis 
of cisplatin derivatives with goals of increased uptake, decreased cytoplasm reactivity and 
efflux, and reduced tolerance of DNA-adducts once formed.10 Alongside these objectives, 
which are synthesis-based, came alternative tactics outside of the drug itself - such as 
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improved delivery, co-administration with pharmacological modulators of resistance 
mechanisms, and combination therapies with molecularly targeted drugs - but these are 
outside the scope of this review. Out of all of the numerous platinum complexes synthesised 
and trialled in this new drive for an improved therapeutic, only oxaliplatin that has so far 
gained approval, but as this overcomes significant cisplatin resistance, it is a valuable 




Figure 1.18 – The first two cisplatin derivatives to gain clinical approval 
 
The activity of oxaliplatin (1R,2R-diaminocyclohexane oxalate-platinum(II)) was reported in 
1978 when a series of compounds with the three possible isomers of the 
diaminocyclohexane carrier ligand (stable groups that remain coordinated to the platinum 
throughout binding rather than acting as a leaving group for aquation) were tested.73 Not 
only was oxaliplatin active but it has since been shown to overcome some cisplatin 
resistance, with one of the key findings being that at high concentrations there was no 
longer a dependence on CTR1 for cellular accumulation which has been shown to be a factor 
in the resistance against the previous two platinum complexes.74 Also, although the adduct 
formed is mainly GpG intrastrand crosslinks they are still structurally different to those 
formed by cisplatin or carboplatin. This is thought to circumvent some of the post-binding 
resistance as there is more destabilisation of the helix, and the diaminocyclohexane ligand is 
directed into the major groove of DNA which could prevent the binding of repair proteins.75 
It was found in clinical trials to be most effective in combination with other drugs (the 
thymidylate synthase inhibitor 5-flourouracil). It is particularly effective against colorectal 
cancers after showing improvements in treatment of cases which were insensitive to the 
previous platins76 and was granted US FDA approval in 2002. 
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Further developments in platinum therapeutics have been made recently with the 
compound satraplatin, a product of the continued collaboration between Johnson Matthey 
PLC and the Institute of Cancer Research after the development of carboplatin.10 Satraplatin 
(bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV) (Figure 1.19) is an orally active 
compound (cisplatin, carboplatin and oxaliplatin are delivered intravenously) designed to 
have a toxicity profile of carboplatin. It showed similar activity to cisplatin and carboplatin 
treatments77, with circumvention of acquired cisplatin resistance mechanisms involving 
reduced transport78, and is under consideration for approval. 
Picoplatin, cis-amminedichloro-2-methylpyridine platinum(II), (Figure 1.19) is another 
compound to come out of the same collaboration, with the design principle of steric bulk 
around the platinum to make the cytoplasmic reactivity with the thiol-containing species 
less favourable and therefore reduce the associated inactivity and efflux out of the cell.79 
Although demonstrating promising in vitro activity and reaching phase III clinical trials for 




Figure 1.19 - Recently trialled platinum therapeutics 
 
To put the success of the approved therapeutics into context, there are, in total, the three 
previously mentioned complexes plus three used exclusively in Japan, Korea and China 





1.3.1.2 Other Transition Metal Centres 
 
Aside from irreversible binding to DNA by platinum complexes, other metal centres can bind 
to DNA to offer similar therapeutic actions. This field of research aims to further improve on 
the drawbacks of current platinum therapeutics by expanding the range of treatable 
cancers, overcoming intrinsic and acquired resistance which can still prevail, and alleviating 
the often severe side effects.50 
Ruthenium has been extensively studied as substitution kinetics, for RuII and RuIII species, 
are similar to platinum(II).50 The first sign of antitumor ruthenium properties was found with 
the inorganic dye ruthenium red in the 1970’s82, followed by a study of the complexes fac-
[RuCl3(NH3)3] and cis-[RuCl2(NH3)4]Cl in the 1980’s
83, which showed promising antitumor 
activity but were limited as drugs by their solubility.84 
A large amount of research has been carried out with RuII half-sandwich arene compounds 
with the general formula [(η6-arene)Ru(YZ)(X)] where YZ is a bidentate chelating ligand and 




Figure 1.20 - General structure of 'piano-stool' complexes 
 
These compounds are often referred to as ‘piano-stool’ complexes and offer flexibility in 
their design by modification of each of the components (arene, YZ or X) to alter the 
thermodynamic and kinetic properties.50 As well as single covalent bond formation from the 
site of the leaving group to the N7 of Guanine, there can also be intercalation by the arene 
component and finally hydrogen bonding from the chelating ligand to the C6=O of 
Guanine.85 This unique binding mode causes unusual distortions that differ from cisplatin. 
Interestingly, in a study with an ovarian cancer cell line, the area of the arene has been 
shown to correlate with its antitumor activity.86 It is believed that, like cisplatin complexes, 
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the aqua species is formed when the chloride concentration drops from 100 µM in the 
intracellular regions to 4 µM in the cell nucleus, as the compound reaches its target.87 
Another class of ruthenium compounds found to have antitumor activity contain the 
arylazopyridine ligands (azpy) with the general formula [Ru(azpy)2Cl2].
88 These compounds 
have several isomers of varying cytotoxicity and DFT calculations have helped rationalise 




Figure 1.21 - From L-R α-, β- and γ-[Ru(azpy)2Cl2] 
 
A similar bisazopyridine ligand has been used to bridge a dinuclear ruthenium complex with 
the formula [Ru2Cl4L2] that has shown in vitro antitumor properties.
90 
Metal complexes including more ruthenium species capable of antitumor activity, have been 
comprehensively covered in the review of non-platinum metallopharmaceuticals by Clarke 
et al.84 
Another metal centre that has been studied more recently is osmium. Although similar to 
ruthenium it was overlooked due to the toxicity of OsO4 and the substitutionally inert 
nature of OsII or OsIII compounds compared to their ruthenium analogues.50 Fine tuning of 
the ligands for thermodynamic and kinetic properties, however, has led to osmium 
complexes of the ‘piano stool’ general structure (Figure 1.20) with cytotoxicity’s comparable 
to cisplatin and carboplatin.91 These complexes are thought to bind to DNA in the same way 
as the ruthenium analogues with a combination of irreversible guanine N7 covalent linkage, 
arene intercalation and hydrogen bonds, although interestingly they have been found to 
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unwind the DNA strands, in contrast to cisplatin lesions which only bend the helix, and also 
do not show cross-resistance with cisplatin.92 
Collaborative work between Sadler and McGowan looked into both ruthenium and osmium 
piano stool complexes where isomerism in the amide linkage (as the YZ component in Figure 
1.20) changed the anticancer activity.93 In this study when the ligand was bound to the 
metal through two nitrogen atoms (Y,Z = N,N in Figure ), rapid binding of the complex to 
guanine occurred and several derivatives showed cytotoxic activity. When the ligands were 
bound through nitrogen and oxygen (Y,Z = N,O), however, the complex did not bind to 
guanine and subsequently had no cytotoxic effects. Following on from the correlation 
between ligand binding mode and cytotoxicity, ruthenium and iridium complexes of the 
piano stool architecture were investigated with a variety of ligands to give (N,N), (N,O) and 
(O,O) ligand binding modes, with a trend in anticancer activity observed of which the (N,O) 
species were the most toxic.94 More recently, McGowan and co-workers have completed a 
comprehensive study into the anticancer activity of a library of ruthenium and iridium 
complexes featuring β–ketoenamine ligands, with results showing the complexes induce 
single strand DNA breaks and cause cell death by apoptosis in a variety of cancerous cell 
lines.95 
 
1.3.2 Non-Classical Therapeutics 
 
The compounds discussed so far all fall into the category of classical chemotherapeutics 
with the aim being the formation of DNA lesions. All of these genotoxic systems form non-
repairable cisplatin-style lesions in the double helix and exploit the fast replication and 
mitotic processes of malignant cells to enhance these effects. A non-conventional target in 
comparison are the proteins and enzymes involved in tumor metabolism, with metal 
complexes again providing some promising interactions in a relatively new field of study.50 
These include gold(I) phosphine complexes that act as inhibitors to some mitochondrial 
enzymes found in elevated levels in the tumor environment.96,97 Gold(III) is isoelectronic and 
isostructural with Pt(II) so analogues to the platin species were soon tried but were found to 
be unstable and susceptible to reduction to metallic gold under physiological conditions.98 
This low stability, however, has been improved upon with gold(III) porphyrin complexes that 
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show cytotoxicity in vitro and in vivo greater than cisplatin and without cross-resistance.99 
Other metals featured in non-classical therapeutic complexes include gallium100, 
ruthenium101 and cobalt102. 
Recent developments have seen two ruthenium compounds show particularly suitable 
therapeutic activity enter ongoing clinical trials: trans-[RuCl4(DMSO)(Im)](ImH) (where 
DMSO = dimethyl sulfoxide and Im = imidazole), known as NAMI-A48, and [RuCl4(Ind)]IndH 




Figure 1.22 - The two ruthenium therapeutics in clinical trials 
 
NAMI-A has a different mode of activity to existing platinum therapeutics as it shows anti-
metastatic activity, that is the prevention of tumours spreading.48,103 Some reports have 
focused on the interaction of these two compounds with differing cell components to DNA, 
in the case of NAMI-A modifying cell invasion and metastasis and for KP1019 promoting 
apoptosis through the mitochondrial pathway, differentiating them from cisplatin and giving 
them the non-classical label.104 In the preclinical studies, however, interactions of KP1019 
with DNA were established through electrophoretic analysis which revealed the ability to 
untwist and bend DNA – a likely cause for the cytotoxic action.103 
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RuIII compounds like NAMI-A and KP1019 are also thought to act as prodrugs and undergo 
reduction to the more reactive RuII species in vivo. Prodrugs are derivatives that are 
transformed into the desired active form in vivo, for example by photoactivation, redox 
activity or ligand substitution.50 This approach was theorised to be effective for RuIII 
compounds as during delivery to the tumour there should be minimal non-target 
biomolecular interactions; therefore avoiding deactivation and side effect toxicities. Once in 
the tumour environment, however, reduction to the corresponding RuII species can occur 
due to the reductive tumour environment – a result of high glutathione concentration, high 
pH, and an insufficient blood supply to rapidly dividing cells lowering the O2 concentration. 
 
1.3.3 Reversibly Binding Metal Complexes 
 
Along with the many metal complexes that irreversibly bind to DNA, there is also a whole 
class of reversibly bound complexes that have been explored for their therapeutic 
properties, with most interest focusing on the intercalating species. There are some 
important characteristics shared by non-covalent metal complexes which include them 
being kinetically inert, a requirement for stability. Most are d6 octahedral or d8 square 
planar, usually a rigid structure is held in place to maximise recognition with DNA, and 
finally preparation is often designed to incorporate photophysical or photochemical 
properties that are of great use in probing or affecting the chemistry.46 
Photoactivation in particular offers the advantage of exclusively treating the local area of 
the tumor and avoiding side effects elsewhere in healthy tissue, with photodynamic therapy 
(PDT) currently used in the clinic to treat readily accessible tumors with the appropriate 
nontoxic photosensitizers.105 The limitation of this approach is  accessibility  of the light 
stimuli to the diseased tissue, and the requirement that the sensitizer needs to be activated 
by light between 650 nm and 900 nm; longer wavelengths are not energetic enough for 
activation, and shorter wavelengths are too energetic and can cause to much off-target 
damage.50 
A typical mechanism for PDT involves a porphyrin-based system becoming photo-excited 
and transferring energy to ground state triplet oxygen (3O2) to generate the highly reactive 
singlet oxygen species (1O2), which damages the DNA and leads to cell death. It must be 
 34 
remembered that tumor environments are often deficient in oxygen (hypoxic) so this 
method is not always viable. Metal-bound porphyrins can have a positive effect on the 




As the interest in intercalation grew and the field expanded as described in section 1.2.5, 
attention soon turned to metallo-intercalators, defined as metal-centred complexes with 
one or more intercalating ligands (Figure 1.23). 
The intercalating ligand acts in the same way as a small organic intercalating molecule, 
unwinding the DNA to enable π-stacking between two base pairs. Once bound the 
intercalating ligand secures the complex in place and governs where the ancillary ligands are 
directed in relation to the double helix.46 The binding affinity of the complex has been 
shown to have a positive correlation with an increase in the area of the intercalating ligand 




Figure 1.23 – Δ-[Ru(bipy)2(dppz)]
2+ showing the general structure of a metallo-intercalator 
(bipy = 2,2’-bipyridine and dppz = dipyrido[3,2-a:2’,3’-c]phenazine) 
 
The first work to show metal complexes binding to DNA via intercalation was carried out by 
Lippard et al. with square planar platinum(II) complexes, originally with terpyridine ligands 
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in 1974 which was soon after confirmed with X-ray diffraction patterns.107,108 This was 
followed by DNA binding studies with other planar heterocyclic ligands attached to the 
platinum and investigation into effects such as ionic strength on these systems binding 
properties.109 
Three-dimensional structures were then investigated in the 1980s at first by Barton et al. 
using the octahedral geometry of zinc(II) with phenanthroline (phen) ligands in a tris-phen 
complex, which showed a stereoselective preference for the DNA binding of one 
enantiomer over the other, and was labelled as partial insertion between the base pairs.110 
This stereospecific DNA binding was then shown with the analogous ruthenium tris-phen 




Figure 1.24 - The two enantiomers of [M(phen)3]
n+ - Λ on the left and Δ on the right (M = 
metal centre, n+ = charge on the metal complex) 
 
The ruthenium systems were chosen both for their kinetically inert characteristics of the low 
spin d6 systems and intense metal to ligand charge transfer (MLCT) band in the visible 
region, and this tris-phen complex has been thoroughly discussed since the first studies 
which concluded it was interacting with DNA through intercalation.112 This intercalation was 
proposed to be the same binding mode for both enantiomers although favoured for the Δ-
enantiomer where the orientation of the non-intercalating ligands matched the right 
handed helical groove, whereas a lower affinity for the Λ-enantiomer was attributed to the 
phosphate backbone restricting access, due to the steric clash with the ligands in this 
conformation, and therefore preventing full intercalation.113 This was concluded from 
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hypochromic shifts - although these were less pronounced than for other species - and 
fluorescence quenching experiments which were proposed to indicate intercalation when 
compared with complexes bound by electrostatic interactions.112 Following on from this 
however, it was proposed that two binding modes exist – intercalation and surface binding – 
with the rates of quenching for both enantiomers still slower than free [Ru(phen)3]
2+ and the 
Δ-enantiomer still binding by intercalation, but the Λ-enantiomer instead bound to the 
surface in a different way with the ancillary ligands following the contours of the groove and 
displacing the intercalating ligand away from the helix, therefore exposing it to the 
quencher.114 1H NMR studies were then used to show these modes of binding were 
consistent.115 
This, however, was contradicted by the findings of Hiort et al. in 1990 which from circular 
dichroism (CD) and linear dichroism (LD) spectroscopy proposed each enantiomer had its 
own binding mode in the major groove, with different stereospecific geometries from steric 
and coulombic factors, but neither interacted through intercalation.116 It was at this time 
that the criteria for intercalation (discussed in section 1.2.5) established by Lerman were 
addressed by Chaires et al. by comparing the viscometry measurements for [Ru(phen)3]
2+ 
with the known intercalator ethidium bromide which lengthens the DNA helix to increase 
the viscosity, and the known groove binder Hoechst 33258 which leaves the DNA helix, and 
viscosity, unperturbed. Neither enantiomer was found to increase the viscosity and 
therefore was not intercalating in the classical way, with the Λ-enantiomer appearing similar 
to Hoechst 33258 and the Δ-enantiomer giving a decrease in viscosity – suggested to be due 
to a partial intercalation acting as a wedge to produce a static bend in the helix.117 The 
binding affinities were also investigated and found to be relatively weak which supported a 
electrostatic binding mode.117 Other spectroscopic and physical techniques were then used 
to confirm two single individual binding modes.118 Coury et al. have also used scanning force 
microscopy (SFM) to show a lack of intercalation into DNA as there was no increase in 
length compared with the elongation induced by the control ethidium bromide.28 
In a further twist, DNA saturation with regard to binding of the two enantiomers was looked 
into by Rodger et al. in 1999 using spectroscopic techniques and computer modelling to 
outline three binding modes: partially inserted with a single phenanthroline ligand parallel 
to the base pairs in the major groove, slotted with one ligand in the minor groove or minor 
facial with two ligands in the minor groove.119 This study concluded that, at all mixing ratios, 
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the partially inserted mode is favoured for the Λ-[Ru(phen)3]
2+, but with Δ-[Ru(phen)3]
2+ the 
minor facial mode is favoured at low concentrations in contrast to the slotting mode at high 
concentrations with some partial insertion also occurring.119 
 
1.3.3.2 The Molecular Light Switch Effect 
 
Metallo-intercalators are capable of probing the structure of DNA without directly 
interacting with it, due to the reversible binding mode and the complex being coordinately 
saturated and substitutionally inert which prevents the formation of covalent linkages, 
along with the photophysical and photochemical properties of the complex that can be 
employed. The molecular light switch effect utilises these properties when a transition from 
one environment to another leads to luminescence where there was previously none, that is 
the light is ‘switched on’ in the new environment. This effect is related to solvachromic 
luminescence when a chemical substance can change colour due to a change in solvent 
polarity, but with the intensity of the emission being the significant variable observed. A 
typical example of a light switch complex is [Ru(bipy)2dppz]




Figure 1.26 - The molecular light switch complex [(bipy)2Ru(dppz)]
2+ 
 
The light switch effect occurs when excited by the suitable wavelength of light, there is a 
charge transfer of an electron from an orbital predominantly metal in character to an orbital 
predominantly ligand in character, known as a metal to ligand charge transfer (MLCT). In the 
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case of [(bipy)2Ru(dppz)]
2+, exciting the complex results in emissive or non-emissive 
deactivation depending on the solvent environment. In aqueous solution there is no 
luminescence as the excited state is non-emissively deactivated through water molecules 
hydrogen bonding with the endocyclic nitrogen atoms of the intercalating ligand, but in 
organic solvents, a solvachromic luminescence is observed as an emissive deactivation 
occurs in the absence of these interactions. 
In complexes with equivalent ligands, such as [Ru(bipy)3]
2+, rapid hopping of the electron 
between ligands occurs, and there is a transient symmetrical charge separation in the 
excited state. The reason for the directional excitation occurring onto the dppz ligand in 
[(bipy)2Ru(dppz)]
2+ is that the electron charge transfer favours the stronger electron 
accepting ligand stabilised by the nitrogen atoms of dppz. The properties of the  
[(bipy)2Ru(dppz)]
2+ complex can be said to consist of two electronically independent parts – 
a [Ru(bipy)3]
2+-like chromophore and a phenazine electron acceptor.121–123 
These molecular light switch complexes were first investigated as a DNA probe by Barton, et 
al.120,124 When this light switch mechanism is transferred to DNA binding, there is non-
emissive deactivation of the excited state when the complex is free in aqueous solution, but 
emissive deactivation is observed when the complex is bound to DNA. This emission is a 
result of the excited state being protected in-between the base pairs from the surrounding 
water molecules; with this degree of protection reflected in the extent of the molecular light 
switch effect.124 In addition, it was shown there is differentiation between A-, B- and Z-DNA 
in the emission spectra.120 The two enantiomers of the complex were then investigated by 
Hiort, et al. and it was shown that each has two distinctive excited state lifetimes that 
seemed related to two different binding modes of the complex.125 One mode has the 
complex intercalating from the minor groove to direct the metal-dppz axis perpendicular to 
the base pairs, with the other mode having the metal-dppz axis aligned along the base pair 
axis.125 The perpendicular binding mode has both nitrogen atoms intercalated into the base 
pair stack and protected from the external solvent to give a long lived excited state, whereas 
the latter binding mode, that can be called side on, leaves one of the phenazine nitrogen 
atoms accessible by water as it points into the major groove, which results in some 
quenching of the excited state although still much slower compared with the compound 
free in solution.125 
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The exact mode of intercalation was debated and in further studies intercalation from the 
major groove was disproved in favour of a minor groove entry, with no room for the two 
different orientations and the bi-exponential decay could be attributed instead to a loading 
effect.126 It was also found that there was preferential binding to d(AT) regions of both calf 
thymus DNA (CT-DNA) and a modified T-4 DNA which has major groove steric hindrance on 
the cytosine bases.127 
Many more metallo-intercalators have been made with a range of transition metal centres, 
including rhenium and platinum complexes with a dppz or similar intercalating ligand, as 




Metallo-insertion is a variation on metallo-intercalation where a planar aromatic ligand 
inserts in-between the base pairs, but rather than unwinding and extending the DNA helix, a 
single base pair is ejected to accommodate the new planar ligand and replace the π-stacking 
interactions.46 
 
1.3.3.4 Hetero-Metallic Complexes 
 
Focusing on ruthenium-platinum complexes, some of the first work done with relevance to 
this project was that of Sahai, et al. in 1986 when they prepared a hetero-oligionuclear 
complex containing one ruthenium and three platinum centres bridged by a quinoxaline 
ligand.129 In the 1990’s more heterometallic complexes were made with a mixed metal 
bimetallic complex of the form [(bipy)2Ru(BL)PtCl2]
2+ (where BL = bridging ligand) was 
synthesised with a 2,3-bis(2-pyridyl)pyrazine (2,3-dpp) bridge by Yam, et al.130  This was 
followed by work from Brewer, et al. with bridging ligands of 2,3-bis(2-pyridyl)quinoxaline 
(dpq) and bis(2-pyridyl)benzoquinoxaline (dpb) (Figure 1.27).131 Subsequent work focused 
on the DNA interactions of these complexes where it was suggested a non-covalent 





Figure 1.27 - Bimetallic ruthenium-platinum complex with bridging ligands dpp, dpq and dpb 
 
Further studies carried out by Brewer, et al. with the same three bridging ligands (dpp, dpq, 
dpb) but 2,2′:6′,2′′- terpyridine (tpy) ancillary ligands produced a series of compounds that 
were shown to feature tunable charge transfer bands based on the stability of the π* 
orbitals on the bridging ligand; and substantial DNA binding for all three.133 In another study 
a series was investigated with the bridging ligand remaining dpp but the ancillary ligands 
varied, and this showed further tunability of the photophysical properties in the ruthenium-
platinum system.134 
An alternative design principle of a more flexible linker between metal centres has also been 
investigated. One study by Schilden et al. in 2004 involved a ruthenium-platinum bimetallic 
linked by a diethyleneglycol unit, of the form [(tpy)Ru(dtdeg)PtCl]3+ (dtdeg = bis[4’-
(2,2’:6’,2’’-terpyridyl)]-diethyleneglycol ether), which was shown to non-covalently bind to 
9-ethylguanine.135 This was based on the hypothesis that the ruthenium moiety displayed 
the known polypyridyl-ruthenium non-covalent DNA binding and increasing the affinity for 
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its target by the 2+ charge, combined with the already cytotoxic platinum compound 
[Pt(tpy)Cl]Cl.2H2O.
107,136,137 
Another ruthenium-platinum complex of interest was synthesised by Haga, et al. in 2006 
with a dual linker tethered to the PtCl2 unit by each reactive amine end to form a 
metallocycle that associated with CT-DNA and also displayed visible-light-induced scission of 
(supercoiled Pbr322) DNA.138 
Bimetallic combinations other than ruthenium-platinum have also been used in the search 
for new therapeutics. For example, by tethering a reactive PtCl2 unit to a known mismatch-
specific rhodium-centred metallo-intercalator, Barton, et al; directed the cisplatin moiety to 
preferentially react with mismatched DNA.139 The rhodium precursor of this molecule has 
been shown to target thermodynamically destabilised mismatched sites in DNA with a hit-
rate of 80%, and interestingly cleaves the DNA backbone upon photoactivation.140 
This research into therapeutic heterometallic complexes forms the basis for my work in 




1.4  Cytotoxicity 
 
A cytotoxic compound is one that can cause damage to living cells, and cytotoxicity can be 
described as the degree to which an agent has a specific destructive action on certain cells. 
The fate of cells exposed to a cytotoxic compound can vary – apoptosis often being the 
dominant mechanism but nonapoptotic mechanisms such as oncosis, autophagy, mitotic 
catastrophe and senescence can also have a role in cell death from treatment with 
conventional chemotherapeutic agents, with the three relevant routes to this project 
described herein.141 
It must be noted that whilst the three routes of apoptosis, oncosis and autophagy are all 
modes of cell death, one often misunderstood term is necrosis, which should be considered 
as the post-mortem cellular changes that occur after cell death that restore an equilibrium 
with a cell’s environment and is thus applicable to both the apoptosis and oncosis.142–144  
Despite the descriptions provided by, for example, Majno et al142 and  Trump et al143, and a 
summary in a specialized 2012 review on oncosis by Weerasinghe et al144, confusion in the 
literature between oncosis and necrosis is still apparent. For example, the 2003 review 
paper by Proskuryakov et al145 – which seeks to describe the differences between apoptosis 
and necrosis – appears to confuse necrotic pathways with oncosis. The review concludes 
that necrosis itself is an alternative programmed cell death mechanism with outcomes that 
lead to very different consequences for the organism affected. Nonetheless, despite this 
confusion in the literature, there are clearly modes of cell death that can be incontrovertibly 




Figure 1.28 – Electron micrographs of polymorphonuclear leukocytes (PNMs) undergoing 





Apoptosis is often referred to as programmed cell death (PCD) and follows a well ordered 
and defined series of cellular events. Although observations had been made for many 
decades previously, the term ‘apoptosis’ and the definition of the distinct morphological 
changes in cells in physiological conditions were introduced by Kerr et al in 1972.147 The 
structural changes during apoptosis initially involve cell shrinkage and nuclei condensation 
followed by nuclear fragmentation and separation of the protruding sections on the cell 
surface formed during the reduction in size. This gives a multitude of membrane bound 
fragments, known as apoptotic bodies, containing compacted but chemically and 
structurally intact organelles and varying nuclear matter. These apoptotic bodies are then 
phagocytosed by other cells – broken down at first by internally contained enzymes 
(autolysis) followed by lysosomal enzyme degradation – to give lysosomal residual bodies.142 
Much work has since been carried out to gain a deeper understanding of this process which 
- as reviewed recently by Fuchs and Steller - is essential to normal development processes 
such as homeostasis, and is involved in both the causation and combatting of disease.148 The 
developmental role of apoptosis is particularly apparent during the focal elimination of cells 
in embryonic development, which is the controlled removal of cells for example to fashion 
limbs and develop initially webbed hands and feet into defined digits.149 
A key discovery for the mechanism behind PCD came from genetic studies in the nematode 
C. elegans identifying specific genes which acted to initiate the program of cell suicide.150,151 
From these genetic studies the machinery behind cell death was found to be a family of 
cysteine proteases referred to as caspases (cysteinyl aspartate-specific proteinases) which 
mediate proteolytic cleavage in dying cells and one of which, caspase 3, can be identified by 
Western blotting as an apoptosis marker.152,153 
There are two signalling pathways for apoptosis – the intrinsic mitochondria-mediated or 
extrinsic extracellular-mediated pathway – although once activated the same caspase 
facilitated mechanism proceeds.141,154 For the intrinsic pathway, stress signals such as DNA 
damage or high levels of reactive oxygen species (ROS) are responsible for activation, as well 
as viral infection or activation of oncogenes. On the other hand, the extrinsic pathway is 




Oncosis is a cellular reaction to injury, causing cell death through a different pathway to that 
of apoptosis and is not commonly implicated in developmental processes. Oncosis has a 
very different morphologically to apoptosis as, in contrast to the steps described above, 
cells swell, there is collapse of the plasma membrane, and then they are rapidly lysed, with 
a resulting efflux of cell remnants into the extracellular space which can potentially induce a 
problematic inflammatory response.144 
Oncosis can be induced by inhibition of cellular energy production, imbalance of 
intracellular calcium flux, generation of ROS, or activation of nonapoptotic proteases - 
events which are all linked and can enhance the activation with multiple triggers.141 One 
biochemical characteristic in the lead-up to oncosis, but not apoptosis, is the initial rapid 
decrease in intracellular ATP. This oncosis-inducing interference with ATP synthesis 
deactivates Na+, Ca+-ATPase in the cell membrane which causes an increased intracellular 
concentration of K+ and Cl- ions and prompts an influx of water and Ca2+ ions – resulting in 




Autophagy is the term used to describe pathways that result in cytoplasmic materials being 
delivered to the lysosome in animal cells for enzymatic degradation and - in contrast to 
apoptosis and necrosis - does not necessarily have to result in cell death.155 It is an adaptive 
process that occurs under certain metabolic stresses or from developmental triggers, and 
results in intracellular protein and organelle degradation, via formation of a double 
membraned encapsulation of cytoplasmic contents, called an autophagosome, which then 
fuses with a lysosome for degradation.141 
Under normal physiological conditions autophagy occurs at basal levels for the turnover of 
cell components but excessive autophagy can result in cell death, for example it has been 
recently shown to be responsible for joint destruction in rheumatoid arthritis.156 
Dysfunctional autophagy pathways have also been implicated in tumorigenesis with studies 
 45 
showing a gene, Beclin 1, responsible for autophagosome formation to be deleted in various 
sporadic human carcinomas.157 
The induction of autophagy can be investigated through the expression of the marker for 
autophagosome formation - the microtubule associated protein-1 light chain 3B (LC3B). 
Western blot analyses can show LC3B-I and LC3B-II, the former being the cystolic form that 
through lipidation is converted to LC3B-II to allow it to associate with autophagic vessels.158 
  
 46 
1.5  Metal Complex Fluorescence Microscopy  
 
The visualisation of cells is key to understanding many cellular processes and whilst this field 
was started with organic DNA-binding molecules, the advantages of various metal 
complexes have become apparent with recent advances overcoming some of the main 
disadvantages of traditional organic dyes such as low water solubility, high toxicity and 
photo bleaching.159 Imaging with metal complexes, on the other hand, offers the advantages 
including the MLCT excitation occurring in the visible region, having a high Stokes shift, and 
possessing chemical and photostability.160 
 
1.5.1 Related Ruthenium Complex Studies 
 
One of the recent advances in live cell imaging with metal complexes came from the Gill, et 
al. in the Thomas group with the binuclear ruthenium complex [((L)2Ru)2(tpphz)]
4+, where L 







Figure 1.29 – (A) The complexes [((L)2Ru)2(tpphz)]
4+ (L = bipy or phen) used by Gill, et al.    
(B) Live cell imaging of chromosomal DNA in the MCF-7 human breast cancer cell line 
 
The phenanthroline complex [((phen)2Ru)2(tpphz)]
4+overcame previous metal complex 
membrane permeability limitations for efficient cellular uptake where the favourable 
properties of the MLCT excitation allowed for high resolution nuclear imaging, seen in 
Figure 1.29 with the example of mitotic chromosomal DNA in cells of the human breast 
adenocarcinoma cell line MCF-7.160 
Other dinuclear complexes studied in the Thomas group for cellular imaging applications 
include iridium-ruthenium species with bipyridine and phenanthroline ancillary ligands, 
which can be cyclometalated in the case of the iridium, as featured in a recent publication 
by Wragg, et al.161 Many studies of metal complex microscopy have used the strategy of 
increasing lipophilicity to enhance passive diffusion, but this approach can produce systems 
that deviate from intended targets and bind to alternative, more lipophilic intracellular 
targets such as membrane structures and the endoplasmic reticulum.162 
Another interesting ruthenium complex studied in the Thomas group which has imaging 
applications through MLCT excitation is [(phen)2Ru(tpphz)]




Figure 1.30 – (A) The metallo-intercalator [(phen)2Ru(tpphz)]
2+ (B) Fixed cell staining of the 





2+ complex has shown, after efficient cellular uptake, 
both effective imaging through MLCT excitation and notable cytotoxic properties. The 
toxicity is comparable to cisplatin and shows little cross resistance in the cisplatin 
sensitive/resistant model of the A2780/A2780cis human ovarian carcinoma cell lines, as well 
as being capable of high resolution nuclear imaging as seen by those obtained by Gill, et al. 
(Figure 1.30).163 This is an example of a theranostic compound – an agent that has both 
diagnostic and therapeutic properties – and forms the basis of this PhD research which 
synthesises several derivatives of [(phen)2Ru(tpphz)]
2+and explores their cytotoxicity, with 
the aid of cellular imaging.  
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2.1  Aims 
 
The initial aim of this project was to synthesise the four complexes 1 – 4 shown in Figure 
2.1. These polypyridyl ruthenium complexes are structural extensions of the complex 











2.2  Synthesis 
 
The first synthetic target was the resynthesis of the complex Ru(tpphz) 1. One conceivable 
route to this complex involves synthesis of the tetrapyridophenazine ligand (tpphz) followed 
by an equimolar ratio reaction with the ruthenium polypyridyl unit (phen)2Ru. However, this 
always yields the dinuclear ruthenium product [{Ru(phen)2}2(tpphz)]
4+ due to the two 
equivalent binding sites of tpphz, the lower solubility of the free ligand, and the high 
stability of the product. An alternative literature route was utilised in the preparation 
whereby the tpphz ligand is covalently synthesized using a precursor ligand already bound 
to the ruthenium centre.2 
First, ruthenium(III) chloride hydrate was coordinated to bidentate phenanthroline ligands 
to make (phen)2RuCl2. The modified phenanthroline ligand 1,10-phenanthroline-5-6-dione 
(DPQ) was then synthesised by a literature preparation3 and coordinated through 
displacement of the two chlorides in the final bidentate site to yield [Ru(phen)2(DPQ)]
2+. In a 
separate synthesis the modified phenanthroline ligand 1,10-phenanthroline-5,6-diamine 
(phen-diamine) was made from DPQ, via the 1-10-phenanthroline-5,6-dioxime intermediate 
(phen-dioxime).4 Finally, the [Ru(phen)2(DPQ)]
2+ complex and phen-diamine were combined 
in a condensation reaction  to form the tpphz ligand already coordinated to ruthenium, and 
yield [Ru(phen)2(tpphz)]
2+, 1. This final reaction was carried out with newly synthesised DPQ 
complex and phen-diamine and executed under nitrogen with dry solvents as per Schlenk 
line techniques. This resulted in an orange precipitate that did not require purification by 
column chromatography; although for small samples of maximum purity column 
chromatography was employed using an alumina stationary phase and an eluent of 
acetonitrile that contained an increasing fraction of water/KNO3. 
For the complex Ru(taptp) 2, a different synthetic approach was employed in which the 
taptp ligand was made first following a literature preparation.5 This ligand has only one 
available bidentate binding site so it could then be reacted with [Ru(phen)2Cl2] to displace 
the two chlorides and form the mononuclear complex [Ru(phen)2(taptp)]
2+; again the 
reaction was carried out under Schlenk line conditions and no further purification was 
required. 
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The dinuclear complexes RuPt 3 and RuRe 4 both use Ru(tpphz) 1 as the starting material. In 
the case of RuPt 3 two different platination methods were attempted. First, 
tetrachloroplatinate, K2[PtCl4] was used to make (DMSO)2PtCl2 which was then reacted with 
Ru(tpphz) 1, as a PF6 salt in acetone. This did not yield the desired product, with unreacted 
Ru(tpphz) 1 collected as the precipitate. Instead, tetrachloroplatinate was directly reacted 
with Ru(tpphz) 1 in a methanol/water solvent mixture. This gave a brown precipitate which 
had the correct M1+ peak in the mass spectrum and a downfield shift in the 1H NMR 
spectrum for the protons closest to the terminal nitrogen atoms; indicative of deshielding by 
the additional PtCl2 unit drawing electron density away from those protons. 
For the complex RuRe 4, the starting material of Ru(tpphz) 1 was reacted with 
pentacarbonyl rhenium(I) chloride, Re(CO)5Cl, in acetonitrile. This yielded an orange product 
which again had the correct M1+ peak in the mass spectrum and a downfield shift in the 
protons closest to the terminal nitrogen atoms from the deshielding effect of the Re(CO)3Cl 
unit drawing electron density. 
The overall reaction scheme for complexes 1 – 4 is shown below in Figure 2.2. Only the 
isolated molecules are shown with additional reagents and conditions omitted for clarity (all 
syntheses contained in Experimental Section 6.2). 
For all aqueous luminescence and cellular studies the complexes were first converted to 
their water-soluble chloride salts. This was achieved by anion metathesis where the PF6 salt 
was first dissolved in acetone and then tetrabutylammonium chloride was added to 
exchange the counter ion and thus precipitate the chloride complex (procedure contained in 









2.3  Luminescence 
 
Since the first demonstration of the DNA light switch effect by Barton, et al.6 with the 
complex [Ru(bipy)2(dppz)]
2+, many ruthenium polypyridyl complexes have been shown to 
have the same property in vitro.7 This effect originates from the metal-to-ligand-charge-
transfer (MLCT) of the system - when photo-excited at a specific wavelength a low oxidation 
state electron rich metal can transfer electron density from its d-orbital to a ligands π* 
orbital and create a high energy unstable excited state. When free in aqueous solution the 
excited state is short-lived due to non-radiative decay through the surrounding hydrogen 
bonds with water molecules. Conversely, if the molecule is bound to DNA (see Introduction 
Section 1.2), it can be protected from the surrounding water molecules in a hydrophobic 
environment which allows the excited state to decay through a radiative path – usually 
phosphorescence. This route of excitation to a triplet state and the phosphorescent 
emission it can then proceed through to return to its singlet ground state are represented in 
the Jablonski diagram below (Figure 2.3).8 
 
                                  
 
Figure 2.3 – Jablonski diagram of a 3MLCT emission 
 
A = Absorption 
ISC = Inter-System Crossing 
F = Fluorescence 
P = Phosphorescence 
S0 = Singlet ground state 
S1 = Singlet excited state 
T1 = Triplet excited state 
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To confirm the complexes display the DNA light switch effect, an aqueous 1 millimolar 
solution of solubilised genomic calf thymus DNA (1 mM CT-DNA) was titrated into a solution 
of the relevant system as an aqueous buffered chloride salt (10 µM, protocol contained in 
Experimental Section 6.3). The sample, contained within a 1 cm path length quartz cuvette, 
was excited at 440 nm upon each cumulative addition of DNA and the emission spectrum 
recorded to observe any change in luminescence with the increasing concentration of DNA. 
It was already established that mononuclear complex 1 does display the DNA light switch 
effect and this provided a positive control.1 Shown below (Figures 2.4 – 2.7) are the series of 
luminescence titrations for complexes 1 – 4, with the emission seen to increase as the DNA 
light switch effect occurs until a point of saturation when all available complex is associated 
with DNA. By plotting ([DNA]/[complex]) versus the fraction bound (gathered from the 
increasing emission) a binding curve of the complex can be obtained, which emphasizes the 
point of saturation as a clear plateau in the curve, and these plots follow each of the 
corresponding luminescence titrations. 
To extract the key value of the equilibrium binding constant, Kb, the binding data must be 
fitted to a Scatchard plot. The most basic form of this is the linear binding isotherm first 
proposed by Scatchard in 1949 for small molecules binding to isolated protein sites9 – a 
relatively simple system that does not account for many overlapping sites in a DNA-ligand 
system that inevitably deviate from linearity. Many models have been created to fit the non-
linear deviation but a popular one for this system, and the one used for this data, is the 
McGhee and Von Hippel (MVH) model (See Experimental 6.3.2 for equation used). The 
parameters of Kb and also the site size occupied by the molecule in number of base pairs, n, 
could be estimated using the software SigmaPlot 13.0 to fit the binding data to a MVH 
model, and are included in Figure 2.8. The approximation of site size is an indicator of the 
number of base pairs occupied by the binding of the molecule, and if the value is below 1, 









Figure 2.4 – (A) Luminescence titration of 10 µM [Ru(tpphz)]Cl2 in aqueous solution (25 mM 
NaCl, pH 7.4) with increasing additions of 1 mM CT-DNA (B) corresponding binding curve   




Ru(tpphz) 1 with increasing CT-DNA concentration

























Figure 2.5 – (A) Luminescence titration of 10 µM [Ru(taptp)]Cl2 in aqueous solution (25 mM 
NaCl, pH 7.4) with increasing additions of 1 mM CT-DNA (B) corresponding binding curve 




Ru(taptp) 2 with increasing CT-DNA concentration


























Figure 2.6 – (A) Luminescence titration of 10 µM [RuRe]Cl2 in aqueous solution (25 mM 
NaCl, pH 7.4) with increasing additions of 1 mM CT-DNA (B) corresponding binding curve 




RuRe 3 with increasing CT-DNA concentration

























Figure 2.7 – (A) Luminescence titration of 10 µM [RuPt]Cl2 in aqueous solution (25 mM NaCl, 
pH 7.4) with increasing additions of 1 mM CT-DNA (B) corresponding binding curve 
550 600 650 700 750 800 850


























For the complex Ru(tpphz) 1, the maximum emission wavelength (λmax) is 617 nm (giving a 
Stokes shift of 177 nm) and this emission increases with each addition of DNA. This complex 
has previously been shown, through viscosity measurements, to reversibly bind to DNA 
through intercalation of the flat planar ligand.1 The binding constant, Kb, and site size, n, 
were calculated using the McGhee Von Hippel model as 4.5 x 105 M-1 and 1.8 respectively. 
For the complex Ru(taptp) 2, the luminescence titration still demonstrated an overall DNA 
light switch effect, with the λmax being 608 and 604 nm before and after saturated binding, 
and therefore a Stokes shift of 164 nm upon DNA binding. This is a slightly shorter 
wavelength emission and Stokes shift compared to complex Ru(tpphz) 1, and it also 
possesses an interesting binding profile.  In DNA-free aqueous buffer,  emission from the 
complex is still quite apparent, and upon small additions of DNA, the emission initially 
decreases before further DNA addition induces the expected enhanced emission of the light 
switch effect. The reason for the distinctive profile is hypothesised as follows: firstly in the 
aqueous buffer solution the excited state may not be as effectively quenched non-
radiatively by hydrogen bonding as there are only the central two nitrogen atoms on the 
ligand (where tpphz has two terminal nitrogen atoms the taptp ligand has aryl C-H units in 
that position). The two contrasting effects in the emission appears to be due to biphasic 
binding where – upon addition of small amounts of DNA – the first binding mode allows 
direct redox quenching of the excited state through the DNA base pairs. Above a critical 
concentration of DNA, a second binding mode occurs in which redox quenching is reduced 
or absent. The two binding phases could be an initial intercalation phase followed by groove 
binding, or vice versa. Whilst the taptp ligand is very similar to tpphz, further 
experimentation would be required to verify which singular or multiple binding mode was 
occurring. The binding constant, for the main light switch phase, has been calculated as 2.1 x 
108 M-1, which is relatively strong and much closer to the that of the groove binders RuRe 3 
and RuRu-bipy (a dinuclear groove binder included for comparative purposes, see 
Experimental 6.2.17) than the intercalator Ru(tpphz) 1; and following on from the above 
hypothesis groove binding could be the second phase, after intercalation at low DNA 
concentrations. 
Complex RuRe 3 also demonstrated the DNA light switch effect. In this case there was a 
larger Stokes shift of 220 nm with the λmax at a longer wavelength of 660 nm. Through 
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viscosity measurements it was revealed that RuRe 3 is a groove binder as it showed similar 
properties to the positive groove binding control, Hoechst 33342 (See Appendix 7.2). This is 
in agreement with the hypothesis that the steric bulk of the Re(CO)5Cl unit would prevent 
intercalation between the base pairs. Interestingly, the binding constant, Kb, for this 
complex was calculated to be 1.6 x 107 M-1 which is two orders of magnitude greater than 
the mononuclear Ru(tpphz) 1. The dinuclear groove binder RuRu-bipy gave a Kb value of 4.5 
x 107 M-1 which is of the same order of magnitude as RuRe 3 (1.6 x 107 M-1) and indicates 
the interaction with the groove is stronger than intercalation via the tpphz ligand. 
Finally, the complex RuPt 4 also demonstrated the DNA light switch effect and had a λmax of 
619 nm (Stokes shift of 179 nm) which was slightly higher than Ru (tpphz) 1 but not 
significantly so. In contrast, to the other complexes, RuPt 4 displays a relatively prominent  
low energy shoulder. Interestingly, the binding curve differs as it is sigmoidal rather than a 
linear gradient, before still plateauing off at the point of saturation. The binding constant 
has been calculated as 8.0 x 107 M-1, which is very similar to the groove binding of RuRe 3 
and RuRu although the mode of binding could in theory be one of three options – groove 











n (base pairs) 
Ru(tpphz) 1 621 617 0.45 ± 0.1   1.8 ± 0.029 
Ru(taptp) 2 608 604 7.2 ± 1.1 1.69 ± 0.025 
RuRe 3 621 660 1.6 ± 0.2 0.77 ± 0.033 
RuPt 4 618 619 80 ± 5.5 0.75 ± 0.004 
RuRu-bipy 621 670 45 ± 3.9 2.20 ± 0.105 
 
Figure 2.8 – Table of emission λmax values, and from a MVH fit of binding data, Kb and n 
 
In summary, all four complexes associate to DNA in cell free conditions. However binding to 
genomic CT-DNA in saline buffer at approximately 22°C is different to physiological cellular 
conditions, so it cannot be an assumed DNA is the intracellular target.  
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3.1  Background 
 
Following the synthesis of complexes 1 – 4, and cell-free DNA binding studies that confirmed 
the complexes displayed DNA light switch effects, attention was turned to cellular studies. 
Whilst platinum-based drugs are still widely used in the clinic as successful anti-cancer 
treatments, one major drawback is intrinsic or acquired resistance.1 New metallodrugs 
could result in improved first- or second-line treatment options if they are able to overcome 
common cisplatin resistance mechanisms. Ruthenium complexes are attracting increasing 
attention as metallodrug leads, with several reaching clinical trials such as imidazolium 
trans-imidazoledimethylsulfoxidetetrachlororuthenate (NAMI-A)2,3 and trans-
[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019)4 (Figure 3.1). 
 
 
Figure 3.1 – Structures of NAMI-A (A) and KP1019 (B) 
 
In this study, the cell lines investigated were A2780 and A2780cis, which are two variants of 
a human ovarian carcinoma line. A2780 is sensitive to cisplatin treatment, whereas A2780cis 
shows an approximately 10-fold increase in therapeutic resistance. The A2780cis cell line 
was originally generated by subjecting A2780 to chronic cisplatin exposure of increasing 
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concentrations (with the resistance maintained in subculture by periodic low level exposure 
- details of cell culture protocol found in Experimental Section 6.4.1).  This protocol 
generates cells with several reported resistance mechanisms to cisplatin, including the loss 
of proficiency of the mismatch repair (MMR) pathway due to methylation and silencing of 
the hMLH1 gene, resulting in an increased ability to repair DNA damage.5,6 Other 
mechanisms implicated are the accumulation of the inactive mutant form of the p53 tumour 
suppressor gene,7 and/or raised cellular content of glutathione (GSH) and an associated 
increase in Multi Drug Resistant Protein 2 (MRP2) expression.8 Further changes in DNA 
damage recognition, cellular signalling and DNA damage repair in this cell line have also 
been reported and could be associated with resistance mechanisms.9 
The cytotoxic response induced in cells by complexes 1 - 4 was first investigated by the 
widely used MTT assay - a colorimetric assessment of cellular metabolic activity. This 
technique utilises 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyletrazolium bromide (MTT), which 
is yellow in colour but is converted by active enzymes to an insoluble, purple formazan 
product (Figure 3.2) (Protocol found in Experimental Section 6.4.2). 
 
 
Figure 3.2 – Conversion of MTT to formazan product  
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3.2  IC50 Determination 
 
A commonly used reference for cytotoxicity is the half maximal inhibitory concentration, the 
IC50 value, which is the concentration of a complex required to inhibit cellular processes in 
half of the treated population (protocol found in Experimental Section 6.4.3). Biological 




Figure 3.3 – Complexes 1 – 4 
 
To ensure experimental techniques were in line with literature methods cisplatin was 
employed as a positive control with the chosen A2780 and A2780cis cell lines, with the 
results from following these procedures shown below (Figure 3.4). The IC50 value for 
cisplatin against A2780 was calculated, via interpolation of the curve, as 2 μM, and for 
A2780cis as 18 μM, which is in line with the 10 fold resistance literature value between the 
two cell lines.10 
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Concentration of cisplatin (log10 M)




















A2780cis treated with cisplatin (24 hours)
A2780cis treated with cisplatin (48 hours)
A2780 treated with cisplatin (48 hours)
3 parameter sigmoidal fit
R2 = 0.9575 
3 parameter sigmoidal fit
R2 = 0.9871
3 parameter sigmoidal fit
R2 = 1.0000
 
Cell line Exposure time IC50 
(hours) (µM) 
A2780cis 24 30 
A2780cis 48 18 
A2780 48 2 
 
Figure 3.4 – A2780 and A2780cis cell viability data for cisplatin 
 
With this protocol experimentally verified, the cell lines A2780 and A2780cis were subjected 
to treatment by complexes 1 – 4. An example of a viability curve, measuring cell viability 
versus increasing concentration of each complex for each cell line, can be seen below. This 
IC50 data is summarised in Figure 3.5. 
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Concentration of Ru(tpphz) 1 (log10 M)



















A2780 treated with Ru(tpphz) 1 (48 hours)
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A2780 treated with Ru(taptp) 2 (48 hours)
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A2780 treated with RuRe 3 (48 hours)
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A2780 treated with RuPt 4 (48 hours)
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A2780cis treated with Ru(tpphz) 1 (48 hours)
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A2780cis treated with Ru(taptp) 2 (48 hours)
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A2780cis treated with RuRe 3 (48 hours)




Concentration of RuPt 4 (log10 M)



















A2780cis treated with RuPt 4 (48 hours)




By obtaining IC50 values for each permutation of complex and cell line, the relative toxicity of 
each complex to the two cell lines can be compared (Figure 3.5). Such an analysis reveals 
the presence or absence of any cross-resistance – in which tolerance to a usually toxic 
substance occurs through exposure to a similarly acting substance.11 From each 
independent experiment an IC50 was obtained, by interpolation of the generated curve, and 
these were averaged for the mean value shown in Figure 3.5. The error could then be 
calculated as the standard deviation of these independent repeats (except for A2780 and 
Ru(taptp) 2 where only one experiment was ran). 
 
Cell Line 
Complex IC50 (μM mean value ± 1 standard deviation of independent values) 
cisplatin Ru(tpphz) 1 Ru(taptp) 2 RuRe 3 RuPt 4 
A2780 2 ± 1 *** 2 ± 1 ** 18 * 9 ± 4 ** 44 ± 5 ** 
A2780cis 22 ± 4 *** 4 ± 2 *** 13 ± 5 *** 27 ± 10 *** 36 ± 3 ** 
 
Figure 3.5 – Table of IC50 values (asterisks indicate independent repeats e.g. ** for n=2) 
 
As can be seen from the estimated IC50 values for the new complexes, there is a range in 
activities and cross-resistance profiles to cisplatin. The resistance factor for cisplatin 
between A2780 and A2780cis recorded in these experiments (approximately 10 fold from 2 
to 22 μM) is in agreement with the literature values. Interestingly, none of the new RuII 
complexes demonstrate such high cross resistance factors. 
The most toxic complex, with the same potency to cisplatin against A2780cis, was 
mononuclear ruthenium Ru(tpphz) 1. In line with the previous reports from the group, this 
compound was not only highly cytotoxic against A2780 (IC50 2.1 μM) but also showed 
appreciable lack of cross-resistance by maintaining a similar level of cytotoxicity against 
A2780cis (IC50 4.4 μM). 
The other mononuclear ruthenium complex Ru(taptp) 2 is not as potent as Ru(tpphz) 1 but 
still shows significant cytotoxicity against A2780 (IC50 18.0 μM) with no cross-resistance to 
A2780cis (IC50 13.2 μM). 
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In contrast to the two mononuclear complexes, the ruthenium-rhenium complex RuRe 3 
displays a relatively high toxicity against A2780 (IC50 8.6 μM) but cross-resistance against 
A2780cis cells (IC50 27.3 μM) is observed - albeit to a lower degree than cisplatin 
(approximately 3 fold versus 10 fold). 
The other heterometallic ruthenium-platinum complex RuPt 4 was notably less cytotoxic 
against A2780 (IC50 44.3 μM) yet, like Ru(taptp) 2, showed an increase in toxicity against 
A2780cis (IC50 36.0 μM). 
These results show that the mononuclear species have good intrinsic cytotoxicity and lack 
cross-resistance with cisplatin. This observation could be as a result of two mechanisms – 
either the potency is an effect of uptake efficiency in both cell lines with the same 
intracellular mechanism for all complexes, or there are differing intracellular mechanisms 
between the complexes that provoke cell death, i.e. a varying response in DNA damage 
repair. A third possibility involves a combination of both factors. 




3.3  Microscopy Studies 
 
Microscopy studies were used to investigate the intracellular mechanism responsible for cell 
death, primarily whether the general mode of cell death fitted with one of the three broad 
categories – apoptosis, oncosis or autophagy – described in more detail in Section 1.4. To 
recap, apoptosis and oncosis are the cellular reactions prior to cell death, whereas necrosis 
is the term used for the degradative reactions that constitute the postmortem cellular 
changes to restore an equilibrium with the environment.12 Apoptosis is indicated by cell 
shrinkage, cytoplasmic blebbing, nuclear fragmentation and marked chromatin 
condensation which all lead to cell fragmentation and formation of apoptotic bodies.13 
Generally, oncosis produces broadly opposite morphological changes, with cell swelling 
accompanied by clearing of the cytosol, dilation of the endoplasmic reticulum (ER) and golgi, 
mitochondrial condensation then swelling, nuclear chromatin clumping and formation of 
cytoplasmic blebs that are organelle free.13 
First, the optimum level of seeding for microscopy experiments was established with the 
appropriate vessel of a 35 mm diameter glass bottomed dish. To target the observation of 
cell death in a short time period of 3 hours, a complex concentration of 50 μM was chosen, 
which is greater than all the previously determined IC50 values, and remained the same for 
all treatments to obtain a basic qualitative comparison of cellular uptake. Images were 
recorded at 2 minute intervals over ten different coordinates within the sample, with 
observations started immediately after treatment in a live cell confocal microscopy chamber 
at 37 ºC with a flow of CO2 present (further detail in Experimental Section 6.5). For each 3 
hour experiment, an equally seeded control dish was included in the chamber and imaged 
at the end to ensure the conditions of the chamber were having no detrimental effect on 
the morphology of the cell population. Also, an equally seeded but untreated dish was 
subjected to the same 3 hour cycle of 2 minute multi-coordinate image acquisition to 
control for light exposure. This protocol was carried out in a succession of experiments for 
complexes 1 – 4 on both A2780 and A2780cis cell lines (Figures 3.6 – 3.14). 
The general observation with all of the complex treatments is that the cell death occurs via 




Figure 3.6 – A2780 cells treated with 50 μM Ru(tpphz) 1 in a live cell microscopy experiment 
as an overlay of phase contrast and epifluorescence (470 nm excitation and >520 nm 




Figure 3.7 – A2780 cells treated with 50 μM Ru(taptp) 2 in a live cell microscopy experiment 
as an overlay of phase contrast and epifluorescence (470 nm excitation and >520 nm 
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Figure 3.8 – A2780 cells treated with 50 μM RuRe 3 in a live cell microscopy experiment as 
an overlay of phase contrast and epifluorescence (470 nm excitation and >520 nm emission 




Figure 3.9 – A2780 cells treated with 50 μM RuPt 4 in a live cell microscopy experiment as 
an overlay of phase contrast and epifluorescence (470 nm excitation and >520 nm emission 
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Figure 3.10 – A2780cis cells treated with 50 μM Ru(tpphz) 1 in a live cell microscopy 
experiment as an overlay of phase contrast and epifluorescence (470 nm excitation and 




Figure 3.11 – A2780cis cells treated with 50 μM Ru(taptp) 2 in a live cell microscopy 
experiment as an overlay of phase contrast and epifluorescence (470 nm excitation and 
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Figure 3.12 – A2780cis cells treated with 50 μM RuRe 3 in a live cell microscopy experiment 
as an overlay of phase contrast and epifluorescence (470 nm excitation and >520 nm 




Figure 3.13 – A2780cis cells treated with 50 μM RuPt 4 in a live cell microscopy experiment 
as an overlay of phase contrast and epifluorescence (470 nm excitation and >520 nm 
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Figure 3.14 – control dishes of untreated cells as an overlay of phase contrast and 
epifluorescence (470 nm excitation and >520 nm emission collected) following the same 
seeding and 3 hour experimental exposure as treated dishes for (A) A2780 (B) A2780cis 
 
To interpret the data further, some quantification was carried out on. Firstly, a fluorescence 
intensity profile was obtained for each experiment, which can be seen plotted together on 
the same graph (Figure 3.15). The data generated from this analysis must be treated with 
care though – it is difficult to directly compare each curve because they are independent 
experiments so there are three areas of variance of particular note. One possible variable 
factor is present due to the intensity of light measured being proportional to that delivered 
to the subject, so discrepancies in laser performance will affect the output. Also, each 
complex will have different photophysical properties, particularly the quantum yield. Finally, 
between samples there are fluctuations in the net number of cells present regardless of 
treatment. Nonetheless, bearing this caution in mind, it can be seen that the samples 
treated with Ru(taptp) 2 complex are considerably more intense than the other complexes 
in both cell lines – this supports the observation of staining of the mass majority of cells in 
these samples, providing a high net fluorescence output. For A2780 treated with Ru(tpphz) 
1 there is also a high fluorescence output, although less than that for Ru(taptp) 2 which 
could be postulated as a difference in the selectivity of staining – Ru(taptp) 2 appears to 
have more indiscriminate whole cell staining whereas Ru(tpphz) 1 is more confined to the 
nuclear regions. Interestingly, the fluorescence from samples of A2780cis treated with 
Ru(tpphz) 1 is much lower than from the A2780 samples, but postulation on this would 
require more experimentation. For the remaining cases of A2780 and A2780cis treated with 
RuRe 3 and RuPt 4 the fluorescence output is lower than the mononuclear complex 
treatment, which is in agreement with the observation of much less cell death and staining; 
and correlates with their lower cytotoxic activity.  




Figure 3.15 – fluorescence intensity profiles of each cell line and complex permutation 
 
By looking at each of the fluorescence profiles in turn, interesting observations can be made 
with regard to the timing of when the fluorescence markedly increases as an indicator of 
cellular accumulation and death (Figure 3.16). From the fluorescence profile of A2780 cells 
treated with Ru(tpphz) 1 it can be seen to have a noticeable increase in intensity from 
approximately 60 minutes onwards, which is indicative of the cellular accumulation and 
death observed qualitatively. In slight contrast, the fluorescence for A2780 cells treated with 
Ru(taptp) 2 shows a similar sharp increase in intensity from approximately 40 minutes 
onwards. If the complex is entering the cell by passive diffusion then this subtle difference 
could be assigned as a result of the increased lipophilicity of the Ru(taptp) 2 complex due to 
loss of 2 hydrogen bonding donor sites; where the taptp ligand features aryl C-H units in 
place of the terminal nitrogen terminal nitrogen atoms on Ru(tpphz) 1. For the samples 
treated with RuRe 3 and RuPt 4 there is a much lower magnitude of fluorescence intensity 
seen and this is represented in the qualitative observation of low cytotoxic activity and 
cellular staining compared to the mononuclear complexes. This fluorescence data could be 
indicative of the relationship between the cellular accumulation of the complexes – 
Ru(taptp) 2 has the fastest comparative uptake, closely followed by Ru(tpphz) 1, whereas 
RuRe 3 and RuPt 4 are much slower to accumulate in cells; in this specific experimental 





 A2780 Ru(tpphz) 1
 A2780 Ru(taptp) 2
 A2780 RuRe 3
 A2780 RuPt 4
 A2780cis Ru(tpphz) 1
 A2780cis Ru(taptp) 2
 A2780cis RuRe 3
 A2780cis RuPt 4
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setup. To fully assess the cellular accumulation there will be a future study to investigate the 
intra-cellular metal content by inductively coupled plasma mass spectrometry (ICP-MS). 
 
       
      
Figure 3.16 – Fluorescence profiles over time (obtained as an average of 5 sample areas) for 
A2780 cells treated with 50 µM (A) Ru(tpphz) 1 (B) Ru(taptp) 2 (C) RuRe 3 (D) RuPt 4 
 
For the mode of cell death, a similar pattern of observations can be seen in each treatment 
leading to the characteristics most similar to an oncosis – clearly distinguished swelling 
before compromised membranes result in the some of the intracellular matter leaking out. 
The fluorescent staining of the cells is often only seen a significant way down the cell death 
pathway as seen in the example below (Figure 3.17). 
 

























Figure 3.17 – Typically observed cell death pathway after A2780 cells were treated with 
RuRe 3 (50 µM, 0-3 hours) (A) phase contrast (B) epifluorescence (ex. 470 nm, em. >520 nm) 
 
These observations were quantified by manual cell measurement using tools found in the 
FIJI imageJ software. The subjects chosen were those cells which at the final time point were 
dead (as judged by previously expansion of cell area to the point of no more cellular 
movement) and comprehensively stained. The perimeter of the cell was recorded for these 
subjects at the first and final time point, which subsequently gave the area of the cell. This 
was repeated for each affected cell in a field of view for 5 different coordinates of each cell 
line and complex permutation. This raw data was used to calculate a difference in area for 
each viable to dead cell as a percentage of the initial area. Looking at samples of individual 
cells this revealed a more subtle observation that the cells underwent a greater range of cell 
size differentiation than first thought, with the majority of dead cells having increased in 
size but to a varying magnitude and with some cases of cell shrinkage too. To ensure the 
mean increase in size was not skewed by those cases of cells that did in fact decrease in size, 
the data for each variable was partitioned into subsets of increasing and decreasing area 
prior to the calculation of respective mean and standard error of the mean values. The 
mean difference in cell size after the cytotoxic response, as a percentage of initial viable cell 
size, with the corresponding standard error of the mean (only positive direction of error 








Figure 3.18 – (A) Mean difference in cell size for A2780 and A2780cis between initial viable 
cells and final dead cells after treatment with the corresponding complex, separated into 
subsets cells with an increase or decrease in size (B) Sample size of each cell line and 
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This data reveals a complex variability in the overall morphology of the cells as they undergo 
a cytotoxic response to the complex treatment. It appears the strongest agreement with the 
typical characteristics of oncosis is for Ru(tpphz) 1 treatment on A2780 cells, with an 
average increase in cell size of approximately 80%, with complexes 2 – 4 increasing in size to 
a lower magnitude of typically around 30-40%. For the A2780 cells which decreased in size, 
there was only one case for RuRe 3, but it was approaching an even split between cell 
swelling and shrinkage after treatment with RuPt 4. For the A2780cis samples treated with 
complexes 1 and 2 there was a smaller mean increase in size than the A2780 analogue’s  
(50% and 30% respectively), but a more notable contrast to A2780 is the cases of cell 
shrinkage, albeit to a small magnitude of 14% and 8% respectively. For the cases of RuRe 3 
and RuPt 4 there is still a prominent mean increase in cell size but for the cases of cell 
shrinkage an increasing magnitude of this effect. The magnitude of the standard error of the 
mean sufficiently validates an appreciable difference in characteristics between variables, 
but as there is some small overlap of ranges the trends should be taken as a general 
comparative oversight. Nevertheless, the difference in profiles between cell swelling and 
shrinkage are apparent and if postulated as a correlation to cases of oncosis and apoptosis, 
there appears to be a trend whereby, following treatment with complexes 1 – 4, the 
A2780cis cell line is more prone to death by apoptosis than the A2780 cell line. 
Furthermore, looking at potential trends between the complexes, the only complex with a 
significant frequency of cell shrinkage in A2780 cells as well as A2780cis is RuPt 4. 
Interestingly, the fluorescence is sometimes seen only after a cell has significantly 
progressed along the cell death pathway – when it is already swollen or displays 
compromised membranes (Figure 3.17). One hypothesis that explains these observations is 
that an extracellular stimulus causes a proportion of the cell death, possibly in the form of 
cell signalling from the minority of cells that are initially affected, before compromised 
membranes remove any barrier to the rapid influx of complex which binds with intracellular 
targets. Another hypothesis is that the complex does immediately enter the cell but in such 
a relatively low concentration the fluorescence is not seen until the membrane is 
compromised in cell death and there is a large influx of complex that facilitates widespread 
binding to those intracellular targets capable of an observable light switch effect. 
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In addition, for the mononuclear complex Ru(tpphz) 1 a further experiment was run with 
4’,6-diamidino-2-phenylindole (DAPI) as a co-stain. DAPI is a known nuclear stain that has an 
excitation/emission profile of 358/461 nm, so its emission was collected from a 405 nm 
excitation. Ru(tpphz) 1 has a profile of 440/521 nm, but has a broad excitation so 470 nm 
was used for two distinct channels. Sample preparation was replicated from the previous 
protocol, but the complex treatment potency was reduced to 25 µM for 2 hours to avoid 
mass cell death with few intact membranes in place. The complex solution was removed 
and cells thoroughly washed with PBS before and after 15 minutes DAPI incubation, prior to 
imaging of the two channels (Figure 3.19). 
 
   
Figure 3.19 – (A) DAPI nuclear staining (blue) (B) Ru(tpphz) 1 staining (red) (C) overlay 
 
Whilst there is mainly nuclear staining from DAPI, as intended, it can be seen from the 
overlap that Ru(tpphz) 1 does stain the nucleus but is not as exclusive as general 
cytoplasmic fluorescence is also observed. 
The occurrence of the contrasting characteristics of cell death within single experiments 
shows the complexity of assigning only one mode of cell death, but oncosis seems the most 
likely cause for the majority of cell death. To gain a more detailed insight into the 
mechanistic characteristics, a proteomic approach was employed. 
  
A B C 
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3.4  Proteomic Studies 
 
To investigate the mechanism of cell death in more detail, a comparison of the protein 
expression levels between treated and untreated cells was carried out. Rather than analyse 
the presence of specific proteins through immunoblotting techniques, a whole proteome 
approach was adopted. This was carried out using the Stable Isotope Labelling by Amino 
Acids in Cell Culture (SILAC) methodology to analyse the ratio of peptides from untreated 
and treated samples (full protocol found in Experimental Section 6.6). 
The basis of this technique involves running two parallel cell cultures in identical conditions, 
with one culture having cells labelled with heavy amino acids incorporated from specially 
formulated media in subculture (RPMI 1640 R10K8 containing L-Arginine 13C6, 
15N4 
hydrochloride and L-lysine-13C6,
15N2 hydrochloride, sourced from Dundee Cell Products with 
full formulation in Experimental Section 6.6.1), and the other culture continuing in media 
without any labelling. After subjecting the two cultures to different experimental conditions, 
two cell lysates can be generated and combined in a 1:1 ratio before purification by SDS-
PAGE. A series of steps are then employed to digest the peptides before a mass 
spectrometry analysis in which pairs of signals can be detected when they have the correct 
difference in mass between regular and labelled peptides. Since the same peptide structure 
is responsible for both signals but originates from the differing cell cultures, the ratio of 
specific [labelled/unlabelled] peptide concentrations in the two populations can be 
determined. In this case the two populations were untreated and treated cultures, so 
individual peptide ratios reveal, up- or down-regulation of specific proteins after treatment 
with a complex. 
One valuable resource on the key analytical technique behind this approach – that is 
peptide sequencing by mass spectrometry – is a recent review by Steen and Mann, which 
includes a summary of the SILAC methodology and a schematic illustrating the process 
which can be seen below (Figure 3.20).14 
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Figure 3.20 – Schematic of SILAC peptide sequencing from the review by Steen and Mann14 
 
Many options are available in the processing of raw data, but the search engine software 
Mascot was used to assign to protein structures using the latest databases. The list of 
proteins, complete with light-heavy ratio, was then filtered through specific criteria using 
the Pegasus program to reveal statistically significant hits (Experimental Section 6.6.6). 
First, the mononuclear complex Ru(tpphz) 1 was investigated, after treatment with the 
previously determined specific complex/cell line IC50 concentration of 4.4 µM for 48 hours, 
provoking approximately half of the cell population to respond to the toxic effects of the 
complex. After cell lysis, protein content determination, normalisation, purification, in gel 
digest, analysis and data processing, the list of generated proteins and their corresponding 
up-regulation factors (that is the ratio of expression between untreated and treated 
populations) is shown below, with the summary included from the open access resource for 











3.6 Promotes endocytosis, possesses opsonic properties and influences 






2.8 RNA-binding factor that recruits target transcripts to cytoplasmic 
protein-RNA complexes (mRNPs). This transcript 'caging' into 
mRNPs allows mRNA transport and transient storage. It also 
modulates the rate and location at which target transcripts 
encounter the translational apparatus and shields them from 




2.7 Actins are highly conserved proteins that are involved in various 






2.4 Microtubule-associated protein that mediates aggregation of 
mitochondria resulting in cell death and genomic destruction 
(MAGD). Plays a role in anchoring the microtubule organizing 
center to the centrosomes. Binds to DNA. Plays a role in apoptosis. 
Involved in the formation of microtubule bundles (By similarity). 
Heme oxygenase 1 
(P09601) 
2.4 Heme oxygenase cleaves the heme ring at the alpha methene 
bridge to form biliverdin. Biliverdin is subsequently converted to 
bilirubin by biliverdin reductase. Exhibits cytoprotective effects 
since excess of free heme sensitizes cells to undergo apoptosis. 
Vimentin 
(P08670) 
2.3 Vimentins are class-III intermediate filaments found in various non-
epithelial cells, especially mesenchymal cells. Vimentin is attached 
to the nucleus, endoplasmic reticulum, and mitochondria, either 




2.3 Part of the AP-3 complex, an adaptor-related complex which is not 
clathrin-associated. The complex is associated with the Golgi region 
as well as more peripheral structures. It facilitates the budding of 
vesicles from the Golgi membrane and may be directly involved in 
trafficking to lysosomes. In concert with the BLOC-1 complex, AP-3 
is required to target cargos into vesicles assembled at cell bodies 
for delivery into neurites and nerve terminals. 
AP2-associated 
protein kinase 1 
(Q2M2I8) 
2.2 Regulates clathrin-mediated endocytosis by phosphorylating the 
AP2M1/mu2 subunit of the adaptor protein complex 2 (AP-2) 
which ensures high affinity binding of AP-2 to cargo membrane 
proteins during the initial stages of endocytosis. Isoform 1 and 
2 display similar levels of kinase activity towards AP2M1. Regulates 
phosphorylation of other AP-2 subunits, AP-2 localization and AP-2-
mediated internalization of ligand complexes. Phosphorylates 
NUMB and regulates its cellular localization, promoting NUMB 
localization to endosomes. Binds to/stabilizes activated form of 






2.2 Guanine-nucleotide releasing factor that promotes the exchange of 
Ran-bound GDP by GTP. Involved in the regulation of onset of 
chromosome condensation in the S phase. Binds both to the 
nucleosomes and double-stranded DNA. RCC1-Ran complex 
(together with other proteins) acts as a component of a signal 
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transmission pathway that detects unreplicated DNA. Plays a key 





2.2 Defines endoplasmic reticulum exit sites (ERES) and is required for 
secretory cargo traffic from the endoplasmic reticulum to the Golgi 
apparatus. SAR1A-GTP-dependent assembly of SEC16A on the ER 
membrane forms an organized scaffold defining an ERES. Required 






2.1 May help direct the assembly of the nuclear lamina and thereby 
help maintain the structural organization of the nuclear envelope. 
Possible receptor for attachment of lamin filaments to the inner 
nuclear membrane. May be involved in the control of initiation of 
DNA replication through its interaction with NAKAP95. 
Thymopoietin (TP) and Thymopentin (TP5) may play a role in T-cell 





2.1 Transcriptional coactivator involved in neuroepithelial stem cell 
differentiation and neurogenesis. Involved in particular in lens 
epithelial cell gene regulation and stress responses. May play an 
important role in lens epithelial to fiber cell terminal 
differentiation. May play a protective role during stress-induced 
apoptosis. Isoform 2 is a more general and stronger transcriptional 
coactivator. Isoform 2 may also act as an adapter to coordinate 




2.0 Cellular uptake of iron occurs via receptor-mediated endocytosis of 
ligand-occupied transferrin receptor into specialized endosomes. 
Endosomal acidification leads to iron release. The apotransferrin-
receptor complex is then recycled to the cell surface with a return 
to neutral pH and the concomitant loss of affinity of apotransferrin 
for its receptor. Transferrin receptor is necessary for development 
of erythrocytes and the nervous system (By similarity). A second 
ligand, the heditary hemochromatosis protein HFE, competes for 
binding with transferrin for an overlapping C-terminal binding site. 








1.9 Component of the COPII coat, that covers ER-derived vesicles 
involved in transport from the endoplasmic reticulum to the Golgi 
apparatus. COPII acts in the cytoplasm to promote the transport of 
secretory, plasma membrane, and vacuolar proteins from the 
endoplasmic reticulum to the Golgi complex. 
Plasminogen 
activator inhibitor 1 
RNA-binding protein 
(Q8NC51) 
1.9 May play a role in the regulation of mRNA stability. Binds to the 3'-
most 134 nt of the SERPINE1/PAI1 mRNA, a region which confers 





1.9 Required for the binding of mRNA to ribosomes. Functions in close 
association with EIF4-F and EIF4-A. Binds near the 5'-terminal cap 
of mRNA in presence of EIF-4F and ATP. Promotes the ATPase 
activity and the ATP-dependent RNA unwinding activity of both 




1.9 Variant histone H2A which replaces conventional H2A in a subset of 
nucleosomes. Nucleosomes wrap and compact DNA into 
chromatin, limiting DNA accessibility to the cellular machineries 
which require DNA as a template. Histones thereby play a central 
role in transcription regulation, DNA repair, DNA replication and 
chromosomal stability. DNA accessibility is regulated via a complex 
set of post-translational modifications of histones, and nucleosome 
remodelling. Required for checkpoint-mediated arrest of cell cycle 
progression in response to low doses of ionizing radiation and for 
efficient repair of DNA double strand breaks (DSBs) specifically 
when modified by C-terminal phosphorylation. 
Brefeldin A-inhibited 
guanine nucleotide-
exchange protein 1 
(Q9Y6D6) 
1.9 Promotes guanine-nucleotide exchange on ARF1 and ARF3. 
Promotes the activation of ARF1/ARF3 through replacement of 
GDP with GTP. Involved in vesicular trafficking. Required for the 
maintenance of Golgi structure; the function may be independent 
of its GEF activity. Required for the maturation of integrin beta-1 
in the Golgi. Involved in the establishment and persistence of cell 
polarity during directed cell movement in wound healing. Proposed 
to act as A kinase-anchoring protein (AKAP) and may mediate 
crosstalk between Arf and PKA pathways. Inhibits GAP activity of 
MYO9B probably through competitive RhoA binding. The function 
in the nucleus remains to be determined. 
DNA-directed RNA 
polymerase I subunit 
RPA1 
(O95602) 
1.9 DNA-dependent RNA polymerase catalyzes the transcription of 
DNA into RNA using the four ribonucleoside triphosphates as 
substrates. Largest and catalytic core component of RNA 
polymerase I. Forms the polymerase active center together with 
the second largest subunit. A single stranded DNA template strand 
of the promoter is positioned within the central active site cleft of 
Pol I. A bridging helix emanates from RPA1 and crosses the cleft 
near the catalytic site and is thought to promote translocation of 
Pol I by acting as a ratchet that moves the RNA-DNA hybrid through 
the active site by switching from straight to bent conformations at 




1.9 Core histone-binding subunit that may target chromatin assembly 
factors, chromatin remodelling factors and histone deacetylases 
to their histone substrates in a manner that is regulated by 
nucleosomal DNA. Component of several complexes which regulate 
chromatin metabolism. These include the chromatin assembly 
factor 1 (CAF-1) complex, which is required for chromatin assembly 
following DNA replication and DNA repair; the core histone 
deacetylase (HDAC) complex, which promotes histone 
deacetylation and consequent transcriptional repression; the 
nucleosome remodelling and histone deacetylase complex (the 
NuRD complex), which promotes transcriptional repression by 
histone deacetylation and nucleosome remodelling; the 
PRC2/EED-EZH2 complex, which promotes repression of homeotic 
genes during development; and the NURF (nucleosome 







Figure 3.21 – Table of up-regulated proteins upon treatment with Ru(tpphz) 1 
 
This approach generated a considerable amount of data and the 25 hits above are a result of 
the following criteria: light/heavy ratio >1.8, number of detected peptides >1, light/heavy 
pair count >1, light/heavy variability between separate pairs <30%. This excluded the 
majority of the data set which contained many instances of peptides appearing only once, 
which may be relevant but cannot be relied upon. It is very difficult to analyse each up-
regulated protein in isolation as everything is part of a vastly complex system intrinsically 
linked, but instead general observations of the types of proteins affected can be made. 
After treatment with the complex Ru(tpphz) 1, there are several proteins being up-regulated 
that are associated with cytoskeletal components - Beta-actin-like protein 2 (2.7), 
Microtubule-associated protein 1S (2.4), Vimentin (2.3) and Lamina-associated polypeptide 
2 (2.1). Also there is a response from several proteins with membrane functions, in 
particular a common theme of endocytic relations – Alpha-2-HS-glycoprotein (3.6), AP-3 
complex subunit delta-1 (2.3), AP2-associated protein kinase 1 (2.2), Protein transport 
protein Sec16A (2.2), Transferrin receptor protein 1 (2.0) and Protein transport protein 
Sec24C (1.9). Another cluster is proteins with nuclear or RNA function – Insulin-like growth 
factor 2 mRNA-binding protein (2.8), Regulator of chromosome condensation (2.2), DNA-
directed RNA polymerase I (1.9), Plasminogen activator inhibitor 1 RNA-binding protein (1.9) 
Ras GTPase-
activating protein-
binding protein 2 
(Q9UN86) 




1.8 Component of the proteolytic cascade acting downstream of the 
26S proteasome in the ubiquitin-proteasome pathway. May be able 
to complement the 26S proteasome function to some extent under 






1.8 Acts as component of the MCM2-7 complex (MCM complex) which 
is the putative replicative helicase essential for 'once per cell cycle' 
DNA replication initiation and elongation in eukaryotic cells. The 
active ATPase sites in the MCM2-7 ring are formed through the 
interaction surfaces of two neighbouring subunits such that a 
critical structure of a conserved arginine finger motif is provided in 
trans relative to the ATP-binding site of the Walker A box of the 
adjacent subunit. The six ATPase active sites, however, are likely to 
contribute differentially to the complex helicase activity. 
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and Eukaryotic translation initiation factor 4B (1.9). These findings imply that three of the 
key cellular functions affected upon treatment are the cells motility, membrane trafficking 
and transcriptional processes. 
One interesting hit not grouped into the generalisations above is the up-regulation of the 
enzyme heme oxygenase 1 (2.4) which is responsible for the degradation of heme to form 
biliverdin, iron and carbon monoxide.16 There are three isoforms and expression of this form 
appears to be induced as a protective response to oxidative stress as biliverdin and bilirubin 
have antioxidant properties.16 An excess of free heme is also a sensitizer for apoptosis so 
up-regulation of this protein could also be a preventative measure against this effect. 
Histone H2AX – a marker for DNA double strand breaks – is up-regulated by a factor of 1.9, 
indicating that this specific type of DNA damage is involved in the cytotoxicity of Ru(tpphz) 
1; this observation indicates DNA is indeed one of the intracellular targets of the complex. 
Histone-binding protein RBBP4 is also up-regulated and this could be due to the increased 
need for chromatin assembly following DNA repair attempts. 
As well as the positive results of what is directly observed, any key omissions of conceivable 
proteins should also be considered and here there is a distinct lack of apoptosis associated 
caspase proteins. Whilst wary of drawing conclusions from possible false negative results, 
there is statistical reassurance in this case as there are numerous members in this family of 
proteins and none show up, which supports the observations from microscopy that oncosis 
is the dominant mode of cell death. 
A pictorial overview of the general observations of which cell processes are affected can be 
obtained from a pie chart whereby the 25 up-regulated proteins have been grouped into 




Figure 3.22 – Pie chart showing the associations of the up-regulated proteins with cellular 
function upon treatment with Ru(tpphz) 1 (4.4 µM, 48 hours) 
 
These are still, however, relatively broad conclusions and more specific outcomes that were 
originally envisioned have not been realised from one experimental run – repeating the 
procedure would offer validation. 
With the aim of gaining insight from comparing and contrasting the data of another complex 
treatment, Ru(taptp) was analysed using the same protocol for peptide sequencing. The 
lysate had been previously generated in the same SILAC experiment as Ru(tpphz) 1, after 
treatment with the previously determined IC50 concentration specific to Ru(taptp) 2 (13.2 
µM) for 48 hours; and the purification by SDS-PAGE had also been run simultaneously. The 
results, after processing of the raw data by Mascot and filtering by the previously used 



















35.7 Neurotrophic protein; induces extensive neuronal differentiation in 
retinoblastoma cells. Potent inhibitor of angiogenesis. 
High mobility group 
protein B2 
(P26583) 
3.3 DNA binding proteins that associates with chromatin and has the 
ability to bend DNA. Binds preferentially single-stranded DNA. 
Involved in V(D)J recombination by acting as a cofactor of the RAG 
complex. 
NHL repeat-







2.3 Transcriptional coactivator involved in neuroepithelial stem cell 
differentiation and neurogenesis. Involved in particular in lens 
epithelial cell gene regulation and stress responses. May play an 
important role in lens epithelial to fiber cell terminal 




2.2 Vimentins are class-III intermediate filaments found in various non-
epithelial cells, especially mesenchymal cells. Vimentin is attached 
to the nucleus, endoplasmic reticulum, and mitochondria, either 





2.0 May be involved in the structural organization of the nucleus and in 
the post-mitotic nuclear assembly. Plays an important role, 









1.9 Serves as the first electron transfer protein in all the 
mitochondrial P450 systems. 
Cell division control 
protein 42 homolog 
(P60953) 
1.9 Plasma membrane-associated small GTPase which cycles between 
an active GTP-bound and an inactive GDP-bound state. In active 
state binds to a variety of effector proteins to regulate cellular 
responses. Regulates bipolar attachment of spindle microtubules to 
kinetochores before metaphase chromosome congression. Plays a 
role in extension and maintenance of the formation of the thin, 
actin-rich surface projections filopodia. Mediates CDC42-
dependent cell migration. 
Insulin-like growth 
factor 2 mRNA-
binding protein 3 
(O00425) 
1.9 RNA-binding factor that may recruits target transcripts to 
cytoplasmic protein-RNA complexes (mRNPs). This transcript 
'caging' into mRNPs allows mRNA transport and transient storage. 
It also modulates the rate and location at which target transcripts 
encounter the translational apparatus and shields them from 
endonuclease attacks or microRNA-mediated degradation. Binds to 
the 3'-UTR of CD44 mRNA and stabilizes it, promoting cell adhesion 
and invadopodia formation in cancer cells. Binds to beta-
actin/ACTB and MYC transcripts. Binds to the 5'-UTR of the insulin-




1.9 Involved in the base excision repair (BER) pathway, by catalyzing 
the poly(ADP-ribosyl)ation of a limited number of acceptor proteins 
involved in chromatin architecture and in DNA metabolism. This 
modification follows DNA damages and appears as an obligatory 
step in a detection/signalling pathway leading to the reparation of 
DNA strand breaks. Mediates the poly(ADP-ribosyl)ation of APLF 
and CHFR. Positively regulates the transcription of MTUS1 and 
negatively regulates the transcription of MTUS2/TIP150. With 
EEF1A1 and TXK, forms a complex that acts as a T-helper 1 (Th1) 
cell-specific transcription factor and binds the promoter of IFN-
gamma to directly regulate its transcription, and is thus involved 
importantly in Th1 cytokine production. Required for PARP9 and 
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Figure 3.23 – Table of up-regulated proteins upon treatment with Ru(taptp) 2 
 
Again the generated proteins form an interesting set of results, with some up-regulated 
proteins common to both Ru(tpphz) 1 and Ru(taptp) 2 treatments, albeit having fewer 
reliable hits from this experiment (13 versus 25). 
There are fewer up-regulated proteins associated with cytoskeletal functions, but vimentin 
still features at a similar factor of increased expression (2.2). Out of the proteins associated 
with membrane functions in the previous data set, none are seen here, but there was an up-
regulation of the membrane-based cell division control protein 42 homolog (1.9) detected. 
Most of the up-regulated proteins are related to nuclear or RNA functions, with several 
common to the Ru(tpphz) 1 analysis - high mobility group protein B2 (3.3), PC4 and SFRS1-
interacting protein (2.3), lamina-associated polypeptide 2 isoform alpha (2.0), Insulin-like 
growth factor 2 mRNA-binding protein 3 (1.9), Poly [ADP-ribose] polymerase 1 (1.9) and 
Prelamin-A/C (1.8). Of particular interest is Poly [ADP-ribose] polymerase 1. This enzyme is 
involved in base excision repair particularly of small, non-helix distorting lesions (rather than 
the related nucleotide excision repair pathway which is activated by large helix distorting 
lesions),17 indicating intracellular DNA binding is involved in the cytotoxicity of Ru(taptp) 2. 
The remaining hits consist of two proteins related to mitochondrial function - 
NADPH:adrenodoxin oxidoreductase, mitochondrial (1.9) and very long-chain specific acyl-
CoA dehydrogenase, mitochondrial (1.8) – and several ambiguous results that do not draw 
on a specific function. The greatest up-regulation by far in this data set is for the pigment 
DTX3L recruitment to DNA damage sites. PARP1-dependent PARP9-
DTX3L-mediated ubiquitination promotes the rapid and specific 




1.8 Prelamin-A/C can accelerate smooth muscle cell senescence. It acts 
to disrupt mitosis and induce DNA damage in vascular smooth 
muscle cells (VSMCs), leading to mitotic failure, genomic instability, 






1.8 This protein is involved in the pathway mitochondrial fatty acid 
beta-oxidation, which is part of Lipid metabolism. 
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epithelium-derived factor(35.7), but information on this protein relates to physiological 
rather than cellular functions. 
Once again, there is no instance of caspase up-regulation, which indicates a lack of 
apoptosis occurring and is in agreement with the microscopy studies conducted. 
The grouping of protein function implies the localisation and effects of the complex are 
nuclear, with cellular functions such as mitochondrial processes and cell motility affected to 
a degree but not in a widespread profile such as Ru(tpphz) 1; which is more toxic. 
The general observation of which cell processes are affected can be summarised in the 
following pie chart featuring the 13 up-regulated proteins grouped into broad categories of 
association with nucleic acid, cytoskeletal, membrane or other functions (Figure 3.24). 
 
Figure 3.24 – Pie chart showing the associations of the up-regulated proteins with cellular 
















3.5  Summary 
 
In conclusion, complexes 1 – 4 display a range of toxicities and furthermore cross-resistance 
profiles for the two A2780 and A2780cis cell lines vary for each complex. The most cytotoxic 
was the mononuclear complex Ru(tpphz) 1 which is as potent as cisplatin but displays 
minimal cross-resistance. Ru(taptp) 2 is not as toxic against A2780 but interestingly shows 
an increase in toxicity against A2780cis. In contrast RuRe 3 is relatively potent against A2780 
cells but exhibits a resistance profile similar to cisplatin. The relatively low cytotoxicity of 
RuRe 3 and RuPt 4 against A2780cis, suggests that the addition of a second metal centre 
offers no improvement in cytotoxic activity. 
Microscopy experiments revealed that the mode of cell death after treatment with all 
complexes is via possible oncosis but with a varying magnitude of cell swelling for each 
complex treatment and also, in addition, a notable minority of cells dying with a net 
decrease in size. The staining occurs throughout the cell and nucleus and the majority of 
fluorescence is seen in the later stages of cell death. 
Proteomic analysis of cells treated with complexes Ru(tpphz) 1 and Ru(taptp) 2 provided a 
wide array of information. Although it is difficult to narrow down any direct relationship 
between changes in the proteome and the complexes’ action, cell processes that appear to 
be affected include cytoskeletal and membrane function and in particular DNA processing. 
Furthermore, indications of direct DNA strand damage, along with the absence of apoptosis 
associated expression, are in agreement with the microscopy observations of likely oncosis.  
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Previous work on rhenium-based complexes has shown that they can produce photo-
activated DNA damage; a notable example being a Re(dppz) “DNA scissor” system with the 
formula [Re(CO)3(py)(L)](OTf) (py = pyridine, OTf = trifluoromethanesulfonate counterion) 
where L is one of the planar aromatic ligands dipyridophenazine (dppz) or 




Figure 4.1 – DNA scissor molecule Re(CO)3(py)(L) (py = pyridine, A: L = dppz, B: L = dppn) 
 
Emission-based titration studies by Yam, et al. on the Re(dppz) and Re(dppn) complexes 
(Figure 4.1) showed they associate with CT-DNA through intercalation.1  Irradiation of the 
complexes in the presence of the plasmid DNA pBR322 resulted in cleavage of the 
supercoiled form (I) to the nicked form (II). Surprisingly, these studies indicated that for both 
of the complexes, singlet oxygen was not involved in the cleavage process. For the dppz 
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species A, direct oxidation of DNA plasmid by the excited state of the molecule was 
implicated. For the dppn species B, inhibition of cleavage in a degassed solution or through 
the presence of an appropriate quencher indicated that the superoxide radical (O2
•-) was 
involved in this process; although the hydroxyl radical (•OH) was likewise implicated as 
decreased cleavage activity was also observed in the presence of hydroxyl scavengers.2 
At the same time, studies carried out by Stoeffler, et al. with a methylpyridine derivative of 
Re(dppz) A investigated the photophysics with and without DNA.3 They concluded that the 
lowest excited state was an intraligand triplet state of dppz, 3ILdppz, with luminescence 
quenched in aqueous solution but present when protected by intercalation in DNA. The 
difference between this species and Ru(II) or Os(II) analogues is a result of the metal to 
ligand charge transfer states, dπ (M) → π* (dppz) 3MLCT, being higher in energy in the Re(I) 
species which allows the low lying intraligand 3ILdppz excited state to dominate the system. 
Given the activity of these rhenium-based complexes, the ruthenium-rhenium complex 
RuRe 3 was investigated to see if it too displayed similar properties. The long-term aim of 
investigating the phototoxic activity of such complexes is towards identifying 
photosensitizers for photodynamic therapy (PDT) applications. PDT is a non-invasive therapy 
regime that can selectively damage diseased tissue through the generation of singlet 
oxygen. This is often achieved by the prodrug sensitizer generating cytotoxic singlet oxygen 
in situ upon photoexcitation through an energy transfer mechanism. The selectivity 
originates from carefully targeted irradiation and offers improvements over orthodox 
therapeutic regimes by reducing side-effects in unaffected tissue.4 
Photosensitisers currently most commonly used in the clinic are tetrapyrrolic structures, but 
- as extended aromatic systems - they can have low water solubility and are often hard to 
synthesise and purify.5 In contrast, the chloride salts of ruthenium polypyridyl complexes 
frequently exhibit very high water solubility and are relatively easy to synthesize, so offering 
an improvement over conventional systems if other characteristics are suitable for this 
application. 
A comparative measure of phototoxic activity for a molecule is the phototoxic index (PI) 
which can be calculated from the dark IC50 divided by the light IC50 – giving a score of the 
increased toxicity under the action of light. An example of the use of this Figure of Merit is 
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given in the study by Howerton, et al., which involves strained ruthenium complexes as 





Phototoxicity Index, PI 
Cell line 
HL60 AS49 AS49 spheroid 
1 3 6 >7.5 
2 >188 136 19 
3 42 208 54 
 
Figure 4.2 – Data collected by Howerton et al. on strained ruthenium complex phototoxicity6  
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4.1.2 Light Irradiation Source Apparatus 
 
The apparatus used to irradiate the sample was a custom made device featuring a 
broadband illumination source (technical specification in Experimental 6.x), fully contained 
in an empty computer base unit, which is referred to as the Light Irradiation Source 
Apparatus (LISA). 
To quantify the power output of this light source, an experiment was carried out with the 
running conditions replicated whilst being monitoring by a power meter. The setup utilised 
was a THORLABS S175C sensor coupled to a PM100USB Power and Energy Meter with the 
readout displayed and stored on a connected netbook. Running three timed periods of 
irradiation in succession within experimental conditions (for three separate samples) 




























































Time (minutes) 2 5 2 15 2 30 
Average Power (W) 0.000 0.075 0.035 0.121 0.040 0.126 
Corrected Power (W) - 0.075 - 0.085 - 0.086 
Energy (J) - 22.6 - 76.9 - 155.7 
Fluence (J cm-2) - 8 - 24 - 48 
 
Figure 4.3 – Table summarising the fluence calculations from timed irradiations 
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4.1.3 Protocol Optimisation 
 
The same protocol as that for the 48 hour IC50 determination was initially used 
(Experimental Section 6.5.4) but four separate plates were employed, and after 24 hours, 
each was irradiated for a varying length of time. Three plates underwent timed exposures in 
the LISA while a dark control remained in the incubator throughout. The dark control was 
essential to provide a comparison in assessing any phototoxicity upon irradiation. Untreated 
control wells served the usual purpose of delineating maximum cell viability. Furthermore, 
not only could they be used to construct curves indicating any effect of increasing 
compound concentration on cell viability, but - through inclusion in each plate 
independently - they also acted as a control for any damaging effects of the radiation alone. 
This ensured the experiment was internally controlled for each variable and avoided any 
false positive results in which increased exposure to the irradiation increased toxicity 
regardless of compound treatment. 
The compound used first was RuRe 3 which had been predicted to exhibit activity, with a 
broad concentration range of 1-200 μM - spanning either side of the previously determined 
IC50 value (28 μM). Early experimentation used only a 20 minute exposure with no dark 
control, but this protocol showed no significant difference in potency, with an IC50 value of 
33 μM being comparable to the previous dark average within error. 
Following this result, experimentation with a macrocyclic molecule which had previously 
shown phototoxic activity resulted in optimisation of the protocol – vide infra. This 
procedure involved a dark control plus three independent plates exposed to light intervals 
of 1, 2.5 and 5 minutes.  
In the initial procedure, after irradiation, the cells were exposed to the complex for 24 
hours. To discount the possible deleterious effect of long term exposure to the complex in 
the dark a different sequence was carried out in which, prior to irradiation, the complex 
containing solution was replaced by media alone followed by 24 hour incubation between 
irradiation and workup by MTT assay. This step was incorporated with the aim of clarifying 
the effects of irradiation upon cells that already contained the compound. This experiment, 
however, still did not reveal significant differences in cell viability on increasing irradiation. 
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Therefore the experiment was run again with an extended periods of light exposure of 5, 15 
and 30 minutes respectively. In these conditions toxicity that correlated with increasing 
irradiation was observed, i.e. there is some phototoxic effect. 
In this successful phototoxicity assay two further observations were made. Under the 
updated conditions, as might be expected, the cells showed a slightly increased 
susceptibility to radiative damage over the 3 timed exposures, however this factor was 
internally controlled through the use of separate plates. The susceptibility to radiative 
damage is quantified by calculating the relative viability of untreated exposed wells against 
the untreated dark control, using a standard MTT assay. An example is provided by the first 
5-15-30 minute experiment. In this case, the 5, 15 and 30 minute control well viabilities 
show a somewhat surprising trend, as they are equal to 133%, 109% and 89% of the dark 
control respectively. The fact that the 5 and 15 minute exposures actually exhibit an 
increase in viability can probably be attributed to the slight increase in temperature that the 
cells are subjected to in the LISA, resulting in increased metabolic activity in the cells, as 
detected by the MTT assay, before the separate deleterious effect of radiative damage 
becomes detrimental overall (as seen by the 30 minute exposure having a relative viability 
of 89%). Again, the effect of this factor on the overall data is mitigated through the 
experiment being internally controlled within each separately exposed plate. This optimised 




4.2  RuRe and RuPt molecules 
 
Using the optimized phototoxicity protocol (described above and in Experimental Section 
6.5.5), the activity of RuRe 3 against the cell line A2780cis was investigated using a 
concentration range of 1 – 200 µM, resulting in a phototoxic effect shown in Figure 4.4. 
 
Concentration of RuRe 3 (log10 M)




















A2780cis treated with RuRe 3, 0 J cm-2
A2780cis treated with RuRe 3, 8 J cm-2
A2780cis treated with RuRe 3, 24 J cm-2
A2780cis treated with RuRe 3, 48 J cm-2
3 parameter sigmoidal fit (R2 = 0.9988)
3 parameter sigmoidal fit (R2 = 0.9996)
3 parameter sigmoidal fit (R2 = 0.9994)
3 parameter sigmoidal fit (R2 = 0.9917)
 
Fluence IC50 concentration Percentage Viability at 10 μM RuRe 
(J cm-2) (μM) (% cells metabolising MTT +/- 1 SD) 
0 18 70 +/- 9 
8 18 72 +/- 5 
24 9 48 +/- 6 
48 3 12 +/- 7 
 
Figure 4.4 – A2780cis cell viability data for RuRe 3 upon irradiation 
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Using the same protocol, the activity of RuPt 4 against A2780cis was also investigated using 
a 1 – 200 µM concentration range (Figure 4.5). This produced contrasting results, as there 
was a smaller phototoxic effect: an observed PI of 2 compared to the RuRe 3 PI of 6. Taking 
the general trend from these experiments, it seems clear that the rhenium centre does have 
an effect on the phototoxic activity of the final system. 
 
Concentration of RuPt 4 (log10 M)




















A2780cis treated with RuPt 4, 0 J cm-2
A2780cis treated with RuPt 4, 8 J cm-2
A2780cis treated with RuPt 4, 24 J cm-2
A2780cis treated with RuPt 4, 48 J cm-2
3 parameter sigmoidal fit (R2 = 0.9883)
3 parameter sigmoidal fit (R2 = 0.9808)
3 parameter sigmoidal fit (R2 = 0.9917)




Percentage Viability at 100 μM RuPt 
(J cm-2) (μM) (% cells metabolising MTT +/- 1 SD) 
0 100 50 +/- 3 
8 86 49 +/- 2 
24 148 58 +/- 3 
48 46 44 +/- 0.1 
 
Figure 4.5 – A2780cis cell viability data for RuPt 4 upon irradiation  
 117 
4.3  RuRe bis-intercalator 
 
To further explore the phototoxicity of ruthenium-rhenium systems an alternative complex 
synthesized by Mr Hiwa Saeed, a fellow member of the Thomas group, was studied. The 




Figure 4.6 – Structure of RuRe bis-intercalator 5 
 
The DNA binding properties of this complex have previously been investigated and it is 
known to demonstrate a high DNA binding affinity to CT-DNA in cell-free conditions.7 
First, using a concentration range of 0.1 – 200 µM, the 48 hour IC50 value of the complex 
was determined to assess its potency against the A2780 and A2780cis cell lines (Figure 4.7). 
Against the A2780 cell line, the IC50 was determined as 11 μM, which is not as potent as 
cisplatin (ca. 2 μM) but still relatively active in therapeutic terms and compared to the series 
of compounds 1 – 4. Against A2780cis, the IC50 of 21 μM shows a two-fold reduction in 
potency versus A2780, but this is still at a similar level of cytotoxicity as cisplatin against this 
cell line (ca. 22 μM).  
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Concentration of RuRe 5 (log10 M)




















A2780 treated with RuRe 5
A2780cis treated with RuRe 5
3 parameter sigmoidal fit (R2 = 0.9946)








Figure 4.7 – Cell viability data for RuRe bis-intercalator 5 
 
The same phototoxicity protocol used for RuRe 3 and RuPt 4 and the A2780cis cell line was 
then carried out with RuRe 5 using a concentration range of 1 – 200 μM (Figure 4.8). 
Complex RuRe 5 demonstrates some phototoxicity against A2780cis but to a much lesser 
degree than RuRe 3 (PI = 2).  
 119 
Concentration of RuRe 5 (log10 M)





















A2780cis treated with RuRe 5, 0 J cm-2
A2780cis treated with RuRe 5, 8 J cm-2
A2780cis treated with RuRe 5, 24 J cm-2
A2780cis treated with RuRe 5, 48 J cm-2
3 parameter sigmoidal fit (R2 = 0.9836)
3 parameter sigmoidal fit (R2 = 0.9868)
3 parameter sigmoidal fit (R2 = 0.9763)
3 parameter sigmoidal fit (R2 = 0.9819)
 
Fluence IC50 concentration Percentage Viability at 100 μM [M] 
(J cm-2) (μM) (% cells metabolising MTT +/- 1 SD) 
0 110 53 +/- 2  
8 83 48 +/- 5 
24 56 42 +/- 4 
48 56 37 +/- 4 
 
Figure 4.8 – A2780cis cell viability data for RuRe 5 upon irradiation 
 
Therefore, with a modest phototoxic index, RuRe 5 is not a favourable lead for applications 
based on this characteristic. This could be due to lower oxygen sensitisation or due to poor 
cellular uptake; with this complex not being taken up so well as RuRe 3, resulting in a low 
intra-cellular concentration. Further substantial experimentation would be required to 
determine this issue further. 
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4.4  Macrocycle Investigation 
 
A further investigation of ruthenium-rhenium systems was facilitated through a study on the 
self-assembled macrocyclic molecule RuRe macrocycle 6A, and its corresponding ruthenium 
monomer “building block” 6B, synthesized by Dr. Mike Walker (Figure 4.9). The singlet 
oxygen quantum yield ф(1O2) of these two molecules had previously been determined by a 
collaborator Luke McKenzie in Weinstein group (protocol in Experimental 6.8). This data 
gave ф(1O2) estimates of 54 ±5% for RuRe macrocycle 6A and 75 ±2% for Ru monomer 6B, 




Figure 4.9 – Structure of RuRe macrocycle 6A, and corresponding Ru monomer unit 6B 
 121 
First, to determine the level of cytotoxicity relative to the other compounds studied, a 48 
hour IC50 protocol on both the A2780 and A2780cis cell lines was carried out in dark 
conditions using a macrocycle concentration range of 1 – 200 μM (Figure 4.10). Against the 
A2780 cell line, an IC50 of 2 μM was determined - a relatively high potency around the same 
magnitude as cisplatin. Interestingly, against the A2780cis cell line there was a considerable 
decrease in potency with an IC50 of 59 μM being observed. 
  
Concentration of RuRe 6A (log10 M)




















A2780 treated with RuRe 6A
A2780cis treated with RuRe 6A
3 parameter sigmoidal fit (R2 = 0.9751)
3 parameter sigmoidal fit (R2 = 0.9799)
 










Using a macrocycle concentration range of 0.1 - 50 μM, its phototoxicity against the A2780 
cell line was assessed (Figure 4.11). In these conditions the macrocycle did show phototoxic 
activity but, with treatment in the dark already producing a potent cyctotoxicity response, 
the increase in toxicity was modest. Despite this small degree of change in the IC50 value, at 
5 μM there is a distinct phototoxic effect as seen at log10(-5.3) in the graph below. 
 
Concentration of RuRe 6A (log10 M)




















A2780 treated with RuRe 6A, 0 J cm-2
A2780 treated with RuRe 6A, 8 J cm-2
A2780 treated with RuRe 6A, 24 J cm-2
A2780 treated with RuRe 6A, 48 J cm-2
3 parameter sigmoidal fit (R2 = 0.9985)
3 parameter sigmoidal fit (R2 = 0.9864)
3 parameter sigmoidal fit (R2 = 0.9982)
3 parameter sigmoidal fit (R2 = 0.9975)
 
Fluence RuRe macrocycle 6A IC50 Percentage Viability at 5 μM RuRe 6A 
(J cm-2) (μM) (% metabolising MTT +/- 1 SD) 
0 6 52 +/- 5  
8 4 46 +/- 3 
24 2 27 +/- 1 
48 2 10 +/- 2 
 
Figure 4.11 – A2780 cell viability data for RuRe macrocycle 6A upon irradiation 
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Apart from the promising phototoxic properties of the macrocycle against the A2780 cell 
line, the low level of classical cytotoxicity against A2780cis in the dark actually gave more 
reason to investigate phototoxicity with this cell line, as there is a large “toxicity window” in 
which the dark properties of the macrocycle could be improved upon. A concentration 
range of 0.1 - 50 μM (plus 100 and 200 µM samples for the dark control) of the macrocycle 
was tested on A2780 using the now established phototoxicity protocol (Figure 4.12). 
 
Concentration of RuRe 6A (log10 M)




















A2780cis treated with RuRe 6A, 0 J cm-2
A2780cis treated with RuRe 6A, 8 J cm-2
A2780cis treated with RuRe 6A, 24 J cm-2
A2780cis treated with RuRe 6A, 48 J cm-2
3 parameter sigmoidal fit (R2 = 0.9822)
3 parameter sigmoidal fit (R2 = 0.9997)
3 parameter sigmoidal fit (R2 = 0.9907)
3 parameter sigmoidal fit (R2 = 0.9775)
 
Fluence RuRe macrocycle 6A IC50 Percentage Viability at 10 μM RuRe 6A 
(J cm-2) (μM) (% cells metabolising MTT +/- 1 SD) 
0 58.9 63 +/- 8  
8 12.0 54 +/- 4 
24 2.2 16 +/- 6 
48 0.4 8 +/- 2 
 
Figure 4.12 – A2780cis cell viability data for RuRe macrocycle 6A upon irradiation 
 124 
This cell line showed a much more notable phototoxic response with a decrease in IC50 
values from 58.9 μM in the dark to 0.4 μM after an exposure of 48 J cm-2. This experiment 
was then repeated, but with a concentration range of 0.1 – 100 μM for both the macrocycle 
and the ruthenium monomer unit side by side. This experiment showed a noticeable 
difference in the activity between monomer and macrocycle, with the macrocycle at the 
higher concentrations becoming markedly more cytotoxic upon irradiation than the 
monomer – clearly indicating that the macrocycle is more phototoxic than the monomer. In 
addition to the differing IC50 values, the full extent of the contrasting phototoxicity can be 






































Fluence RuRe macrocycle 6A IC50 Ru monomer 6B IC50 
(J cm-2) (μM) (μM) 
0 58.7 >50 
8 8.7 >50 
24 1.2 30.2 
48 0.3 19.5 
 
Figure 4.13 – A2780cis cell viability data for RuRe 6A and Ru 6B upon irradiation 
 
This photoactivation by a low light dose indicates a promising photophysical profile for 
potential PDT applications. Metal directed self-assembly is a very active field of research and 
the interactions of various architectures with biomolecules have been investigated, for 
example the cage systems of the Therrien group have been used as delivery vectors for DNA 
probes and therapeutics including PDT sensitizers,8,9 and although the mechanisms are 
unknown, some metallocages have proven to be independently cytotoxic.10 That said, the 
RuRe macrocycle 6A is the first intrinsically phototoxic example of such architecture. 


































ReI mononuclear units are known to have rich photochemistry, but this is the first example 
of a PDT agent constructed by metal-directed self-assembly. 
To compare the intracellular accumulation between Ru macrocycle 6A and Ru monomer 6B, 
inductively coupled mass spectrometry (ICP-MS) analysis of metal content was used after 
treatment with 50 and 100 µM complex concentrations for 12 hours (Figure 4.14). 
 
 
Complex Intracellular metal concentration (mmol L-1) 
50 µM Ru monomer 6B 2.75E-02 
100 µM Ru monomer 6B 1.37E-01 
50 µM RuRe macrocycle 6A 1.80E-01 
100 µM RuRe macrocycle 6A 1.96E-01 
Control 4.50E-03 
 
Figure 4.14 - Intracellular metal content (ruthenium) data from ICP-MS analysis 
 
This intracellular metal concentration was calculated by taking the initial concentration of 
ruthenium in µg L-1 from the submitted sample and converting it to total number of moles 


































Intracellular ruthenium concentration of Ru 6B/RuRe 6A
 127 
of complex per sample; from the known volume, relative molecular mass of ruthenium and 
chemical structure of the complex. The number of moles could then be applied to the 
previously determined number of cells per sample and finally by using an estimated cell 
volume assumption of 2 x10-12 L the intracellular metal concentration could be obtained; 
presented above in the units of mmol L-1. 
From these data two key observations can be made, the first being the clearly increased 
intracellular accumulation of RuRe macrocycle 6A versus Ru monomer 6B at equivalent 
treatment concentrations by comparing both the 50 µM mono v macro and the 100 µM 
mono v macro pairing. Comparing the ruthenium concentration after treatment with 100 
µM Ru monomer 6B and 50 µM RuRe macrocycle 6A (the central 2 columns in Figure 4.14), 
reveals that even when the monomer concentration is double the treated concentration of 
the macrocycle it has still not reached the same intracellular accumulation. 
The second observation is that the difference in intracellular accumulation between the two 
complexes is much less at the 100 µM concentration (discrepancy of 0.059 mmol L -1, or the 
monomer accumulation is 70% that of the equivalent macrocycle) than the 50 µM 
concentration (discrepancy of 0.152 mmol L-1, and in contrast the monomer accumulation is 
only 15% that of the macrocycle).  This observation correlates with the trend in phototoxic 
activity where there is a greater contrast between monomer and macrocycle at 50 µM than 
100 µM; indeed after a 100 µM treatment with Ru monomer 6B appreciable phototoxic 










4.5  Summary 
 
The molecules that have been investigated for phototoxicity show a varied response which 
can be seen in the table summarising the dark IC50, light IC50 and phototoxic index (PI) of 
complexes 3-6 against the cell line A2780cis (Figure 4.14). 
 
Complex 
dark IC50 light IC50 
PI 
(µM) (µM) 
RuRe 3 18 3 6 
RuPt 4 100 46 2 
RuRe bis-intercalator 5 110 56 2 
RuRe macrocycle 6A 59 0.3 197 
 
Figure 4.15 – Table summarising the PI of complexes 3-6 
 
Although RuPt 4 and RuRe bis-intercalator 5 showed low light-dependant activity with a PI 
of 2, the ruthenium-rhenium complex RuRe 3 has a modest PI of 6, which nonetheless offers 
some promise as a lead for related compounds. The greatest phototoxicity with a PI of 197 
was observed for the RuRe macrocycle 6A which, at the highest dosage of light, far exceeds 
the toxicity of cisplatin against a cell line with increased resistance.   
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5.1  Conclusions 
 
By addressing the original aims of this project, the studies presented in this thesis have 
produced interesting results that span the interface of chemistry and cell biology. 
Originating in chemistry, the syntheses of complexes 1 – 4 were achieved and in vitro 
studies established that they were all capable of binding to DNA, which induced a light 
switch effect. This association occurs through different binding modes:  Ru(tpphz) 1 
intercalates between the base pairs whilst RuRe 3 is a groove binder; which is not surprising 
with the molecular shape of the rhenium unit deviating from a planar arrangement. These 
findings led to the hypothesis that DNA binding occurs in the cellular environment, although 
there could still be other intracellular targets in addition to or in place of DNA. 
The interdisciplinary nature of the investigation resulted in assays being conducted for 
anticancer activity and it found all complexes induce a cytotoxic response in the cisplatin 
sensitive/resistant model A2780/A2780cis cell line. The potency and cross-resistance 
profiles of the four complexes varied, with a clear series from most toxic to least toxic of 
Ru(tpphz) 1 > Ru(taptp) 2 > RuRe 3 > RuPt 4. The lack of cross-resistance between A2780 
and A2780cis (which usually shows 10 fold resistance against cisplatin) was apparent for 
both mononuclear complexes Ru(tpphz) 1 and Ru(taptp) 2. Time lapse microscopy 
experiments involving cells treated with the complexes revealed a likely oncotic mode of cell 
death. Notably widespread luminescence associated with DNA was only observed after this 
cell death pathway had significantly proceeded. A whole-proteome analysis employing SILAC 
techniques to investigate the expression response of the cell line A2780cis before and after 
treatment with complexes Ru(tpphz) 1 and Ru(taptp) 2 did not reveal any conclusive 
evidence of particular intracellular mechanisms although it did reveal a distinct lack of 
caspase up-regulation indicating that apoptosis can probably be ruled out. 
Toxicity studies were extended to investigate the light dependence of toxicity for complexes 
RuRe 3, RuPt 4, and two separately synthesised compounds RuRe bis-intercalator 5 and 
RuRe macrocycle 6A; after the protocol was optimised whilst examining the latter complex. 
This uncovered phototoxic activity in the complex RuRe 3, which although only modest (PI = 
6), was greater than that for RuPt 4 (PI = 2) and the potential bis-intercalator RuRe 5 (PI = 2). 
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In stark contrast the PI of macrocycle 6A was very high with an approximate 200-fold 
increase in cytotoxicity under the highest dose of light, which places it in a similar bracket to 
current photodynamic therapy agents. Further to this, the corresponding mononuclear 
ruthenium monomer 6B differed in activity and was much less potent, demonstrating an 
interesting contrast between monomer and macrocycle activity. 
Further work, described below, will increase the impact of the main focus of this study by 
elucidating much more mechanistic detail for the cytotoxic action of Ru(tpphz) 1 and 
Ru(taptp) 2 in particular. 
 
5.2  Future Work 
 
Despite considerable progress in discovery and development of targeted agents exploiting 
the molecular basis of cancer, such agents are less effective in more common solid tumours. 
Cytotoxic agents continue to be of major importance in treatment of many cancers. 
Platinum(Pt)-based drugs are currently the most used cancer therapeutics in certain 
settings. It is estimated that 50-70% of all cancer patients have been treated with a Pt-based 
drug. The cellular target of these drugs is DNA, with the complex forming guanine adducts. 
Patients often have a high initial response to Pt-based chemotherapy, but subsequently 
become refractory, and many die with progressive chemo-resistant disease. Inherent and 
acquired drug resistance, involving changes in ion transporter expression and alterations in 
the DNA damage response, is very common and alternative therapies to address this issue 
are urgently required.  
Metal coordination complexes can exhibit reactivity not possessed by either metal or 
organic ligands alone. Such reactivity may be fine-tuned by changes in properties of bound 
ligand or by variations in metal and oxidation state, and in the case of Ruthenium (Ru) which 
allows for more varied co-ordination geometries than Pt, provides a highly versatile 
platform offering significant potential for innovative drug discovery, design and 
development. My PhD studies have identified several potential leads with cytotoxicities 
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comparable to that of cisplatin but importantly, maintain this potency in cancer cells 
previously exposed to, and having an increased tolerance of, cisplatin.  
Treatment with Pt-based drugs results in the evolution  of tumour cell  resistance. 
Mechanistic analysis of a new generation of Ru(II)-based compounds with cytotoxic activity 
comparable to cisplatin, but which show no cross-resistance in cisplatin-resistant cells will 
inform progression of this important, chemically tractable class of compounds for 
therapeutic development. 
In the next steps on this project a range of cell biology approaches will be used to (i) 
understand the molecular basis for the variation in cytotoxic potency of complexes 1 – 4, 
with the goal of understanding the structure-activity relationships and uptake mechanisms 
governing cytotoxicity of this series of compounds, (ii) identify molecular mechanisms by 
which complexes 1 – 4 induce cell death in cisplatin-resistant cancer model cells, and (iii) 
identify intracellular signalling pathways activated following exposure to complexes, as a 
means to identify the primary target of complexes Ru(tpphz) 1 and Ru(taptp) 2, all of which 
are esssential to progress complexes into candidate leads for theraputic drug development. 
The experimental plan in more detail will be as follows. 
i) The molecular basis for the variation in cytotoxic potency of complexes 1 – 4:  
(A) This will involve use of inductively coupled mass spectrometry (ICP-MS) to determine 
intracellular levels of each complex over time to establish whether alterations in uptake 
characteristics explain differences in cytotoxic potency of complexes 1 – 4. 
(B) To establish the identity of the transporter(s) responsible for the cytotoxic efficiency of 
Ru(tpphz) 1, a siRNA screen of the human SLC transporter family will be undertaken, 
utilising the siRNA Screening Facility in the department of Biomedical Science.  This 
technology determines extent of uptake in each case by analysis of the aggregate 
luminescence following each individual transporter knockdown. Once a specific transporter 
or subset of transporters has been identified, experiments will be designed to establish 
whether a single transporter is responsible for the variable uptake efficiency of complexes 1 
– 4, or whether complexes 2 – 4 are taken into cells by a different, or additional, sub-family 
of transporters. 
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ii) As outlined the initial studies presented in this thesis indicate induced cell death is 
through oncosis, full determination of the mechanism of cell death will require more 
extensive studies. Three major morphological types of cell death can be distinguished: 
apoptosis, autophagy and oncosis. Following treatment, these may be distinguished by 
microscopy and the use of key biochemical markers. In order to establish which pathway(s) 
complexes 1 – 4 act to induce cell death, complex-treated cells will be monitored for the 
timely appearance of key markers of apoptosis (activated caspase 3; appearance of DNA 
single-strand breaks, determined by Western blotting) autophagy, (immunofluorescence 
microscopical analysis of Beclin II and LC3-II) or oncosis (time-lapse microscopy of cell and 
mitochondrial membrane swelling).  
iii) Identification of intracellular signalling pathways activated following exposure to 
complexes: To build upon the initial SILAC study and gain a more detailed insight into 
mechanisms by which complexes induce cell death, quantitative phosphoproteomics, a 
method of characterising proteins subject to post-translational modifications through 
phosphorylation (a reversible modification that determines protein function and 
localisation) will be employed. These data will provide insight into molecular signaling 
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All reactions were carried out under a nitrogen atmosphere unless otherwise stated. 
Reaction vessels containing solid starting materials underwent three cycles of alternating 





All chemicals were brought from commercial sources and used as supplied unless stated. 
Ruthenium complexes were treated as toxic. 
 
6.1.3 Nuclear Magnetic Resonance Spectroscopy (NMR) 
 
1H NMR spectra were recorded on a Bruker AM250 machine working in Fourier transform 
mode. The following abbreviations are used in the annotation of 1H spectra: s = singlet, d = 
doublet, dd = doublet of doublets, t = triplet, tt = triplet of triplets, q = quintet and m = 
multiplet. 
 
6.1.4 Mass Spectroscopy (MS) 
 
Fast-atom bombardment (FAB) mass spectra (MS) were recorded on a Kratos MS80 mass 
spectrometer working in positive ion mode. 
 
6.1.5 Elemental microanalysis 
 
CHN analyses were acquired using a Perkin Elmer 2400 CHN elemental analyser.   
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To a solution of 1,10-phenanthroline (2.73 g, 15.16 mmol) in 60% sulfuric acid, potassium 
bromate (2.75 g, 16.47 mmol) was added in batches over a period of 30 minutes and stirred 
at room temperature for 20 hours. The solution was poured over ice and carefully 
neutralised to pH 7 using a saturated solution of sodium hydroxide. The solution was then 
filtered, extracted with dichloromethane and evaporated to dryness. The crude product was 
recrystallised from methanol and dried in vacuo to yield a bright yellow solid (2.88 g, 13.71 
mmol, 87.8 %). 
1H NMR (400 MHz, CDCl3) δ 9.14 (dd, J = 1.8, 4.7 Hz, 2H), 8.53 (dd, J = 1.8, 7.9 Hz, 2H), 7.62 













A mixture of 1,10-phenanthroline-5,6-dione (1.15 g, 5.50 mmol), hydroxylammonium 
chloride (1.35 g, 19.3 mmol) and barium carbonate (1.66 g, 8.25 mmol) were placed in 
ethanol and stirred under reflux for 12 hours. After removal of the solvent, the residue was 
treated with 40 mL of 0.2M HCl, stirred for 30 minutes, collected by filtration, washed with 
water and ethanol and dried in vacuo to give a pale green solid (1.32 g, 7.14 mmol, 77.0 %). 
1H NMR (400 MHz, DMSO-d6) δ 8.80 (m, 3H), 8.28 (dd, J = 1.7, 8.0 Hz, 1H), 8.22 (dd, J = 1.7, 
7.9 Hz, 1H), 7.55 (m, 3H). 
















1,10-phenanthroline-5,6-dioxime (0.50 g, 2.090 mmol) and Pd/C (10%, 0.55 g) were added 
to ethanol (300 mL, anhydrous) and purged with N2. The mixture was then heated to reflux 
under N2 and a solution of hydrazine monohydrate (9 mL) in ethanol (36 mL, anhydrous) 
was added over a period of 1 hour, before allowing the reflux to continue for a further 12 
hours. The solution was then filtered through a hot pad of celite and washed with boiling 
ethanol until the filtrate was colourless. The solvent was removed from the filtrate under 
reduced pressure and the residue triturated with water (30 mL) and left for 16 hours at 4 ºC. 
The solid was separated by filtration, washed with cold water and dried in vacuo to give a 
brown solid (0.291 g, 1.391 mmol, 66.6 %). 
1H NMR (400 MHz, DMSO-d6) δ 8.78 (dd, J = 1.4, 4.1 Hz, 2H), 8.49 (dd, J = 1.5, 8.4 Hz, 2H), 
7.61 (dd, J = 4.2, 8.4 Hz, 2H), 5.25 (s, 4H). 













A mixture of 1,10-phenanthroline-5,6-dione (0.88 g, 4.19 mmol), ammonium acetate (4.56 
g, 59.16 mmol) and sodium sulphite (0.091 g, 0.72 mmol) in ethanol (15 mL, anhydrous) was 
heated to reflux under N2 for 2 hours. After cooling to room temperature water (20 mL) was 
added and the viscous precipitate collected by filtration, washed with water, methanol and 
acetone before being triturated in refluxing ethanol (100 mL), hot filtered, washed with 
ethanol and dried in vacuo to give a pale yellow solid (0.177 g, 0.46 mmol, 22.0 %). 
1H NMR (500 MHz, TFA-d) δ 10.34 (dd, J = 0.9, 8.2 Hz, 4H), 9.38 (dd, J = 0.8, 4.9 Hz, 4H), 8.44 
(dd, J = 5.1, 8.2 Hz, 4H). 















1,10-phenanthroline-5,6-diamine (0.21 g, 1.0 mmol) and 9-10-phenanthroquinone (0.21 g, 
1.0 mmol) were purged with N2, mixed in ethanol (160 mL, dry) and the solution heated to 
reflux for 3 hours. The precipitate was collected by hot filtration, washed with boiling 
ethanol, diethyl ether and dried in vacuo to give a light brown solid (0.091 g, 0.24 mmol, 
23.7 %). 
1H NMR (400 MHz, TFA-d) δ 10.46 (dd, J = 1.1, 8.3 Hz, 2H), 9.90 (d, J = 8.0 Hz, 2H), 9.50 (d, J = 
6.3 Hz, 2H), 9.29 (d, J = 4.9 Hz, 2H), 9.09 (d, J = 7.8 Hz, 2H), 8.55 (q, J = 4.5 Hz, 2H), 8.28 
(m, J = 4.1 Hz, 2H), 7.71 (td, J = 7.4, 31.0 Hz, 2H). 















RuCl3.xH2O (0.500 g, 2.41 mmol), phenanthroline (O.687 g, 3.81 mmol) and LiCl (0.458 g, 
10.80 mmol) were mixed in DMF (10 mL, anhydrous) and heated to reflux under N2 for 8 
hours [Ru(III)/Ru(II) reduction, DMF oxidation]. After cooling to room temperature acetone 
(50 mL) was added and the solution stored at 0ºC for 12 hours. The precipitate was collected 
by filtration, washed with acetone, water, diethyl ether and dried in vacuo to give a black 
solid (1.258 g, 2.36 mmol, 97.9 %). 















RuCl3.xH2O (1.000 g, 3.84 mmol), 2,2-bipyridine (1.200 g, 3.81 mmol) and LiCl (3.040 g, 24.60 
mmol) were mixed in DMF (10 mL, anhydrous) and heated to reflux under N2 for 8 hours 
[Ru(III)/Ru(II) reduction, DMF oxidation]. After cooling to room temperature acetone (70 
mL) was added and the solution stored at 0ºC for 12 hours. The precipitate was collected by 
filtration, washed with acetone, water, diethyl ether and dried in vacuo to give a black solid 
(0.937 g, 1.93 mmol, 50.3 %). 















Ru(phen)2Cl2 (0.500 g, 0.94 mmol) and DPQ (0.254 g, 1.21 mmol) were purged with N2, 
mixed in ethanol:water (1:1, 20 mL, N2 flushed) and the solution heated to reflux under N2 
for 3 hours. After cooling to room temperature an aqueous solution of NH4PF6 was added 
and the resulting precipitate collected by filtration, washed with water, diethyl ether and 
dried in vacuo to give a brown solid (0.370 g, 0.38 mmol, 41.0 %). 
1H NMR (400 MHz, CD3CN) δ 8.73 (dd, J = 1.1, 8.3 Hz, 2H), 8.61 (dd, J = 1.1, 8.3 Hz, 2H), 8.51 
(dd, J = 1.2, 7.9 Hz, 2H), 8.27-8.35 (m, 6H), 7.93 (d, J = 5.2 Hz, 4H), 7.84 (dd, J = 5.3, 8.3 Hz, 
2H), 7.62 (dd, J = 5.2, 8.3 Hz, 2H), 7.51 (dd, J = 5.6, 8.0 Hz, 2H). 
MS; m/z (%): 817 (50) [M](PF6)













Ru(bipy)2Cl2 (0.400 g, 0.83 mmol) and DPQ (0.174 g, 0.83 mmol) were purged with N2, mixed 
in ethanol:water (1:1, 20 mL, N2 purged) and the solution heated to reflux under N2 for 3 
hours. After cooling to room temperature an aqueous solution of NH4PF6 was added and the 
resulting precipitate collected by filtration, washed with water, diethyl ether and dried in 
vacuo to give a brown solid (0.609 g, 0.67 mmol, 80.7 %). 
1H NMR (400 MHz, CD3CN) δ 8.55 (d, J = 8.1 Hz, 3H), 8.11 (tt, J = 1.5, 7.9 Hz, 2H), 8.00 (d, J = 
5.3 Hz, 1H), 7.86 (d, J = 5.6 Hz, 1H), 7.77 (d, J = 5.6 Hz, 1H), 7.63 (dd, J = 5.6, 8.0 Hz, 1H), 7.45 
(tq, J = 1.4, 7.3 Hz, 2H). 
MS; m/z (%): 769 (100) [M](PF6)








6.2.10  [Ru(phen)2(tpphz)](PF6)2 




1,10-phenanthroline-5,6-diamine (0.103 g, 0.49 mmol) dissolved in hot methanol (40mL, 
anhydrous) was added to a boiling solution of [Ru(phen)2(DPQ)](PF6)2 (0.200 g, 0.21 mmol) 
in acetonitrile (10mL, anhydrous) and heated to reflux under N2 for 6 hours. After cooling to 
room temperature the solution was filtered, washed with acetonitrile and to the 
concentrated filtrate an aqueous NH4PF6 solution was added. The resulting precipitate was 
collected by filtration, washed with water, ethanol, diethyl ether and dried in vacuo to give 
an orange solid (0.171 g, 0.15 mmol, 72.4 %). 
1H NMR (400 MHz, CD3CN) δ 9.65 (d, J = 8.0 Hz, 1H), 9.42 (d, J = 7.8 Hz, 1H), 8.67 (t, J = 8.3 
Hz, 1H), 8.53 (s, 1H), 8.33 (s, 2H), 8.24 (d, J = 4.8 Hz, 1H), 8.13 (d, J = 4.8 Hz, 1H), 7.79 (q, J = 
6.9 Hz, 3H), 7.71 (dd, J = 5.2, 8.3 Hz, 1H). 
MS; m/z (%): 991 (100) [M](PF6)






6.2.11  [Ru(bipy)2(tpphz)](PF6)2 




1,10-phenanthroline-5,6-diamine (0.266 g, 1.26 mmol) dissolved in hot methanol (135mL, 
anhydrous) was added to a boiling solution of [Ru(bipy)2(DPQ)](PF6)2 (0.608 g, 0.67 mmol) in 
acetonitrile (30mL, anhydrous) and heated to reflux under N2 for 6 hours. After cooling to 
room temperature the solution was filtered, washed with acetonitrile and to the 
concentrated filtrate an aqueous NH4PF6 solution was added. The resulting precipitate was 
collected by filtration, washed with water, ethanol, diethyl ether and dried in vacuo to give 
an orange solid (0.4296 g, 0.40 mmol, 59.3 %). 
1H NMR (400 MHz, CD3CN) δ 9.62 (dd, J = 1.4, 8.1 Hz, 1H), 9.46 (d, J = 8.1 Hz, 1H), 8.63 – 8.57 
(m, 3H), 8.29 (dd, J = 1.2, 5.3 Hz, 1H), 8.18 (td, J = 1.4, 8.0 Hz, 1H), 8.10 (d, J = 5.4 Hz, 1H), 
8.06 (dd, J = 1.2, 7.8 Hz, 1H), 7.94 (d, J = 5.5 Hz, 1H), 7.90 (dd, J = 5.3, 8.1 Hz, 1H), 7.83 
(dd, J = 4.4, 8.1 Hz, 1H), 7.54 (tt, J = 1.3, 7.7 Hz, 1H), 7.37 (tt, J = 1.4, 5.8 Hz, 1H). 
MS; m/z (%): 943 (100) [M](PF6)





6.2.12  [Ru(phen)2(taptp)](PF6)2 




[Ru(phen)2Cl2] (0.26 g, 0.5 mmol) and taptp (0.191 g, 0.5 mmol) in ethylene glycol (100 mL) 
were heated to 150 °C under N2 for 6 hours. After cooling to room temperature an equal 
volume of aqueous NH4PF6 solution was added. The resulting brown precipitate was 
collected by centrifugation, washed with water, ethanol and diethyl ether using the same 
technique and dried in vacuo to give a brown solid (0.362 g, 0.32 mmol, 63.8 %). 
1H NMR (400 MHz, CD3CN) δ 9.90 (dd, J = 1.2, 8.2 Hz, 2H), 9.64 (dd, J = 1.3, 7.9 Hz, 2H), 8.83 
(d, J = 7.9 Hz, 2H), 8.65 (d, J = 8.3 Hz, 4H), 8.31 (s, 4H), 8.26 (dd, J = 1.2, 5.3 Hz, 2H), 8.19 
(dd, J = 1.2, 5.3 Hz, 2H), 8.08 (dd, J = 1.2, 5.2 Hz, 2H), 7.99 (t, J = 6.8, 2H), 7.94 (t, J = 7.1 Hz, 
2H), 7.86 (d, J = 8.4 Hz, 1H), 7.85 (d, J = 8.3 Hz, 1H), 7.70 (t, J = 5.3 Hz, 2H), 7.68 (t, J = 5.3 Hz, 
2H). 
MS; m/z (%): 989 (50) [M](PF6)






6.2.13  [Ru(bipy)2(taptp)](PF6)2 




[Ru(bipy)2Cl2] (0.26 g, 0.5 mmol) and taptp (0.191 g, 0.5 mmol) in ethylene glycol (100 mL) 
were heated to 150 °C under N2 for 6 hours. After cooling to room temperature an equal 
volume of aqueous NH4PF6 solution was added. The resulting brown precipitate was 
collected by centrifugation, washed with water, ethanol and diethyl ether using the same 
technique and dried in vacuo to give a brown solid (0.297 g, 0.27 mmol, 54.7 %). 
1H NMR (400 MHz, CD3CN) δ 9.95 (dd, J = 1.3, 8.2 Hz, 2H), 9.67 (dd, J = 1.3, 8.0 Hz, 2H), 8.86 
(d, J = 8.3 Hz, 2H), 8.58 (d, J = 15.2 Hz, 2H), 8.56 (d, J = 15.2 Hz, 2H), 8.25 (dd, J = 1.2, 5.3 Hz, 
2H), 8.16 (dt, J = 1.4, 8.0 Hz, 2H), 8.00 (m, 8H), 7.91 (d, J = 5.4 Hz, 2H), 7.77 (d, J = 5.7 Hz, 
2H), 7.51 (t, J = 7.2, 2H), 7.28 (t, J = 7.4, 2H). 
MS; m/z (%): 941 (65) [M](PF6)












[Ru(phen)2(tpphz)](PF6)2 (0.040 g, 0.035 mmol) and K2[PtCl4] (0.0146 g, 0.035 mmol) were 
mixed in methanol:water (1:1, 20mL, N2 purged) and heated to reflux under N2 for 12 hours. 
After cooling to room temperature the methanol was removed under reduced pressure, the 
precipitate collected by filtration, washed with ethanol, methanol and hexanes. The 
collected precipitate was dissolved in acetonitrile and re-precipitated by addition of diethyl 
ether, collected by filtration, washed with ether and dried in vacuo to give a brown solid 
(0.029 g, 0.024 mmol, 69.1 %). 
1H NMR (400 MHz, CD3CN) δ 9.84 (d, J = 7.7 Hz, 2H), 9.58 (d, J = 8.7 Hz, 2H), 9.49 (s, 2H), 8.66 
(t, J = 8.4 Hz, 6H), 8.52 (s, 2H), 8.32 (t, J = 5.6Hz, 8H), 8.21 (t, J = 7.8 Hz, 2H), 8.08 (d, J = 5.0 
Hz, 2H), 7.97 (dd, J = 5.5, 8.0 Hz, 2H), 7.69 (dd, J = 5.2, 8.4 Hz, 6H). 
MS; m/z (%): 1257 (100) [M](PF6)











[Ru(phen)2(tpphz)](PF6)2 (0.40 g, 0.35 mmol) and Re(CO)5Cl (0.14 g, 0.39 mmol) were mixed 
in acetonitrile (100 mL, dry) and heated to reflux under N2 for 16 hours. After cooling to 
room temperature the volume of acetonitrile was decreased under reduced pressure and 
the complex was precipitated by addition of diethyl ether. The precipitate was collected by 
centrifugation, washed with diethyl ether and dried in vacuo to give an orange solid (0.28 g, 
0.19 mmol, 55.0 %). 
1H NMR (400 MHz, CD3CN): δ 10.12 (t, J = 7.5 Hz, 2H), 9.93 (d, J = 10.0 Hz, 2H), 9.60 (d, J = 
5.0 Hz, 2H), 8.67 (d, J = 10.0 Hz, 4H), 8.34-8.17 (m, 10H), 8.08 (t, J = 5.0 Hz, 2H), 7.94-7.88 
(m, 2H), 7.74-7.63 (m, 4H). 
MS; m/z: 1297 [M](PF6)
+. Accurate Mass: Calc. for RuReC51H28N10O3F6PCl [M](PF6)
+: 
1297.0277, Observed: 1297.0260. 
Elemental Analysis: Calc. for RuReC51H28N10O3ClP2F12: C 42.50; H 1.96; N 9.72. Observed: C 










[Ru(bipy)2(tpphz)](PF6)2 (0.30 g, 0.28 mmol) and Re(CO)5Cl (0.11 g, 0.30 mmol) were mixed 
in acetonitrile (80 mL, dry) and heated to reflux under N2 for 16 hours. After cooling to room 
temperature the volume of acetonitrile was decreased under reduced pressure and the 
complex was precipitated by addition of diethyl ether. The precipitate was collected by 
centrifugation, washed with diethyl ether and dried in vacuo to give an orange solid (0.30 g, 
21 mmol, 77.9 %). 
1H NMR (400MHz, CD3CN): δ 10.09 (2H, t, J = 9.4 Hz), 9.92 (2H, dd, J = 6.2 Hz, 3.1 Hz), 9.56 
(2H, t, J = 1.6 Hz), 8.55 (4H, dd, J = 18.8 Hz, 6.2 Hz), 8.28 (2H, t, J = 6.2 Hz), 8.18-8.25 (2H, m), 
8.13 (2H, t, J = 9.4 Hz), 7.97-8.05 (4H, m), 7.86 (2H, t, J = 4.7 Hz), 7.77 (1H, d, J = 6.2 Hz), 7.71 
(1H, d, J = 6.2 Hz), 7.49 (2H, t, J = 6.2 Hz), 7.23-7.30 (2H, m). 
MS; m/z: 1249 [M](PF)6
+. Accurate Mass; Calc. for RuReC47H28N10O3F6PCl [M](PF)6
+: 
1249.0277. Observed: 1249.0217. 
Elemental Analysis; Calc. for RuReC47H28N10O3ClP2F12: C 40.50; H 2.03; N 10.10. Observed: C 
40.12; H 1.88; N 9.82. 
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6.2.17  [(Ru(bipy)2)2(tpphz)](PF6)4 




Ru(bipy)2Cl2 (0.535 g, 1.10 mmol) and tpphz (0.173 g, 0.449 mmol) were mixed in 
ethanol:water (1:1, 40mL, N2 purged) and heated to reflux under N2 for 12 hours. The 
solution was cooled to room temperature and stored at 4ºC for 16 hours. The solution was 
filtered, ethanol removed under reduced pressure, filtered again and an aqueous solution of 
NH4PF6 was added to the filtrate. The resulting precipitate was collected by filtration, 
washed with water and dried in vacuo. The crude product was dissolved in acetonitrile and 
reprecipitated on addition of diethyl ether, collected by filtration, washed with diethyl ether 
and dried in vacuo to give a red solid (0.922 g, 0.51 mmol, 93.2 %). 
1H NMR (400 MHz, CD3CN) δ 9.98 (dd, J = 1.2, 8.2 Hz, 2H), 8.58 (dd, J = 8.3, 15.5 Hz, 6H), 8.32 
(dd, J = 1.2, 5.3 Hz, 2H), 8.17 (dt, J = 1.4, 7.9 Hz, 2H), 8.08 - 8.01 (m, 6H), 7.90 (d, J = 5.0 Hz, 
3H), 7.77 (d, J = 5.1 Hz, 3H), 7.52 (tt, J = 1.3, 5.7 Hz, 2H), 7.29 (tt, J = 1.4, 5.9 Hz, 2H). 








6.2.18  Anion Metathesis 
 
For aqueous photochemistry, including DNA binding, and all cellular studies, the chloride 
complex ([M]Cln) corresponding to the initially synthesised hexafluorophosphate ([M](PF6)n) 
complex was used. The hexafluorophosphate salt of each complex was dissolved in the 
minimum volume of acetone and a saturated solution of ammonium chloride in acetone 
added. The resultant precipitated chloride salt was collected by filtration, washed with cold 
acetone and dried in vacuo.  
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6.3  DNA Binding Studies 
 
6.3.1 DNA Preparation 
 
Calf thymus DNA (CT-DNA) was dissolved in aqueous buffer (25 mM NaCl, 5 mM Tris, pH = 7) 
and broken into an average of 150-200 base pair fragments by sonication (2 × 15 minutes). 
The purity of the sample was determined by UV-vis spectroscopy, with A260nm/A290nm > 1.9 
indicating a protein-free sample. The concentration of CT-DNA was determined by UV-vis 
spectroscopy (ε280nm = 13200 M-1 cm-1). 
 
6.3.2 Luminescence Titration 
 
A solution of the complex (concentration stated) was dissolved in aqueous buffer (25 mM 
NaCl, 5 mM Tris, pH = 7.4) and loaded into a quartz cuvette. This was allowed to equilibrate 
at 25°C for 30 minutes and the emission spectra recorded. 2 – 3 μL of a concentrated stock 
CT-DNA solution in aqueous buffer (typically 200 μM) was added and the solution mixed by 
pipette. The emission spectrum was recorded and whilst showing an enhancement in 
emission this procedure was continued until the emission became constant. 
The maxima of each emission spectrum were then carried forward to calculate the fraction 
bound. This could then be plotted against the concentration of DNA divided by the 
concentration of complex to generate a binding curve. 
A Scatchard plot6 could be generated using the McGhee and Von Hippel (MVH) model to 
account for non-linear deviation associated with the complex overlapping binding site 
system of DNA base pairs. The MVH equation used in the SigmaPlot 12.0 software was:  
𝑟
𝐶𝑓
= 𝐾 ∙ (1 − 𝑛𝑟) (
1 − 𝑛𝑟




Data points between a bound ligand fraction of 0.3 and 0.9 were used as the model is 
inaccurate at high and low concentrations. 
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6.4  Cellular Studies 
 
6.4.1 Complex preparation 
 
Stock solutions were made up in a solution of one part phosphate buffered saline (PBS) to 
one part high purity milli-Q® water with sonication and gentle heating (60ºC max) to aid 
dissolution at a high concentration, followed by sterile filtration with a 0.20 µm filter. 
 
6.4.1 Cell Culture 
 
A2780 and A2780cis cell lines were cultured in RPMI-1640 medium. All growth medium was 
supplemented by 2 mM L-Glutamine, 100 IU ml-1 penicillin, 100 µg ml-1 streptomycin and 
10% v/v fetal bovine serum (FBS). Cultures were grown within the appropriate range of 
confluence at 37°C in 5% CO2 / 95% air. Cultures were routinely subcultured using trypsin 
(0.1% v/v in PBS) at 80 – 90% confluence and used between passage numbers 6 – 60. 
 
6.4.2 Cytotoxicity (MTT assay) 
 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was used to determine 
the cell viability upon treatment with varying concentrations of complex. In the 
mitochondria of living cells MTT is reduced to a purple formazan product by reductase 
enzymes. This conversion can only occur in active mitochondria so the amount of formazan 
produced is directly proportional to the number of viable cells within the culture. The 
amount of formazan can be quantified by absorbance between 500 – 600nm and the 
toxicity of a treatment deduced by comparison of the formazan content for exposed cells 
against that of an untreated control. Different cell cultures can show different enzymatic 
activity so comparisons drawn are only valid within the assay. 
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6.4.3 IC50 values 
 
Cell cultures were grown on 48 well plates and allowed to grow for 24 hours before 
treatment with a complex of various concentrations (maintaining a ratio of 10% PBS/H2O: 
90% medium throughout all solutions) in triplicate for the given incubation time of 24 or 48 
hours. Solutions were removed and the cells incubated with MTT (0.5 mg ml-1 dissolved in 
PBS) for 30 – 40 minutes. The MTT was removed and formazan product eluted using 110 
µl/well acidified isopropanol, 100 µl/well of which was transferred to a 96 well plate for the 
absorbance to be quantified by spectrophotometer (540 nm, referenced at 640 nm). An 
average absorbance for each concentration was calculated and cell viability was determined 
as a percentage of the untreated negative control wells (10% PBS/water: 90% medium, 
average of triplicate). This data was plotted in a graph of concentration against cell viability 
to produce a curve from which the IC50 could be estimated by interpolation. 
 
6.4.4 Light Irradiation Source Apparatus (LISA) 
 
The apparatus used to irradiate the samples was a custom made device featuring a 
broadband illumination source fully contained in an empty computer base unit, referred to 
as the Light Irradiation Source Apparatus (LISA). The technical specifications of the bulb 
contained within are as follows (Table 1). 
 
Product Code 871691 
International Model Number HC01080i 




Operating Hours 15000 
Colour Temp 4000K 
Lumens 5400 lm 
Dimming No 
Dimensions (length x diameter) 256mm x 80mm 
 
Table 1 – Specification of the bulb contained within the irradiation apparatus 
 159 
6.4.5 Photocytotoxicity (phototoxicity) 
 
Cell cultures were grown on 48 well plates at a seeding density of 50,000 cells per well and 
allowed to grow for 24 hours. The cells were then treated with complex (solubilised in and 
maintained at 10% PBS/water: 90% medium throughout all solutions) of a 1 – 100 μM 
concentration range, in triplicate, and incubated for 24 hours. All complex solution (and 
control media) was removed from the cells and replaced with regular growth medium 30 
minutes prior to irradiation. Of the four prepared well plates, one remained in the incubator 
whilst the other three were exposed to the LISA for the duration of 5, 15 or 30 minutes 
(corresponding to light doses of 8, 24 or 48 J cm-2) before being incubated for a further 24 
hours after culmination of light treatment. All media was then removed and cells incubated 
with MTT (0.5 mg ml-1 dissolved in PBS) for 30 – 40 minutes. The MTT was removed and 
formazan product eluted using 120 µl/well acidified isopropanol, 100 µl of which was 
transferred to a 96 well plate for the absorbance to be quantified by spectrophotometer 
(540 nm, referenced at 640 nm). An average absorbance for each concentration was 
calculated and cell viability was determined as a percentage of the untreated negative 
control wells (10% PBS/water: 90% medium, average of triplicate). Data were plotted in a 
graph of concentration against cell viability to produce a curve from which the IC50 value 




6.5  Microscopy 
 
6.5.1 Sample preparation and treatment 
 
Cell culture samples were prepared by first pre-coating 35 mm glass bottomed tissue culture 
dishes with poly-l-lysine (10 minutes on, aspirate and 5 x PBS wash to remove excess). 
Dishes were then seeded with cells at a density of 150,000 cells/dish and incubated for 24 
hours to allow sufficient adherence. 
For all of the experiments carried out in Section 3.1 the cells had all medium removed, were 
washed with PBS and the complex added as a 50 µM solution composed of 10% 
PBS/H2O:90% medium. 
For the DAPI co-stain, the complex was removed after 2 hours, 1x PBS wash, 15 minutes 




Following treatment with the complex, the cell samples were placed in the live cell 
microscopy chamber (37 °C and 5% CO2) and immediately imaged using a 100x plan 
apochromat (1.4NA) objective lens on a Nikon Ti inverted microscope.  Samples were 
illuminated at 405 nm using a Lumencor spectraX solid state light engine, and emission from 
the sample at 640–800 nm was collected using an Andor Zyla sCMOS camera.  All images 
were taken using the Nikon Elements software in a programmed cycle of a multiple 
coordinate set every 2 minutes for 3 hours to construct each time lapse sequence. 
A control dish of equally seeded cells having only 10% PBS/H2O:90% medium replaced with 
fresh solution before the experiment remained alongside each treated sample experiment 
in the live cell chamber and was imaged after 3 hours to ensure there was no deterioration 
of cell morphology in the ambient conditions. In addition, a control experiment was run with 
an equally seeded dish imaged on the same cycle (multiple coordinate images every 2 
minutes for 3 hours) to assess the effects of microscope light exposure. 
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6.6  SILAC Proteomics 
 
6.6.1 Cell culture 
 
An A2780cis cell line culture was first established in regular RPMI 1640 medium 
(supplemented by 2mM L-Glutamine, 100 IU ml-1 penicillin, 100 µg ml-1 streptomycin and 
10% v/v dialysed FBS) before being split into two parallel populations which were identically 
sub-cultured but with one continuing to use the regular RPMI medium and one using SILAC 
RPMI medium containing labelled amino acids (supplemented with 2mM L-Glutamine, 100 
IU ml-1 penicillin, 100 µg ml-1 streptomycin and 10% v/v dialysed FBS). Labelled SILAC media 
was used for 6 passages to ensure heavy amino acid incorporation by exceeding the 
suggested 10-12 cell cycle period. The type of labelling used was the heavy combination 
featuring both of the amino acid isotopes R10 (L-ARGININE 13C6, 
15N4 HYDROCHLORIDE) and 
K8 (L-LYSINE-13C6,
15N2 HYDROCHLORIDE). Dundee Cell Products was used to purchase all 
SILAC media and dialyzed FBS with the following catalogue entries and following media 
composition: 
Catalogue Number: DS1002 Description: SILAC Dialysed calf serum (MWCO 10,000 Da) 
Catalogue Number: LM021 Description: SILAC RPMI 1640 R10K8 
 
CAS Number  Component  Molecular Weight  Concentration, g/L  
AMINO ACIDS  
56-40-6  Glycine  75  0.010  
74-79-3  L-Arginine free base (R10 LABELLED) 174  0.200  
70-47-3  L-Asparagine anhydrous  132  0.050  
56-84-8  L-Aspartic acid  133  0.020  
30925-07-6  L-Cystine dihydrochloride  313  0.0652  
56-86-0  L-Glutamic acid  147  0.020  
70-00-1  L-Histidine  155  0.015  
51-35-4  L-Hydroxy-L-Proline  131  0.020  
73-32-5  L-Isoleucine  131  0.050  
61-90-5  L-Leucine  131  0.050  
657-27-2  L-Lysine hydrochloride (K8 LABELLED) 183  0.040  
63-68-3  L-Methionine  149  0.015  
63-91-2  L-Phenylalanine  165  0.015  
147-85-3  L-Proline  115  0.020  
56-45-1  L-Serine  105  0.030  
72-19-5  L-Threonine  119  0.020  
73-22-3  L-Tryptophan  204  0.005  
69847-45-6  L-Tyrosine Disodium Salt Dihydrate  261  0.02883  
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72-18-4  L-Valine  117  0.020  
VITAMINS  
67-48-1  Choline chloride  140  0.003  
58-85-5  D-Biotin  244  0.0002  
137-08-6  D-Ca Pantothenate  477  0.00025  
59-30-3  Folic acid  441  0.001  
87-89-8  Myo-Inositol  180  0.035  
98-92-0  Nicotinamide  122  0.001  
150-13-0  P-Aminobenzoic Acid (PABA)  137  0.001  
58-56-0  Pyridoxine Hydrochloride  169  0.001  
67-03-8  Thiamine Hydrochloride  337  0.001  
83-88-5  Riboflavin  376  0.0002  
127-47-9  Vitamin A Acetate  328  0.0001  
68-19-9  Vitamin B12  1355  0.00001  
INORGANIC SALTS  
13477-34-4  Calcium Nitrate Tetrahydrate  0.100  
7487-88-9  Magnesium Sulfate Anhydrous  120  0.04884  
7447-40-7  Potassium Chloride  75  0.400  
7647-40-15  Sodium Chloride  58  6.000  
144-55-8  Sodium Bicarbonate  84  2.000  
7558-79-4  Sodium Phosphate Dibasic Anhydrous  142  0.8  
OTHER COMPONENTS  
70-18-8  L-Glutathione reduced  370  0.001  
   
 
6.6.2 Cell treatment and lysis 
 
Cell cultures were prepared in 100 mm tissue culture dishes and incubated for 24 hours 
prior to complex treatment. The cells were treated with complex at the 48 hour IC50 
concentration but only incubated for 24 hours before all complex solution was removed, 










6.6.3 Bradford protein assay 
 
The cell lysates were subjected to a Bradford protein assay to determine the protein 
concentration in each sample. The protocol followed was that produced by Bio-Rad, and 
first involved generating a standard calibration curve using Bovine Serum Albumin (BSA) 
through the following steps: 
1. Prepare dye reagent by diluting 1 part Dye Reagent Concentrate with 4 parts distilled, 
deionized (DDI) water. 
2. Prepare five dilutions of BSA – 2.000, 1.000, 0.500, 0.250 and 0.125 mg/mL. 
3. Pipet 100 μL of each standard solution into a clean, dry disposable polystyrene cuvette, 
and repeat to assay in triplicate. 
4. Add 990 μL of diluted dye reagent to each tube and mix with reverse pipetting. 
5. Incubate at room temperature for 5 minutes. 
6. Measure absorbance at 595 nm in a spectrophotometer. 
A graph was then produced by plotting concentration of BSA against absorbance, and an 
equation of the subsequent line could be calculated which could be used to determine a 
protein concentration given an absorbance in this linear range (see below). The protocol 
was subsequently repeated for the cell lysate samples, which were diluted and each protein 
concentration determined using a Microsoft Excel worksheet programmed with the 
equation of the standard calibration line and the appropriate formula calculations.  
 
 








0.000 0.200 0.400 0.600 0.800 1.000
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6.6.4 Protein purification (SDS-PAGE) 
 




10% acrylamide gels were prepared by firstly creating the resolving gel using the following 
component quantities; with the ammonium persulfate (APS) and 
tetramethylethylenediamine (TEMED) added last to initiate gel polymerisation:  
Resolving Gel 




1.5M TrisHCl, pH 8.8 
10% SDS 10% APS TEMED 






1.5M TrisHCl, pH 6.8 
10% SDS 10% APS TEMED 
5 mL 3.4 mL 0.83 mL 0.63 mL 50 µL 50 µL 5 µL 
 
Polymerisation of the resolving gel was first initiated (with APS and TEMED) before being 
poured into the gel casting apparatus (5 mL per gel), ethanol added and left to set for 1 
hour. The ethanol was then removed, stacking gel polymerisation was initiated (with APS 
and TEMED), the solution poured on top of the set resolving gel, well comb inserted and left 
to set for 45 minutes. The comb was then removed and the wells rinsed with running buffer.  
 
Sample Preparation 
Sample buffer was made according to the following concentrated formula, which was then 
diluted 5 fold with MQ H2O and 50 µL β-mercapto ethanol added to 950 µL diluted sample 




0.5M TrisHCl, pH 6.8 
Glycerol SDS Bromophenol Blue 
5x 1.825 mL 3.125 mL 5 mL 1 g 50 µL 
Using the pre-determined protein concentrations of the cell lysates and the sample volume 
to determine the mass of protein present in each sample, dilutions could be calculated to 
create new samples of normalised protein content between the complex treated lysate and 
untreated lysate which were then used to make a mixed sample, maintaining the same total 
protein content, of 1:1 treated : untreated lysates. All three samples (treated, untreated and 
mixed, corresponding to light, heavy and mixed amino acids) were then diluted 2:1 with 2x 
sample buffer and heated for 3 minutes at 95°C to ensure full protein denaturation. 
 
Gel Electrophoresis 
Running buffer was prepared as a 2L solution of 25 mM Tris, 192 mM and 0.1% SDS: 
Concentration ddH2O Tris base Glycine SDS 
1x Up to 2 L 6.04 g 28.8 g 2 g 
 
The gels were secured in place on each side of the gel electrophoresis equipment, the inner 
chamber and the lower chamber of the tank were filled with running buffer and the samples 
loaded into the wells, along with a protein marker ladder each side, before being ran at  150 
volts. When the protein marker had proceeded down the majority of the gel, the 
electrophoresis was stopped and the gel stained with collodial coomassie to visualise the 
sample protein bands and confirm a degree of separation had occurred. 
 
6.6.5 In-gel digest of SDS-PAGE gel 
 
The completed SDS-PAGE gels were subjected to the following in-gel digest protocol to 




Solution 1: 200 mM ammonium bicarbonate (ABC), 40% acetonitrile (ACN) 
(1.58g ABC, 40 mL ACN, 60 mL MQ H2O) 
Solution 2: 50 mM ammonium bicarbonate 
(0.395 g ABC, 100 mL MQ H2O) 
Solution 3: 50 mM ammonium bicarbonate, 50% acetonitrile 
 (0.395 g ABC, 50 mL ACN, 50 mL MQ H2O) 
Solution 4: 40 mM ammonium bicarbonate 
 (0.316 g ABC, 9 mL ACN, 91 mL MQ H2O) 
Solution 5: 100% acetonitrile 
 (100 mL ACN) 
Solution 6: 5% formic acid (FA) 
 (5 mL FA, 95 mL MQ H2O) 
Solution 7: 50% acetonitrile, 5% formic acid 
 (50 mL ACN, 5 mL FA, 45 mL MQ H2O) 
Solution 8: 1 mM HCl 
 (25 µL 4M HCl up to 100 mL with MQ H2O) 
Reduction Buffer: 10 mM dithiothreitol (DTT), 50 mM ammonium bicarbonate 
 (0.0155g DTT, 10 mL Solution 2) 
Alkylation Buffer: 55 mM iodoacetamide (IAA), 50 mM ammonium bicarbonate 
 (0.10172 g of IAA, 10 mL Solution 2) 
Trypsin solution: 0.02 µg/µL 
(1 vial of proteomic grade trypsin TPCK treated 20 µg, add 100 µL of Solution 8, then 
900 µL of Solution 4) 
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Band excission and destain 
1. Carefully wash the gel several times with MQ H2O. 
2. Within a fume hood, excise each gel lane into 10 equal width bands with a fresh 
scalpel blade and transfer into a fresh siliconized Eppendorf tube. 
3. Cover each gel piece with 200 µL Solution 1, incubate at 37°C for 30 minutes. 
4. Discard supernatant. 
5. Repeat step 3 with fresh Solution 1. 
6. Dry down gel pieces in vacuum concentrator for approximately 30 minutes. 
 
Reduction and alkylation of proteins 
1. Add 200 µL of Reduction buffer (prepared fresh) to each gel piece and incubate at 
56°C for 1 hour. 
2. Centrifuge gel pieces in Eppendorf tube at 13000 x g for 10 minutes. 
3. Discard supernatant 
4. Add 200 µL of Alkylation buffer (prepared fresh) to each gel piece and incubate at 
room temperature for 30 minutes in the dark. 
5. Wash each gel piece with 200 µL of Solution 2 and leave at room temperature for 15 
minutes. 
6. Discard supernatant. 
7. Repeat steps 5 and 6 once more. 
8. Wash each gel piece with 200 µL of Solution 3 and incubate at 37°C for 15 minutes.  
9. Centrifuge gel piece in Eppendorf tube at 13000 x g for 10 minutes. 
10. Discard supernatant. 
11. Dry down gel pieces in vacuum concentrator for approximately 30 minutes. 
 
Enzymatic digestion 
1. Add 20 µL of Trypsin solution (equivalent to 0.4 µg trypsin) to each gel piece. 
2. Add 50 µL of Solution 4 to each gel piece, ensuring full coverage by fluid. 
3. Incubate at 37°C overnight. 
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Peptide extraction 
1. Centrifuge gel piece in Eppendorf tube at 13000 x g for 10 minutes 
2. Collect supernatant to a fresh siliconized Eppendorf supernatant collection tube 
(SCT). 
3. Add 20 µL of Solution 5 to each gel piece, briefly vortex and incubate at 37°C for 15 
minutes. 
4. Add 50 µL of Solution 6 to each gel piece, briefly vortex and incubate at 37°C for 15 
minutes. 
5. Vortex each tube briefly, centrifuge gel piece in Eppendorf tube at 13000 x g for 10 
minutes, remove supernatant and add to the corresponding SCT. 
6. Repeat steps 3 to 5 once more. 
7. Add 50 µL of Solution 7 to each gel piece, briefly vortex and incubate at 37°C for 30 
minutes. 
8. Vortex each tube briefly, centrifuge gel piece in Eppendorf tube at 13000 x g for 10 
minutes, remove supernatant and add to the corresponding SCT. 
9. Discard gel piece. 
10. Place supernatant collection tubes in vacuum concentrator and dry down extracted 
peptides overnight. 
11. Store supernatant collection tubes at -20°C ready for analysis. 
 
6.6.6 Data processing 
 
After the samples were analysed by mass spectrometry, the data was processed to assign 
the detected peptide sequences to their corresponding proteins using the Mascot software 
search engine; which utilises several primary sequence databases. 
The Perseus software suite was used to filter the entire data set for statistically significant 
information. The criteria applied to isolate up-regulated proteins were: Number of peptides 
> 1, Light/Heavy ratio > 1.8, Light/Heavy Count > 1, Light/Heavy Variability < 30%. 
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6.7  Intracellular metal content (ICP-MS) 
 
The intracellular metal content was calculated using the following protocol for inductively 
coupled mass spectrometry (ICP-MS). 
 
Cell culture 
1. Seed cells in 60mm dishes 
2. Incubate for 24 hours 
3. Treat cells with complex at a set concentration and time 
4. Remove complex solution 
5. Wash with PBS 
6. Add 500 µL serum free media and 1 mL trypsin solution 
7. Incubate for 3 minutes and shake to detach some of the cells 
8. Scrape to detach the remaining cells (some complexes can neutralise trypsin) 
9. Harvest cells into Eppendorf tubes and centrifuge (4000 rpm, 3 minutes)  
10. Remove supernatant and resuspend in 500 µL serum free media 
11. Remove 20 µL to count cells and calculate the cell number in the remaining volume 
 
ICP-MS Sample preparation 
1. Transfer each sample completely to a glass vial with plastic lid (no metal or rubber 
insert) and add 2 mL 60% nitric acid 
2. Heat at 60°C overnight to dissolve all of the sample into a colourless solution 
3. Add approximately 8 mL MQ H2O to each sample to make a total volume of 10 mL 
4. Submit for ICP-MS analysis of appropriate metal nuclei 
 
With the results in µg L-1, and a known sample volume and cell number the total metal mass 
per cell could be calculated. This can be used to calculate moles of metal, and therefore the 
moles of compound, per cell. Finally, with the assumption of a cell volume of 2 x10 -12 L an 
estimate of intracellular concentration in mol L-1 could be deducted. 
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6.8  Singlet Oxygen Quantum Yield 
 
Emission quenching was accompanied by singlet oxygen generation as shown by the O2 
(1Δg)  3O2 phosphorescence at λ > 1100 nm.
7 Singlet oxygen quantum yield, φ(1O2), was 
determined through measurement of phosphorescence intensity in dichloromethane 
employing 355 nm excitation and perinaphthenone as the standard.8 
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7.1  NMR Spectra 
 
1,10-phenanthroline-5,6-dione        [Exp. 6.2.1 pg. 132] 




1,10-phenanthroline-5,6-dioxime        [Exp. 6.2.2 pg. 133] 
(phen-dioxime) in (CD3)2SO 
 
 
1,10-phenanthroline-5,6-diamine        [Exp. 6.2.3 pg. 134] 
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tetrapyridophenazine          [Exp. 6.2.4 pg. 135] 





[Ru(phen)2(DPQ)](PF6)2          [Exp. 6.2.8 pg. 139] 





[Ru(bipy)2(DPQ)](PF6)2          [Exp. 6.2.9 pg. 140] 






[Ru(phen)2(tpphz)](PF6)2       [Exp. 6.2.10 pg. 141] 





[Ru(bipy)2(tpphz)](PF6)2       [Exp. 6.2.11 pg. 142] 










(Red lines = tpphz protons a,b,c,d,e,f and Blue lines = phen protons 3,4,5,6,3’,4’,5’,6’)  




(Red lines = tpphz protons a,b,c,d,e,f and Blue lines = phen protons 3,4,5,6,3’,4’,5’,6’)  
tetraazaphenanthrenotriphenylene       [Exp. 6.2.5 pg. 136] 





[Ru(phen)2(taptp)](PF6)2       [Exp. 6.2.12 pg. 143] 






[Ru(bipy)2(taptp)](PF6)2       [Exp. 6.2.13 pg. 144] 





[Ru(phen)2(tpphz)PtCl2](PF6)2      [Exp. 6.2.14 pg. 145] 






[Ru(phen)2(tpphz)Re(CO)3Cl](PF6)2     [Exp. 6.2.15 pg. 146] 




(red lines = tpphz protons a,b,c,d,e,f and blue lines = phen protons 3,4,5,6,3’,4’,5’,6’)  
 
[Ru(bipy)2(tpphz)Re(CO)3Cl](PF6)2      [Exp 6.2.16 pg. 147] 
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(RuRe-bipy) in CD3CN 
 
(red lines = tpphz protons a,b,c,d,e,f and blue lines = phen protons 3,4,5,6,3’,4’,5’,6’)  
 
[(Ru(bipy)2)2(tpphz)](PF6)4       [Exp. 6.2.17 pg. 148] 
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7.2  Viscometry 
 
The following data was collected by Isabel Griffiths (Level 4 Masters student) using a Canon 
viscometer (size 50) immersed in a water bath maintained at 26 °C. For each solution the 
1/R (R = ([DNA]/[complex]) value falls between 0 – 0.3 and 20 minutes equilibration was 
allowed after each complex addition. Capillary tube flow rates were ran in triplicate and an 
average value calculated. The figure below shows the relative viscosity (η/η0)
1/3 of 50 µM 
CT-DNA upon an increasing concentration ([DNA]/[complex])-1 of RuRe 3, the model 






















7.3  UV-vis Spectra 
 
The following data was collected by Isabel Griffiths (Level 4 Masters student) using a Varian 
Cary 50 Probe UV-vis spectrophotometer and Cary Win UV software, and shows the UV-vis 
absorption spectra and assignment of Ru(tpphz) 1, RuRe 3, and for the bipy derivatives Ru-
bipy-tpphz and RuRe-bipy, all as a PF6 salt in acetonitrile. 
 
 
Complex λmax / nm ε / M-1 cm-1 Assignment 
Ru(tpphz) 1 
225 114334 π→π* 
245 105802 π→π* 
265 165529 π→π* 
315 63140 π→π* 
365 35836 π→π* 
380 51195 π→π* 
450 27304 MLCT 
RuRe 3 
265 154143 π→π* 
280 148362 π→π* 
305 75145 π→π* 
370 34682 π→π* 

























Complex λmax (nm) ε (M-1 cm-1) Assignment 
Ru-bipy-tpphz 
245 92559 π→π* 
282 154265 π→π* 
315 63521 π→π* 
365 27223 π→π* 
380 43557 π→π* 
450 25408 MLCT 
RuRe-bipy 
245 66265 π→π* 
280 168675 π→π* 
325 48193 π→π* 
370 32129 π→π* 







Also obtained (below) were the UV-vis spectra for RuRe 3 as both a hexafluorophosphate 
salt in acetonitrile and chloride salt in H2O, showing very little change and validating an 
assumption of the same photophysical properties before and after metathesis from 

























Complex λmax (nm) ε (M-1 cm-1) Assignment 
RuRe 3 
220 63319 π→π* 
265 79694 π→π* 
280 84061 π→π* 
305 40393 π→π* 
365 20742 π→π* 
380 24017 π→π* 

































RuRe 3 Cl 
RuRe 3 PF6 
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Abstract: Although metal ion directed 
self-assembly has been widely used to 
construct a vast number of macrocycles 
and cages, it is only recently that the 
biological properties of these systems 
have begun to be explored. However, 
up until now, none of these studies have 
involved intrinsically photo-excitable 
self-assembled structures. Herein we 
report the first metallomacrocycle that 
functions as an intracellular singlet 
oxygen sensitizer. Not only does this 
Ru2Re2 system possess potent 
photocytotoxicity at light fluences 
below those used for current medically 
employed systems, it offers an entirely 
new paradigm for the construction of 
sensitizers for photodynamic therapy. 
Keywords: Self-assembly • singlet 




Photodynamic therapy, PDT, is a non-invasive therapy regime in 
which light is used to selectively damage diseased tissue, usually 
through the in situ creation of reactive oxygen species (ROS).[1-5] 
Commonly, this is accomplished through a prodrug photosensitizer 
molecule that generates cytotoxic singlet oxygen via excited-state 
energy transfer. PDT has been successfully employed to treat a 
range of cancers[6] and other disease states.[7] 
One advantage of PDT is that cell death can be targeted to 
specific locations through a carefully selected combination of 
sensitizer and light; minimising many of the undesired side-effects 
of conventional therapeutic regimes. The majority of 
photosensitizers in clinical use are tetrapyrrolic structures. [8,9] 
However, these structures have a number of disadvantages; for 
example, as extended aromatic systems they often display relatively 
low water solubility and they can be difficult to synthesize and 
purify. In recent years - due to their good water solubility, attractive 
optical properties, and high photostability - transition metal 
coordination compounds have been investigated as alternative 
photosensitizer leads.[10] In particular, RuII complexes have attracted 
much attention and one such complex is currently entering Phase I 
trials as a PDT sensitizer for bladder cancer.[11] 
Meanwhile, over the last two decades, interest in metal directed 
self-assembly has exploded, leading to a huge variety of often very 
complex molecular architectures.[12-14] Many of these systems are 
hosts, and have been developed as devices such as sensors for ions 
and molecules or even catalysts.[15-17] Although the interaction of 
such architectures with biomolecules has been investigated; 
originally much of this work focused on helicate structures, 
producing several promising potential therapeutics. [18-20] 
It is only more recently that the bioactivity of 
metallomacrocycles and cages has begun to be examined.[21,22] In 
this context, perhaps the most well-studied cage systems are those 
reported by the Therrien group; for example, these architectures 
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have been successfully employed as in cellulo delivery vectors for a 
variety of “payloads” including cytotoxic therapeutics, [23,24] 
luminescent DNA probes,[25] and porphyrin-based sensitizers for 
PDT.[26] Furthermore, a number of metallocages have been 
identified as promising anticancer therapeutic leads in themselves, 
although the exact molecular basis of observed cytotoxicity in such 
systems is largely unidentified or poorly understood. [27,28] 
 
Scheme 1 Structures discussed in this study. 
In this context, we have previously reported on the 
synthesis[29,30] and structure[31]  of self-assembled, kinetically inert, 
water-soluble metallomacrocycles, such as 1 (Scheme 1). These 
systems which – because they are based on inert d6-metal ions - are 
high stable in aqueous solution  possess highly structured, binding 
pockets composed of hydrophobic aromatic residues that bind to 
biomolecules with high affinity in biologically relevant 
conditions.[32-34] Since these macrocycles incorporate polypyridyl 
RuII and ReI units that are related to systems being explored as PDT 
sensitizers, [10,11,35] we investigated the cellular internalisation 
properties and photocytotoxicy of 1 towards human cancer cells. 
Employing clinically relevant light doses, we find that 
metallomacrocycle 1 is successfully internalised by cells where it 
functions as a potent photosensitizer though ROS generation that 
results in plasma membrane damage.   
Results and Discussion 
In combination with light microscopy, the MLCT (metal to ligand 
charge-transfer) emissive properties of Ru(II) polypyridyl 
complexes provide a useful property by which to assess the cellular 
internalisation of a complex of interest;[36,37] a concept that may be 
extended to hetero bi-metallic systems.[38] As both macrocycle 1 and 
its “building block” mononuclear complex 2 display RuIIqtpy 
3MLCT-based luminescence on photoexcitation at 458 nm[30,31] we 
initially explored cellular localisation using confocal laser scanning 
microscopy (CLSM) and fixed MCF7 human breast cancer cells. 
Surprisingly - even though 2 is emissive whether or not it is bound 
to biomolecules such as DNA and the barrier to transport across the 
plasma membrane has been removed by fixation - no intracellular 
emission from mononuclear complex 2 was observed. In contrast, 
macrocycle 1 does localise in fixed MCF7 cells. Although some 
non-specific nuclear staining is observed, the macrocycle 
particularly brightly stains the lipid rich regions of the cell, such as 
the nuclear membrane and endoplasmic reticulum (ER) – Figure 1 
and SI. 
 
Figure 1. (A) CLSM images of fixed MCF7 cells stained with 1 for emission at 640-700 
nm (3MLCT emission of 1). (B) Phase Contrast image at 485 nm (1MLCT absorbance 
of 1). (C) Merged image. [1] = 100 M.. 
As expected from the fixed cell studies, live MCF7 cells shows 
no intracellular emission from 2, indicating that live cells do not 
take up the complex; however addition of macrocycle 1 produced 
very different results – Fig 2. After 20 minutes incubation with 200 
M of the macrocycle, the media was removed. Following washing 
with PBS, the cells were placed in complex-free fresh media and 
imaged through CLSM using monochromated laser light exciting 
into the MLCT of 1 at 488 nm. Although initial images showed only 
plasma membrane staining over a period of <10 mins, cells began to 
display dramatic changes in both dye localisation and cellular 
morphology with prolonged light exposure - Fig 2A. During the first 
hour after exposure, 1 begins to localize within cells with evidence 
of nuclear accumulation and particularly intense emission being 
observed from nucleoli. After this period, general staining of the 
nuclear membrane and other membrane-enclosed structures in the 
cytoplasm such as endosomes, lysosomes, and the ER was 
increasingly observed. Gross cell swelling and the generation of 
growing amounts of apparently dead cells, along with complex-
stained cell debris, accompanied the shifts in cellular localization of 
1 - Fig 2 B. 
These cellular responses, which are characteristic of 
oncosis/necrosis processes,[39,40] are often consequences of in cellulo 
1O2 generation.
[41] Furthermore, these changes only occur after 
exposure of treated cells to light, clearly indicating a phototoxic 
response: if cells are treated with the same concentration of 1 but 
kept in the dark they still display normal morphology, even after two 
hours exposure – See SI. 
It is notable that final localization in necrotic cells, where 
membranes have been disrupted, is very similar to that observed in 
fixed cells, indicating that the initial target of 1 in live cells is the 
plasma membrane. This hypothesis is consistent with the images in 
Fig 2 showing the complex accumulating at the plasma membrane at 
early time-points before it localizes within intracellular 
compartments, including the cell nucleus, as plasma membrane 
integrity is increasingly compromised. A similar effect has been 
reported to occur on cell treatment with lipophilic mononuclear RuII 
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complexes.[42] Given these striking results, the ability of 1 and 2 to 
generate singlet oxygen on photo-excitation was investigated. 
 
Figure 2. (A). Top panels: CLSM images of live MCF7 cells pre-treated with 1 ([1] = 
200 M, 20 mins) before exposure to 488 nm light over a 100 minute time course. 
MLCT emission (640-700 nm) Lower panels: detailed Image of the single cell shown in 
the white box in the upper panels (B). Time dependent emission profile of the same cell 
illustrating the increase in intensity and the appearance of strong nucleolus signal after 
initial plasma membrane staining. 
Singlet oxygen quantum yields were directly measured by 
assessing luminescence at 1270 nm following photoexcitation of 
hexafluorophosphate salts of the complexes in acetonitrile. An 
optically matched solution of phenalenone was used as a reference 
sensitizer. This led to (1O2) estimates of 54 ± 5 % and 75 ± 2 % for 
1 and 2 respectively.  These figures probably reflect the lower 
energy, slightly shorter excited state lifetime of 1 in water (667 nm, 
490 ns) compared to 2 (657 nm, 511 ns). 
Since 1 binds to biomolecules such as DNA with high affinities 
>106 M-1 and has a (1O2) value comparable to previously reported 
sensitizers, it seems the biological action of 1 is through singlet 
oxygen sensitization. To test this hypothesis, DNA was selected as a 
representative biomolecule to examine the ability of 1 to induce 
singlet-oxygen mediated damage upon MLCT photoexcitation in 
cell-free experiments. 
 
Figure 3. Photocleavage of supercoiled pBR322 DNA (3 μg) y 1 under illuminated 
condition (476 nm, 100 mW, 10 minutes exposure) in 50 mM Tris-HCL buffer. Forms I 
and II are supercoiled and nicked circular forms of DNA, respectively. (A) Lane 1, 
DNA control; lane 2, DNA + 1 (10 µM); lane 3, DNA + 1 (20 µM); lane 4, DNA + 1 
(30 µM) ; lane 5, DNA + 1 (40 µM). (B) Lane 1, DNA control; lane 2, DNA + 1; lane 3, 
DNA + 1 + NaN3  (200 µM) ; lane 4, DNA + 1 + DMSO (2 µL); lane 5, DNA + 1 in 
D2O; lane 6, DNA + 1 in argon; lane 7, DNA + 1 in dark.. 
Treatment with 25 µM 1 followed by 10 minutes illumination at 
480 nm produces significant cleavage of supercoiled (form I) 
pBR322 plasmid DNA in buffered aqueous solutions, Fig 3A. 
Complete cleavage is observed at concentrations above 40 μM. 
The mechanism of photocleavage was explored through further 
experiments involving pBR322 and a range of different inhibitors – 
Fig 3B. In the dark no significant cleavage is observed, confirming 
light is necessary for nuclease activity.  Since hydroxyl radical 
scavengers such as DMSO do not inhibit plasmid cleavage, it is 
unlikely that this radical is responsible for cleavage. In contrast, 
photocleavage is not observed under argon indicating the 
involvement of dioxygen. To confirm that photoinduced cleavage 
involves singlet oxygen, experiments were carried out in the 
presence of sodium azide and D2O. Sodium azide is a very effective 
1O2 quencher and - since 
1O2 has a longer lifetime in D2O compared 
to H2O - the deuterated solvent potentiates the activity of singlet 
oxygen. As shown in Fig 3B (lanes 3 and 5), the cleavage of 
pBR322 is inhibited by the presence of sodium azide and enhanced 
in D2O, confirming that 
1O2 is responsible for the cleavage reaction. 
Having confirmed that macrocycle 1 is phototoxic to MCF7 
cells and induces damage to biomolecules by singlet oxygen 
generation, we quantified its photo-cytotoxicity towards A2780cis 
ovarian cancer cells, we chose this second cell line as it is highly 
resistant to the commonly employed PtII-based therapeutic cisplatin. 
To aid comparisons, complex 2 was investigated in parallel studies. 
Cells were pre-treated with concentration gradients of 1 or 2 for 
24 h before complex removal and exposure to increasing fluences of 
white light. The impact of each treatment upon cell viability was 
determined through MTT assay (MTT = 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide) 24 h after light treatment. 
Data were normalized against cells not exposed to the complexes 
but treated with the relevant light dose, yielding the half-inhibitory 
IC50 values summarized in Table 1 and Figure 4. 
Table 1. IC50 Values for 1 and 2 towards the cisplatin-resistant cell line A2780cis in the 
presence and absence of light. 
Fluence (J cm
-2
) IC50 concentration (μM) for complexes.
[a] 
1 2 
0 61.7 > 100 
8 8.5 > 100 
24 1.2 28.8 
48 0.3 22.9 
[a] In same conditions, the cytotoxicity of cisplatin is IC50 = 22.9 μM. 
These data show that in the dark both 1 and 2 display low 
cytotoxicity. Complex 2 is particularly inactive (IC50 > 100 µM) 
and, although 1 does demonstrates some potency, it is still 
approximately three-fold less toxic (IC50 =61.7 µM) towards a 
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cisplatin resistant line than cisplatin itself. However, on exposure to 
light, 1 produces a dramatic impact upon cell viability. 
As illustrated in Fig 4a, cell viabilities are sensitive to both the 
concentration of 1 and light dosage: even when exposed to low 
fluences of 8 or 24 Jcm-2, 1 now demonstrates potent cytotoxicity, 
over an order of magnitude greater than its dark value. In fact at a 
higher light dose of 48 Jcm-2, the IC50 decreases to 0.3 μM; a value 
two orders of magnitude more potent than cisplatin. 
 
Figure 4. Light and dark cell viability figures on exposure to varying light fluences and 
different concentration of macrocycle 1 and mononuclear complex 2. 
In contrast, 2 produces only minimal phototoxic effects at high 
concentrations and light doses – Fig 4b. For example, at a fluence of 
48 Jcm-2 (a fluence less than half of that used with the licenced PDT 
sensitizer photofrin) the photocytotoxicity (PI) index - where PI = 
IC50(light)/IC50(dark) – for the complexes showed that whilst PI(2) 
< 5, PI(1) = 206.  Thus, on exposure to light, macrocycle 1 displays 
nanomolar cytotoxicity in cisplatin resistant cells at fluences that are 
lower than those required for a clinically approved sensitizer. 
Given that 2 actually has a higher (1O2) than 1, the dramatic 
differences in cytotoxicities and PI between the mononuclear 
complex and the macrocycle can be attributed to their contrasting 
cellular uptake properties; a well-established principle in the cell 
biology of ruthenium polypyridyl complexes.[43] To quantify this 
effect, relative cellular accumulation of both compounds in 
A2780CIS cells was determined using inductively coupled plasma 
mass spectrometry (ICP- MS). Cells were incubated for 12 hours 
with 50 µM concentrations of 1 or 2 - the highest concentration 
employed in the experiments summarized in Figure 4 – before 
intracellular Ru and Re content was determined. This analysis 
confirmed that ruthenium intracellular concentrations are 
approximately seven times higher on treatment with 1 compared to 2 
– see SI. Since the macrocycle contains two Ru centres, in terms of 
molarity, this corresponds to a 3.5-fold preferential increase in 1 
over 2. Further analyses of the ICP-MS experiments with 1 confirm 
that the intracellular ratio of [Ru]:[Re] is 1:1, providing further 
evidence of macrocycle uptake into cells. Furthermore, the fact that 
low levels of 2 enter cells explains why some phototoxicity is 
observed for this complex at higher exposure concentrations and 
fluences. 
Conclusion 
 In summary, for the first time, a metal complex PDT sensitizer has 
been constructed through metal directed self-assembly of photo-
excitable oligonuclear metallomacrocycles.  The striking bioactivity 
of this system can be largely attributed to its more favourable 
cellular uptake properties compared to its mononuclear building 
block. Presumably, this observation is due to a previously reported 
effect, the overall charge density/lipophilicity of the macrocyclic 
assembly is lower than that of the corresponding mononuclear 
complex. Since the novel macrocyclic PDT sensitizer discussed in 
this study has been self-assembled from mononuclear complex 
“modules”, architecturally complex systems with new properties and 
functions can be readily constructed from relatively simple, 
previously reported, building blocks. Through this new paradigm, 
systems with enhanced uptake and tuneable photo-redox properties 
can be targeted. For example, as our previous studies indicate, [32-34] 
by judicious selection of ancillary and bridging ligand, cellular and 
subcellular binding properties of these novel PDT sensitizers can be 
selectively modulated to produce highly targeted PDT regimes. 
Furthermore, as recently demonstrated in a number of studies, it  
is possible to construct RuII-based systems that can be photo-excited 
within the therapeutic optical window.[44-47] For example, since 
oligonuclear RuII complexes often display high two-photon 
absorption, 2PA, cross-sections,[48-50] using this modular approach, 
the design of macrocyclic systems for 2PA-PDT can be readily 
envisioned. Such studies will provide the basis of future 
publications. 
Experimental Section 
See SI for experimental details.  
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Experimental details 
All chemicals and solvents were purchased from Sigma unless otherwise stated. Complexes 1 




H NMR and mass spectra data were in 
agreement with previously-reported results. 
 
DNA photocleavage 
Photoinduced cleavage of supercoiled (SC) pBR322 DNA by the complexes was studied by 
agarose gel electrophoresis. The reactions were carried out under illuminated conditions 
using 476 nm CW laser (100 mW). The sample was prepared in a dark room at room 
temperature using SC DNA (3 µL, ~3 µg) in 50 mM Tris-HCl buffer (pH 7.2) containing 50 
mM NaCl and varying concentrations of the complex. The solution path length used for 
illumination in the sample vial was 6 mm. After photoexposure, the sample was incubated for 
1 h at 37 °C, followed by the addition of the loading buffer containing 25% bromophenol 
blue, 0.25% xylene cyanol, and 30% glycerol (2 µL), and the solution was finally loaded on 
an 0.9% agarose gel containing 1.0 µg/mL ethidium bromide. Electrophoresis was carried out 
for 1 h at 60 V in TAE (Tris-acetate-EDTA) buffer. Bands were visualized by UV light and 
photographed.  
 
Singlet Oxygen generation 
Singlet oxygen quantum yield (φΔ) in dichloromethane was determined as previously 








Light Irradiation Source Apparatus 
The apparatus used to irradiate the samples was a custom made device featuring a broadband 
illumination source fully contained in an empty computer base unit, referred to as the Light 
Irradiation Source Apparatus (LISA). The technical specifications of the bulb contained 
within are as follows (Table 1). 
 
Product Code 871691 
International Model Number HC01080i 
Description CFL 80W E40 Integrated Clusterlite 4000K 
Watts 80W 
Cap E40 
Operating Hours 15000 
Colour Temp 4000K 
Lumens 5400 lm 
Dimming No 
Dimensions (length x diameter) 256mm x 80mm 
 
Table 1 – Specification of the bulb contained within the irradiation apparatus 
 
Determination of Fluence 
In order to quantify the power output of this light source, an experiment was carried out with 
the running conditions replicated whilst being monitoring by a power meter. The setup 
utilised was a THORLABS S175C Sensor coupled to a PM100USB Power and Energy Meter 
with the readout displayed and stored on a connected netbook. Running the three timed 
periods of irradiation in succession as under experimental conditions (for three separate 





































































Time (minutes) 2 5 2 15 2 30 
Average Power (W) 0.000 0.075 0.035 0.121 0.040 0.126 
Corrected Power (W) - 0.075 - 0.085 - 0.086 
Energy (J) - 22.6 - 76.9 - 155.7 
Fluence (J cm
-2
) - 8 - 24 - 48 
 
Table 2 – Table summarising the fluence calculations from timed irradiations 
 
Cell Culture 
A2780 and A2780CIS cell lines were cultured in RPMI-1640 medium. All growth medium 
was supplemented by 2mM L-Glutamine, 100 IU ml
-1
 penicillin, 100 µg ml
-1
 streptomycin 
and 10% v/v fetal bovine serum (FBS). Cultures were grown within the appropriate range of 
confluence at 37°C in an atmosphere of 5 % CO2 / 95% air. Cultures were routinely 
subcultured using trypsin (0.1% v/v in PBS) at 80 – 90% confluence. Cell lines were used 
between passage numbers 6 – 60. 
 
Confocal microscopy 
Cells were seeded in 6 well plates and luminescently imaged on a Zeiss LSM 510 META 
upright confocal laser microscope using 40x and 63x water immersion objectives. Where 
appropriate, cell fixation was achieved using 5% paraformaldehyde for ten minutes followed 
by permabilisation using 0.1 % Triton. 1 and 2 were excited with an Ar-ion laser at 458 nm 
and emission collected at 640-700 nm using a polychomric (META) detector. Live cell 
imaging experiments involved constant laser exposure 0 – 100 mins with images recorded 






Cell cultures were grown on 48 well plates at a seeding density of 50,000 cells per well and 
allowed to grow for 24 hours. The cells were then treated with compound (solubilised in 10% 
PBS/water: 90% medium) of a 1 – 100 μM concentration range, in triplicate, and incubated 
for 24 hours. All compound solution (and control media) was removed from the cells and 
replaced with regular growth medium 30 minutes prior to irradiation. Of the four prepared 
well plates, one remained in the incubator whilst the other three were exposed to the LISA for 
the duration of 5, 15 or 30 minutes (corresponding to light doses of 8, 24 or 48 J cm
-2
) before 
being incubated for a further 24 hours after culmination of light treatment. All media was 
then removed and cells incubated with MTT (0.5 mg ml
-1
 dissolved in PBS) for 30 – 40 
minutes. The MTT was removed and formazan product eluted using 120 µl/well acidified 
isopropanol, 100 µl of which was transferred to a 96 well plate for the absorbance to be 
quantified by spectrophotometer (540 nm, referenced at 640 nm). An average absorbance for 
each concentration was calculated and cell viability was determined as a percentage of the 
untreated negative control wells (10% PBS/water: 90% medium, average of triplicate). Data 
were plotted in a graph of concentration against cell viability to produce a curve from which 





Supplementary Figure 1 - Emission spectra (left) of fixed MCF7 cells stained with 1 (right) 





Supplementary Figure 2 - (A) Live MCF7 cells stained with 1 ([1] = 200 M) but not 
exposed to continuous laser light. Cells imaged 100 min after complex addition. (B) Emission 
profile of cells (across white line) illustrating that the majority of staining is restricted to the 
plasma membrane. 
 
Supplementary Figure 3 - cellular uptake levels of 1 and 2 in A2780CIS cells (50 M, 12 
hr), as quantified by ICP-MS analysis of Ru content. 
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